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 General introduction 3
1.1 Drooling
1.1.1. General remarks
Physicians working in pediatric care are confronted with a number of impairments, 
disabilities, and related problems in social participation. The specialist for rehabilitation 
medicine has the explicit task to propose, execute and coordinate adequate therapy 
programs during developmental ages of the handicapped child. In the enormous 
range of possible treatment options it can be difficult to decide about priorities 
and to choose the optimal treatment with respect to the childs phase of life and its 
perpectives. In collaboration with the parents and other team members the doctor 
should carefully weigh the pros and cons of any intervention with respect to the benefit 
and the disadvantages for the child: physically as well as emotionally. With regard to 
time-management in medical practice it can almost be regarded as an art to secure 
that existing impairments and problems get enough attention. The motivation must 
always be to optimize the child’s opportunities to develop, depending on his or her 
functional status. 
By far, impairments and disabilities of movement and posture get the greatest attention 
of workers in the field of rehabilitation. The efforts to gain improvement in stature and 
gait are encouraged by parents desperately trying to stimulate independent mobility 
for their child, which is generally considerate to be one of the most important goals 
to achieve. Apart from mobility, oral-motor achievements are of great importance for 
social functioning with speech definitely as the most appreciated capability. Oral motor 
skills, resulting in adequate handling of saliva and food, are important conditions for 
oral integrity that support social acceptance and integration. Impairment in basic 
functions such as sucking, swallowing, breathing, and coughing will frequently result 
in clinical problems of which drooling is an example. Drooling is clinically expressively 
apparent in one of three cases of children with cerebral palsy (CP). It is one of the 
problems that may be ignored or over-looked in the wide variety of disabilities the child 
is confronted with.
Drooling in children with CP is the central theme in this thesis: a complex problem that 
is difficult to treat. In fact, it is a problem that the child and his parents have to cope 
with. Blasco’s definition is often quoted: “drooling is the unintentional loss of saliva 
and contents from the mouth”. It is a normal clinical manifestation in the growing 
child, up to the age of 18 months1. Crysdale argued that drooling beyond the age of four 
www.droolinginfo.org
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is considered as abnormal2. Nevertheless, drooling frequently persists in children with 
poor neuromuscular coordination, mental retardation or learning disabilities, as well 
as in patients who have lost the structural integrity of their jaws, lips or oral cavity3-5. 
The dribbled saliva will soil furniture, carpets, toys, books and clothing. Even the 
clothing of caretakers may become wet. In modern times there is risk that computers, 
communication aids and other electronic devices are damaged.
1.1.2. Drooling in cerebral palsy
The prevalence of drooling has been studied in only a small number of studies. A 
considerable diversion in outcome exists. The results of these studies cannot be 
straightforwardly compared due to a variation in research design, patient selection, and 
data presentation. The main problem seems to be the quantification of salivary flow 
rate or drooling for research purposes. Salivary flow can vary from minute to minute 
depending on factors such as hunger, thirst, fatigue, anxiety, and excitement. Other 
influences are the circadian rhythm and changes over time. In previous studies drooling 
has been reported to be a significant problem in about 10% of a Swedish population 
of children with cerebral palsy showing ‘embarrassing drooling’6. In another study 
children with CP showed moderate to serious drooling in about 10 to 37.4% of cases7. 
In a recent study the prevalence of drooling was investigated in a population across 
dental age. Sixty-eight percent of the patients suffered from spasticity of which 45% had 
a quadriplegia. Of the total population, 58% had a drooling condition to some extent 
(33% severe drooling, 9% moderate drooling and 16% mild drooling). The authors 
concluded that the degree of drooling decreased as the dental age increased8.
Although no definite conclusion can be drawn from the literature it seems reasonable 
to accept that one out of three children with cerebral palsy drools to some extend (Fig 
1.1). Saliva spilled from the mouth is referred to as anterior drooling, which is clearly 
visible. This must be separated from posterior drooling in which saliva, probably mixed 
with food components, is spilled through the faucial isthmus creating a great risk of 
aspiration.
Drooling influences the individuals’ health in some respects1;9-12. Children suffering 
from severe drooling frequently have a chronically irritated, chapped, or macerated 
skin over the chin and peri-oral region leading to cheilitis in 67% of cases13. In cool 
weather the dampness from saliva is chilling and spilled saliva may even freeze if too 
little attention is paid. Although seldom of clinical relevance, there may be chronic loss 
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of fluid and nutrients. Serous problems with respect to general health are related to 
posterior drooling. Children with inadequate swallowing activities frequently aspirate 
their own saliva, which in turn may cause recurrent pneumonia.
Some authors recognize drooling as one of the most common dysfunctions in 
children with CP and perhaps the most problematic in terms of social environment 
and relationship 12;14;15. The diversity of the problem has been documented during a 
consensus meeting in 1991 organized by P.A. Blasco and the consortium on drooling16. 
The constant presence of saliva will impair articulation and the possibilities of effective 
and satisfactory communication. The unsightly nature and odor, in combination with 
salivary spray when the individual talks, sneezes or coughs can result in a degree of 
social alienation from peers and other members of society. The involved children will 
receive fewer hugs and kisses since drooling is cosmetically unappealing1;11;12. Drooling 
is stigmatizing and the individual may not succeed to fully integrate into society11;17. It 
must be emphasized that drooling children are frequently underestimated with respect 
to their mental capacities.
Generally, drooling tends to be worse if there is moderate or severe mental retardation. 
Patients of normal intelligence who are aware of the problem are less likely to interact 
with other children concerning normal peer activities10;18-21. “The distress and social 
Figure 1.1: The child with cerebral palsy and severe drooling
Printed with approval of the parents.
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stigma of continuous drooling is so disturbing to even the moderately retarded child 
that many consider it their worst affliction”18.
Drooling is not only a problem for the child itself but is also of serious social and 
emotional meaning to the family. Bachrach et al asked parents of more than 1400 
patients with CP to complete questionnaires that included a question about drooling22. 
Thirty-four percent indicated that drooling was sometimes a problem ‘requiring a bib’, 
and 16% responded that it was often a problem ‘requiring daily clothing changes’. 
Caretakers such as parents, teachers, and therapists often spend much time in 
suctioning and cleaning the child’s mouth or changing cloths. Drooling warrants 
treatment when it interferes with the patient’s well-being23.
1.1.3. The mechanism of drooling
The submandibular glands are the main paired glands producing about 70% of high 
viscosity resting saliva14. In addition, resting saliva is composed of secretions from 
the parotid glands (~ 25%) and the sublingual glands (~ 5%). The large parotid glands 
are capable of producing great amounts of watery saliva that is secreted promptly as a 
reaction to tactile or gustatory stimulation of the oral mucosa for example during eating 
or drinking. Authors generally agree that the saliva production is within normal limits 
in CP. Hypersalivation or hypersialorrhea, a situation in which excessive secretion of 
saliva occurs, is rarely recognized in drooling children with cerebral palsy7;15;24-27.
The normal pathway of saliva from the oral cavity to the esophagus depends on 
cognitive awareness of social norms, an intact sensitivity in the oral region, and a well 
developed coordination of oro-facial, palato-lingual and head- and neck musculature. 
Due to developmental retardation and oral movement disorders, primary functions 
such as sucking, chewing and swallowing may be disturbed starting predominantly at 
early age. One out of 3 children suffering from CP is considerate to have serious oral 
impairment. About 90% of cases are recognized in preschool and school age28. Mal-
coordination of muscles involved in the oral stage of swallowing leads to excessive 
pooling of saliva in the anterior mouth with resultant loss of saliva from the mouth12. 
Disorders of tongue mobility are the most common finding encountered in drooling 
children. Constant tongue thrusting may lead to proclination of the upper teeth, further 
deteriorating the anatomy. Tongue trusting activities are normally present at birth to 
aid sucking but should disappear at around the age of three months.
The absence of lip closure is probably a causative as well as an aggravating factor. 
Effective lip closure is sometimes prevented by spastic contractions of the mouth-floor 
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muscles or the upper-lip elevator muscle. The effect of insufficient mouth closure on 
drooling has been reported4. Harris described drooling children with CP swallowing 
inefficient also demonstrating a poor synchrony of lip closure3. Lip closure is an 
important condition to build up negative pressure during the oral phase of swallowing. 
In a study with a group of unaffected children, a group of drooling CP children and a 
group of non-drooling children with CP the oral phase of swallowing was investigated29. 
This phase is characterized by two stages. During the ‘suction’ stage liquid placed 
under the tongue or behind the lower lip, is sucked over the tongue and then propelled 
towards the pharynx. In contrast to normal children and non-drooling children with 
CP it was demonstrated that 57.5% of the drooling children with CP did not close 
their lips during swallowing. Residual liquid in the mouth after swallowing occurred 
in 78.1% of the drooling children. The second ‘propelling’ stage did not differ between 
the drooling children and the other two groups. Koheil et al found that the pharyngeal 
and esophageal phases of swallowing in normal subjects and drooling patients were 
similar30. In addition, Sochaniwskyj suggested children with CP to differ from normal 
children in their lower frequency of conscious swallowing31.
Other contributing conditions to drooling are a decreased intra-oral sensitivity 
and a hypo-active gag reflex. The relation between oral sensation and drooling was 
investigated by Weiss-Lambrou et al. Children with drooling scored significantly lower 
on tests of oral sensation than did non-drooling patients32.
Children with CP frequently have stasis of saliva in their mouth located sublingually 
and in the buccal pools. Due to incoordinate movements saliva may find its’ way to the 
posterior side of the tongue and leak into the hypopharynx. This ‘posterior drooling’ 
may be apparent because it often presents with congested breathing or a loud and 
alarming rattle in the throat. Because of unrecognized aspiration recurrent silent 
pneumonia may occur. This morbidity leads to anxiety and refusal to swallow33;34. The 
risk of posterior drooling can be enhanced by the fact that many of the patients are 
taken care of in a supine position during a substantial part of the day.
A complex interaction exists between gastro esophageal reflux and salivary flow rate. In 
healthy subjects, exposure of the distal esophagus to the acid contents of the stomach 
results in an immediate increase of saliva secretion. The assumed function of this is 
that swallowed saliva plays a role in the defense against acid-induced injury to the 
esophageal mucosa. It is suggested that reflux in children with CP causes stimulation 
of pH-sensitive receptors in the distal esophageal mucosa, which activates the 
esophageal-salivary reflex leading to an increase of salivary flow rate35;36.
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Chronic gastro esophageal reflux itself is a well-known clinical entity causing aspiration 
with recurrent pneumonia37-39. Up to 60% of severely impaired children may aspirate40. 
Aspiration aggravates when the situation is complicated by inefficient posture or 
deformity of the spine and trunk.
Because of the esophageal-salivary reflex, gastro esophageal reflux may cause 
deterioration of either anterior or posterior drooling.
1.1.4. The treatment of drooling
The goal of any drooling treatment will be a reduction in visible spill of saliva 
or a decrease of posterior drooling. Non-invasive therapies to reduce drooling 
comprise: 1) behavioral techniques, 2) speech therapy (early intervention by oral 
neurodevelopmental techniques) to optimizing oral sensation and to train oral motor 
skills, 3) the administration of anticholinergic drugs, and 4) (intra-ductal) radiation. 
Surgical procedures include: 1) salivary gland excision, 2) salivary duct rerouting, or 
3)a combination of these. Other less successful techniques have been performed like 
Chorda tympani neurectomy to eliminate parasympathetic stimulation to the salivary 
gland.
The intra-glandular injection of Botulinum toxin is a non-surgical approach, although 
invasive with the need of injections and of anesthesia, in children.
The above-mentioned interventions differ in their basic approach. The first option for 
treatment is to modify and optimize the individuals’ capability to handle the secreted 
saliva. Behavioral therapy, oral-motor therapies, or specific handling techniques by the 
speech therapist are generally used.
A second strategy encompasses procedures designed to reduce salivary flow in 
order to diminish drooling. This can be achieved by reduction of secretion from the 
parenchyma e.g. radiation of the salivary gland, neurectomy, anticholinergic drugs, 
intra-glandular Botulinum toxin injections, or by blocking the salivary flow after its 
secretion e.g. legation of the salivary ducts. A more rigorous way is to excise salivary 
glands.
The final category of interventions comprises procedures intending to re-direct the 
salivary flow in order to support oral management of saliva e.g. rerouting of a salivary 
ducts.
The mode of drooling treatment will depend on a variety of factors such as age, medical 
diagnosis, the general state of health, mental ability, the anatomy of the oro-facial 
region, and the severity and frequency of drooling. Diverting opinions exist as to what 
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would be the best management. Some authors abominate surgical procedures pointing 
at the operation risks, also fearing for possible adverse effects and the irreversibility of 
the interventions. In general, surgery is recommended only if conservative measures 
fail to reduce drooling. Among many surgeons the question is whether such an 
attitude is still defensible given the overall good results of surgery presented in the 
literature41. Surgical interventions are advocated as a definite solution for drooling; the 
re-routing of Wharton’s ducts in combination with excision of the sublingual glands 
being the present standard procedure2;42. In a letter to the editor Blasco reacted to this, 
writing: “The general conclusion that ‘each of the surgical procedures described has 
its devotees and detractors’ is an understatement, and this apparent bias renders the 
surgical literature on this subject uncommonly difficult to interpret. At a conference in 
1999, known as the Blasco Statement, concern was voiced that the severity of surgical 
complications is generally underreported and under-emphasized” 1;16. 
A review of the surgical literature shows serious side effect such as wound dehiscence, 
parotitis, cysts, stenosis, and fistulae. Nearly all of the patients will have transient 
postoperative facial or cheek swelling for a few days. Parents have to be informed that 
tube feeding might be required during this period. Hospital stay ranges from 3 to 7 
days among the different authors18;43.
In the discussion about conservative measures it is stated that success rates are 
low and demand great efforts of caregivers and substantial time investment of the 
health-care system, with related costs. Solicitors of the non-surgical approach plea 
for a thorough evaluation and instruction by the speech therapist focused on oral 
stimulation or eating and drinking programs.
Occupational-, physical-, and speech therapists have used handling techniques and 
assistance equipment to help control drooling. Primary goals are: enhancing head 
control, normalizing muscle tone, stabilizing body posture, promoting jaw stability, 
eliciting mouth and lip closure, decreasing tongue-thrust, and facilitating swallowing.
The application of anticholinergic drug is more or less regarded as the classical way 
to treat drooling. To date the long term use of anticholinergics is no longer advised 
because of serious side effects occurring in most patients44. 
In 1999 a conference of the drooling consortium took place to elaborate consensus 
about the strategy of the treatment of socially disabling drooling16. Based on this 
declaration and given the recently added possibility of Botulinum toxin treatment, the 
interventions to manage saliva or to treat drooling can be categorized into conservative 
measures, non-surgical/invasive interventions, and surgical procedures (Table 1.1)
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Table 1.1: Schematic presentation of the treatment options for drooling
 Conservative  Non-surgical/  Surgical procedures 
 measures invasive interventions
Approach/interventions speech therapy,  intra-glandular BoNT*  rerouting of  
 occupational and  injections Whartons’ ducts in  
 physical therapy  combination with  
   sublingual gland  
   excision 
Effect Improvement of oral  Re-direction of   Re-direction of the 
 motor skills and  salivary flow rate salivary flow 
 regulation of  
 sensibility  
 Reduction of tongue  
 trusting 
 Improvement of  
 swallowing 
 Improvement of body  
 posture
Duration of effect As long as therapy is  6 to 12 months Definite 
 continued Probably longer  
  intervals if repeated  
  injections are given
Adverse effects None None Varying, dependent 
  Only if BoNT is wrongly  on the specific 
  injected as can happen  approach 
  when no ultrasound  Infection, nerve 
  guidance is used  damage, 
   Ranulae, swelling  
   with consequent  
   feeding problems, 
   Stenosis, fistulae.
Contra-indications None Previous surgical  Disturbed   
  intervention in one of pharyngeal 
  the major salivary  or esophageal 
  glands. phase of   
  Known hypersensibility  swallowing. 
  to Botulinum toxin or  A history with 
  any other part of the  recurrent  
  formulation aspiration. 
   Prior surgery of the  
   parotids
Preferred age groups Not specified 4 years and older 7 years and older
*BoNT: Botulinum Neuro Toxin Type-A
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1.2. Anatomy and function of the salivary glands
Drooling and the treatment of drooling form the central theme in this study. The 
salivary glands are the targeted organ of the experimental intervention (Botulinum 
toxin injections) as well as the control intervention (scopolamine application). In the 
next section the functional anatomy of the salivary glands and the function of saliva 
are discussed.
1.2.1. The functional anatomy of the salivary glands
During early development the salivary glands arise as buds from the epithelial lining of 
the mouth; the parotid appears during the fourth week in the angle between the maxillary 
process and the mandibular arch; the submandibular (also called: submaxillar) gland 
appears in the sixth week, and the sublingual during the ninth week in the hollow 
between the tongue and the mandibular arch. The salivary glands are compound 
acinous glands, encased in a fibrous connective tissue capsule and grouped in three 
paired sets of large glands: the parotid-, submandibular-, and sublingual gland (Fig 1.2).
In addition, the mucous of the oral cavity (palate, lips, cheeks) and the tongue contains 
numerous minor salivary glands. The capsules of the salivary glands send septa into 
the substance of the glands, dividing them into lobules (Fig 1.3). The presence of a 
capsule and lobules is of significance in certain clinical situations or diagnostic and 
therapeutic procedures.
Figure 1.2: The location of the major salivary glands
parotid gland
sublingual gland
submandibular gland
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All glands of the oral cavity have a system of branching ducts (Fig 1.4). The secretory 
portions or acini of the pure mucous glands are usually long, branching tubulus. In the 
serous and mixed glands, the secretory portions vary from simple oval to tubulo-acinar 
forms with irregular outpockeings. The intra-lobular ducts are thin, branched tubulus 
called the intercalated ducts. Branches of the next larger order are the so-called striated 
ducts, also located in the interior of the smallest lobulus. The saliva is then collected 
in lobular and interlobular ducts and finally secreted through the larger primary or 
excretory ducts.
Figure 1.3: Macroscopic image of the submandibular gland
Figure 1.4: Reconstruction of a terminal portion of the submandibular gland
 
b, cross section of a purely serous terminal portion, showing basal lamina; c, cross section of a purely 
mucous terminal portion; d, cross section through as intercalated portion; e, cross section through a 
salivary duct.
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The salivary glands may be classified in three categories (mucous, serous or mixed 
glands), according to the type of their secretory cells. Mucous cells elaborate a viscid 
secretion that consists almost exclusively of mucin. In glands with only serous cells, the 
secretion is a watery liquid that lacks mucus but contains, salts, proteins, and enzymes. 
The serous cells in the various oral glands have a similar microscopic structure even 
though they are not functionally identical. Some of them might be described as muco-
serous. Mixed glands produce a viscid liquid that contains mucins, salts, and enzymes. 
The relative numbers of the two types of cells vary within wide limits.
1.2.2. The neurological control of saliva secretion
Local reflexes of olfactory, gustatory and masticatory origin that stimulate the 
autonomous nerve system generate activation of the salivary glands. The salivary 
glands also secrete when mechanical, thermal, pain, or chemical stimuli act upon the 
nerve endings in the oral mucous membrane, or as the result of certain psychological 
stimuli. Distention of the gut and increased motility of the gut are also contributing 
factors. Tactile stimuli play an important role in the mouth, eliciting qualitative as 
well as quantitative modifications in secreted saliva. It is important to realize that the 
process of saliva secretion is of multifactorial origin, which can explain the continuous 
variation in production level.
The secretory function of the salivary glands serves under a complex higher neural 
control. Each salivary gland is provided with sensory afferent nerves. The salivary glands 
receive a dual autonomous supply: the parasympathetic and sympathetic  nervous 
fibers. These two systems demonstrate less opposing action than was formerly thought. 
The secretory cells from serous and sero-mucous salivary glands can be stimulated by 
both sympathetic (α-adrenergic and β-adrenergic) and parasympathetic stimuli. On 
the contrary, mucous salivary glands are mainly stimulated parasympathetic.
The parasympathetic stimuli (neurotransmitter: acethylcholine) to submandibular 
(submaxillary) and sublingual glands originate in the superior salivatory nucleus (Fig 
1.5). The secretory nerve fibers decent a short distance through the glossopalatine 
nerve and than continue in the facial nerve (VII). They run through the chorda 
tympani branches of the facial nerve to the lingual nerve to end in the submandibular 
(submaxillary) ganglion from which the postganglionic fibers reach the submandibular 
glands as well as the sublingual glands.
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Figure 1.5: Autonomic innervation of the mouth and pharynx
Parasympathetic nerve branches through the Facial nerve (VII) and sympathetic branches to the 
submandibular and sublingual glands. (From: The Ciba Collection of medical illustrations, volume 3,  
Frank H. Netter, M.D.)
Figure 1.6: Autonomic innervation of the mouth and pharynx
 
Parasympathetic branches through the Glossopharygeal nerve (IX) and sympathetic branches to the 
parotid gland (From: The Ciba Collection of medical illustrations, volume 3, Frank H. Netter, M.D.)
Parasympathetic
Sympathetic
Parasympathetic
Sympathetic
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Parasympathetic stimuli to the parotid gland originate in the inferior salivatory 
nucleus and leave the brain via the glossopharyngeal nerve (IX) (Fig 1.6). They pass 
the tympanic plexus to continue in the small superficial petrosal nerve to end in the 
otic ganglion. The postganglionic nerve fibers are distributed to the parotid gland via 
the auriculotemporal nerve.
The sympathetic (neurotransmitter: nor-adrenaline) preganglionic fibers originate 
in the intermedio-lateral cell column of the first and second thoracic cord segments 
and go to the superior cervical sympathetic ganglion (Fig 1.5 and 1.6). Here the fibers 
effect synaptic connection with the postganglionic nerve fibers. The postganglionic 
sympathetic nerve fibers reach the parotid gland via a neural web, running with the 
external carotid artery and the middle menigeal artery, whereas the submandibular and 
sublingual glands are reached by fibers running along with the submental branches of 
the facial artery and the external maxillary artery.
Parasympathetic nerves provide the main drive for the secretion of fluid by the glands. 
Sympathetic impulses appear to evoke specialized responses that tend to modulate 
the composition of the saliva45;46. For example, stimulation of the parasympathetic 
nerves of the submandibular glands causes the secretion of abundant thin saliva, rich 
in water and salts but poor in organic substances. Stimulation of the sympathetic 
nerve, on the contrary, yields a small quantity of thick saliva, with a high content of 
organic substances. 
It is a misconception that stress induced dryness of the mouth is due to sympathetic 
inhibitory fibers. This dryness originates from regulatory mechanisms in higher centers 
that inhibit salivary centers.
The preganglionic neurons of both the sympathetic and parasympathetic system 
as well as the postganglionic parasympathetic neurons secrete acethylcholine. The 
sympathetic postganglionic fibers secrete noradrenalin.
1.2.3. Saliva secretion
The parotid glands contain mainly serous acinar secretory cells. The submandibular 
glands are mixed, with the serous acini greatly outnumbering the mucous acini. The 
sublingual glands are also mixed but here the mucous elements predominate47.
The speed of the secretory process through the ducts determines how much electrolytes 
are secreted.
The most important salivary electrolytes are Na+, K+,  Cl–, and HCO3
– ions. The uptake 
from the blood serum forms an active process. Also Ca2+ and Mg2+ are present. 
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Proteins and glycoproteins are synthesized within the secretory cells48. In the pure 
mucous sublingual glands the cytoplasm contains mucigen, the antecedent of mucin. 
Each of the major salivary glands produces its own spectrum of proteins.
1.2.4. The function of saliva 
Saliva composition is a major factor influencing the bacterial flora of the mouth and 
the formation of dental caries and plaque. Saliva helps to protect against tooth decay 
in several ways:
1. Saliva flow helps dilute and clear dietary sugars.
2.  High pH (bicarbonate) buffers acids generated by bacterial fermentation.
3.  Calcium and phosphorus supersaturation drives toward mineralization.
4.  IgA from mucosal plasma cells is transcytosed into saliva.
5.  Antimicrobial peptides and proteins, e.g. lysozyme and lactoferrin.
Saliva itself plays an important role in the preparation and digestion of the food offered 
to the mouth and in protecting the teeth and the oral soft tissues. The total secretion 
of saliva of the parotid, submandibular, sublingual, and the many buccal glands may 
be up to 1000 ml per day for adults. The production in especially young children will 
be substantially less.
Saliva contains essential substances: α-Amylase for the digestion of starches (parotid 
gland and submandibular gland), mucus for lubricating purposes (submandibular, 
sublingual, buccal glands), and  ions like potassium, bicarbonate, sodium, and 
chloride. The pH of the saliva varies from 6.6 to 7.4, which is regarded as a favorable 
range for the optimal digestive action of α-Amylase.
The oral soft tissues are lubricated by the saliva, which makes phonation and good 
food passage possible. Swallowed saliva plays an important role in the defense against 
acid-induced esophageal mucosa injury, and against microbial infections.
Lubrication feels comfortable, as it is functional. The salivary mucins provide an 
effective barrier against environmental influences and they help to keep the tissues in 
a hydrated state49.
The presence of nerve growth factor and epidermal growth factor in the submandibular 
saliva may accelerate wound healing.
Under basal conditions saliva of the mucous type is secreted in amounts of up to 
0.5 ml/min. The majority of this volume comes from the submandibular, sublingual 
and buccal glands. This secretion plays an important role in maintaining oral tissue 
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healthy. The mouth is loaded with pathogenic bacteria that can easily destroy tissues 
and cause dental caries. However saliva helps to prevent deteriorating processes 
in several ways. The flow of saliva washes away the bacteria and the saliva contains 
enzymes and microbial proteins to destroy them.
1.3. Infantile Encephalopathy and Cerebral palsy
Different opinions exist on the definition of cerebral palsy. The following section 
describes the terms ‘infantile encephalopathy’ and ‘cerebral palsy’. Although infantile 
encephalopathy is not a central issue of this thesis, it is described to distinguish it 
clearly from cerebral palsy. Cerebral palsy is described to delineate the definition that 
was adopted for this study.
1.3.1. Infantile Encephalopathy
Infantile encephalopathy (IE) is not a term used widely in clinical practice and it brings 
forward some basic misunderstandings because it lacks one strict definition. Infantile 
encephalopathy can be regarded as an umbrella term to describe all progressive, 
non-progressive, congenital or acquired cerebral lesions emerging in the developing 
brain early in life. The syndrome is clinically presenting with motor-, cognitive-, and 
perceptive impairments. One of the first physicians who used the term infantile 
encephalopathy was the English physician William John Little (1810-1894). He gave a 
historical lecture in 1861: ‘On the influence of abnormal parturition, difficult labours, 
premature birth and asphyxia neonatorum on the mental and physical condition of the 
child, especially in relation to deformities’50. In addition, he stated that some of the 
clinical pictures were non-progressive disorders restricted to movement and posture 
that began in childhood. Other names that contributed to the description were Freud, 
Starr and the Sayre’s (sr and jr). Freud was very pessimistic and wrote about infantile 
encephalopathy as a ‘tragic chapter’ in medical practice and supported the quotation 
by Starr:’ ....a chronic disease incurable by medical treatment’. Some authors only 
used the term to describe “a diffuse disorder of the brain in which at least two of 
the following symptoms should be present: altered state of consciousness, altered 
cognition or personality, and seizures”51. By no means is infantile encephalopathy a 
classifying diagnosis as it covers a broad complex of symptoms.
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1.3.2. Cerebral Palsy
Cerebral Palsy (CP) in fact means brain (cerebral) paralysis (palsy). As one of the first, 
W. Phelps used the term in 1937. He outlined a variety of types in detail based on 
topographical as well as physiological features. The work of several physicians resulted 
in a definition published by the Little Club in 1958:
‘Cerebral palsy is a persistent though not unchanging disorder of movement and 
posture, appearing early in life and due to a non-progressive lesion of the brain, the 
result of the interference during its development’.  Although the brain lesion remains 
the same, the resulting movement disorder may change, for either the better or the 
worse. A lot of variations on the theme have been proposed by several authors with 
among them: Pohl (1950), Denhoff (1951), Glidden Brooks (1956), Mc. Keith (1958), 
Bobath (1959), and Bax(1964).
Cerebral palsy can be referred to as a group of neurological disorders with impairment 
of motor function and loss of functional skills primarily caused by abnormalities in 
the pyramidal and extra-pyramidal tracts, resulting in a UMNS (upper motor neuron 
syndrome). A brain lesion will seldom selectively affect the motor areas. Several centers 
will usually be involved simultaneously, thus the picture will be that of a motor lesion 
combined with a variety of other defects, such as: mental retardation; epilepsy; visual 
and auditory disorders, etc.
The symptoms, present in the first year of life, may gradually improve and processes 
leading to the disappearance of cerebral palsy can continue after the first years of 
life52;53. 
A more recent consensus meeting in the early nineties of the last century brought up 
a revised definition of CP: ‘an umbrella term covering a group of non-progressive, but 
often changing, motor impairment syndromes secondary to lesions or anomalies of 
the brain arising in the early stages of its development’54;55.
The term cerebral palsy according to this definition has been adopted in this study with 
the annotation that the clinical picture might be complicated by other symptoms and 
disorders and is not solely restricted to movement and posture. To meet this last point 
the term ‘infantile encephalopathy’ would be more correct because it encompasses 
the diversity of neurological syndromes; it leaves the possibility whether or not motor 
disorders dominate. According to international standards, however, the term CP will 
be used as a diagnostic entity.
Cerebral palsy is common and it affects 1.5 to 2.5 per live births in the United States and 
Australia56;57. More than 100.000 Americans less than 18 years of age have neurological 
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abnormalities attributed to cerebral palsy.  Recently an epidemiological survey has been 
performed in the Netherlands. The calculated prevalence equaled 2.44 for the period 
1986-198858. As the result of a European collaboration project (Surveillance of Cerebral 
Palsy in Europe) a prevalence was found of 2.08 in the period 1980 - 199059.  
In 1827 Cavauvieilh probably was the first to make a statement about the 
neuropathological origin of CP and mentioned cerebral hemi atrophy as the cause 
of hemiplegia. Since than several opinions and convictions have been reviewed with 
respect to the etiology of CP: cerebral sclerosis (Brissaud 1880), subdural hemorrhage 
(McNutt 1885), abnormal pregnancy, difficult labour and delivery, anoxia (Little, 1862), 
infections for example scarlet fever (von Heine 1860), chickenpox (Freud, 1891). 
Strumpell (1899) wrongly attributed cerebral palsy to a form of ‘polio-encephalitis’. 
But he seems to have recognized clear pictures of CP resulting from different causes 
including para-infectious encephalopathy, cerebral embolism, or thrombosis.
Cerebral palsy is mainly caused by one of a variety of diseases and disturbances 
occurring during pregnancy, for example infections (rubella virus, cytomegalo virus, or 
toxoplasmosis), exposure to toxins, malformation of the brain, abnormalities in blood 
flow, genetic disorders, and complications of multiple birth. Cerebral palsy from such 
early causes is referred to as congenital and frequently related to preterm birth and low 
birth weight.
The majority of children afflicted do not acquire the condition from childhood injuries 
or diseases. Post neonatal events such as meningo-encephalitis, trauma, or occlusion 
of a cerebral artery or vein account for 12 to 21 % of all cases of CP60;61. Peri-natal events 
or intra-partum damage such as asphyxia, brain hemorrhage, or jaundice account for 
3-12 % of all cases62;63.
The incidence and prevalence of CP is not declining in spite of major improvements 
in obstetrical and perinatal care. The calculated CP prevalence rose significantly over 
time for the dutch situation: from 0.77 (1977-1979) to 2.44 (1986-1988). The survival 
of preterm and ‘small for date’ infants has added new problems to healthcare in the 
past decades. Beyond any doubt, CP, the spastic syndrome as well as extra pyramidal 
syndromes, and the consequent disabilities are part of these problems. The rate of CP 
in full-term infants with birth weights less than 1500 g appeared to be 25 to 30 times 
higher than among newborns weighing 2500g or more64. In an extended research 
program among pre-term infants with low birth weights in the Netherlands a 40 times 
higher risk was estimated (POPS: project on pre-term and small for gestational age 
infants, 1993)65;66.
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Thrombi-embolic processes during pregnancy seriously contribute to the risk for CP. 
The immature brain is vulnerable to non-traumatic intra-cranial hemorrhage, which 
develops in 40% of all newborn infants with a birth weight below 1500 gram. 
From several studies it is clear that twin and higher-order multiple birth infants are at 
increased risk for CP67;68. In part, this is related to low birth weight frequently occurring 
in twins. However, normal birth weight twins also have a higher risk for CP than the 
normal population. Twinning, low birth weight, and premature delivery, although 
frequently related, appear to be separate factors increasing the risk for CP69.
In a study by Minakami, twins conceived after ovarian induction, were followed70. The 
risk of an adverse outcome after 1 year including death, CP, and mental retardation was 
2.8 times higher in monochorionic twins. A twin to twin transfusion syndrome might 
explain part of this problem71. 
Over the last decades assisted reproductive techniques together with ovarian induction 
have found their way to the regular medical practice. In particular woman of 35 years and 
older, and higher educated couples make use of these techniques. Between 1980 and 
1993 in the United Kingdom, the twin pregnancy rate increased by 25% and the higher-
order pregnancies more than doubled72. The risk for complications during pregnancy 
increases beyond the age of 35 and is even higher in cases of multiple gestations, 
for this age group. In-uteri death of one twin or a child of a higher-order pregnancy 
increases the risk of CP for the surviving child(ren) by more than 10-fold67.
Taken the above mentioned points into account together with the problems still occurring 
at delivery there is little expectation that the incidence of CP will diminish in the next years. 
From this it seems certain that clinicians and other workers in the field of rehabilitation 
medicine will continue to be faced with the problems of CP in the near future.
1.4. Botulinum toxin and scopolamine
Intra-glandular injection with Botulinum Neuro Toxin Type-A (BoNT) is the experimental 
intervention evaluated in this study. The injections will be compared to a period of 
scopolamine application. Both, BoNT and scopolamine are discussed in the next 
section in order to provide basic background of the treatments.
1.4.1. Botulinum Toxin
The hypothesis of this study is based on the fact that injected BoNT leads to inhibition 
of cholinergic nerve endings. The seven identified toxin sero-types (A,B,C1,D,E,F and 
G) are anti-genitically distinct but also have a number of features in common: 1) they 
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are synthesized by the anaerobe Clostridium Botulinum bacteria, 2) and they all are 
of the same molecular weight (~ 150 kDa)73. Some authors rather distinguish an 8th 
subtype: C2 (Table 1.2). 
Table 1.2: Botulinum Toxin Types, Target Sites, Discoverers, and Year Discovered
Type Target Discoverer Year
A SNAP-25 Landman 1904
B VAMP Ermengem 1897
C Syntaxin Bengston & Seldon 1922
D VAMP Robinson 1929
E SNAP-25 Gunnison 1936
F VAMP Moller & Scheibel 1960
G VAMP Gimenez & Ciccarelli 1970
The complete gene sequences of the ‘type A-Hall’ strain Clostridium botulinum 
bacteria (Allergan), has been described. The reported sequence information for type 
A-Hall strain will potentially facilitate elucidation of the toxins interactions with the 
nontoxin proteins in the complex.
The toxin is synthesized as a relatively inactive single chain polypeptide. When acted 
upon by proteolitic enzymes this molecule is nicked to yield the fully active di-chain 
polypeptide composed of a heavy chain (H-chain) and a light chain (L-chain) linked 
together by a disulphide bond73. The mode of action for each of the sub-types is specific, 
all resulting in a well documented anticholinergic effect in the pre-synaptic nerve 
ending74-76. By far, the type-A neurotoxin (1296 amino acids) is the most frequently 
applied toxin for clinical use. In this study, BOTOX® (Allergan B.V., Nieuwegein, The 
Netherlands) was used; a type-A neurotoxin hemagglutinine/protein complex (900 
kDa) of vacuum-dried purified toxin. Each vial contains 100 U (Units) corresponding 
with 5 Ng purified toxin type-A, also containing human serum albumin and sodium 
chloride. One unit of the toxin corresponds to the estimated median intra-peritoneal 
lethal dose (LD50%) in mice. These specific dosages are estimated by means of 
bioassays that are unique for each formulation. As a consequence the dosing scheme 
of different BoNT products cannot be straightforwardly compared*. 
*The pharmaceutical form of BOTOX® is a powder which can be reconstituted with 0,9% NaCl. After reconstitution 
the attained solution can be used for 2 weeks provided it is kept in a refrigerator at approximately 2-8°C.
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BONT can enter the body from three sides of production: 1) by adsorption from the 
intestine, 2) by adsorption from a wound, or 3) by injection. 
For clinical use the toxin should be injected into a target organ. After injection it will 
spread in the surrounding tissue by diffusion. The extent of this phenomenon depends 
on the injected volume and concentration of the toxin77. Within the parenchyma 
Botulinum toxin type-A, like the other sub-types, is capable of binding (Fig 1.7a) to 
the plasma membrane of cholinergic terminal nerve endings by the H-chain78-81. This 
process is irreversible. A process of internalization (Fig 1.7b) by endocytosis follows, 
in which the toxin enters the nerve cell encaged in a vesicle. Translocation (Fig 1.7c) 
occurs in which the toxin crosses the vesicle membrane and is released into the cytosol. 
The H-chain is mainly responsible for the binding and translocation processes. In this 
sense the H-chain is capable of targeting the L-chain precisely and selectively. On 
entering the cytoplasm the di-chained molecule splits.
The toxic activity is performed by the L-chain82. In case of the A subtype, the L-chain 
cleaves the SNAP-25 enzyme (synaptosomal-associated protein with a molecular 
weight 25 kDa): a cytoplasmatic protein that is located at the cell membrane of the 
terminal nerve ending and that is required for the release of the neurotransmitter 
acethylcholine. This is the process of blockage (Fig 1.7c). Functional restoration and 
reinnervation in realized by axonal sprouting (Fig 1.7d)
Under normal excitatory conditions, SNAP-25 is capable of linking to SNARE (soluble 
N-ethyl-maleimide sensitive factor attachment protein receptor) proteins within the cell 
membrane. Once the SNAP-25 protein is linked in the SNARE complex it is resistant 
to BoNT proteolysis83. 
Clostridial toxins are large proteins and they are immunogenic. Anti-BoNT antisera 
can prevent toxicity and provide recovery from botulism84;85. On the other hand 
these antibodies can diminish a therapeutic effect. Protective, neutralizing anti-BoNT 
antibodies are known86-88. However, also non-neutralizing antibodies, directed against 
the hemagglutinin protein of the complex, may be produced89. These antibodies do not 
influence the toxicity of the BoNT. Just a few patients develop anti-BoNT-A antibodies, 
particularly when large therapeutic doses of the toxin are injected. Patients who develop 
neutralizing antibodies to one BoNT serotype may benefit from other serotypes. For 
example, the application of BoNT-B, might be an alternative to overcome a therapeutic 
barrier from type A toxins90.
Compared to the first release of pharmaceutical BoNT, Allergan has improved 
the product. The first form of toxin complex contained 25 ng whereas the present 
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formulation contains 5 ng of the toxin protein complex. In a study by Aoki it was 
found that the complex from the new bulk retains the same efficacy but elicit less 
immunogenicity91;92.
Figure 1.7: Schematic presentation of the mode of action of Botulinum toxin-Type A
Figure 1.7a: After injection the heamag-glutinine-
toxin complex diffuses though the parenchyma 
and binds to the plasma membrane by the toxin’s 
heavy chain.
Figure 1.7b: The heavy chain induces a process of 
endocytosis. As a result the toxin is incorporated 
in the cytoplasm in a vesicle. The synaptic vesicles, 
containing Acethylcholine, still function properly. 
Figure 1.7c: After release into the cytosol the light 
chain binds to SNAP-25, which forms a blockage in 
the formation of the SNARE complex, preventing 
the excretion of Acethylcholine.
Figure 1.7d: The effect of BoNT is overcome by 
collateral sprouting and restoration of function at 
the neuro-glandular junction (indicated by circle).
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1.4.2. Scopolamine
Scopolamine (hyoscine) is a belladonna alkaloid. Scopolamine, like atropine, is an 
antimuscarinic agent, which produces competitive antagonism of the actions of 
acetylcholine, which can be overcome with increasing concentrations of acetylcholine. 
Scopolamine, at usual dosages, produces CNS depression. However, excitement, 
restlessness, hallucinations, or delirium may paradoxically occur. In addition to its 
systemic anticholinergic effects, scopolamine is effective in motion sickness.
Using the transdermal system (1.5 mg) for topical application behind the ear scopolamine 
is well absorbed. The drug is thought to be almost completely metabolized in the liver and 
excreted in the urine. The duration of action of the transdermal system is up to 72 hours.
Hypersensitivity to scopolamine or to any ingredient in the formulation; pyloric 
obstruction; tachycardia secondary to cardiac insufficiency or thyrotoxicosis are 
contraindications for use. Caution to use is advised in patients taking drugs that act on 
the CNS as well as in patients with urinary bladder neck obstruction. Caution should be 
exercised when administering an anti-emetic drug or antimuscarinic drug to patients 
suspected of having intestinal obstruction (e.g., pyloric obstruction).
Adverse effects can be of different origin. Cardiovascular: bradycardia, tachycardia, 
hypotension. CNS: sedation, drowsiness; irritability, disorientation, hallucinations, 
impairment of memory and concentration, dizziness, confusion, acute toxic psychosis 
(resolves 24 to 36 hours after removal of the transdermal patch). Gastrointestinal: 
dry mouth; constipation. Ocular: blurred vision, dilated pupils. Dermatological: local 
irritation. Isolated cases of rashes and erythemas have been reported. Other: difficulty 
in urinating, rashes, erythemas.
1.5. Outline of the study
1.5.1. Primary objective
To evaluate the effect of Botulinum toxin on severe and socially disabling drooling in 
children with cerebral palsy.
1.5.2. Research questions
1. Does BoNT influence the submandibular salivary glands?
 * What effect does injected Botulinum toxin have on the salivary flow rate?
 *  What is the proportional effect of Botulinum toxin injections (treatment intervention) 
 on the salivary flow rate compared to scopolamine application (control inter- 
 vention)?
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2.  Does drooling diminish if salivary flow rates are reduced? 
 * What effect does intraglandular injected Botulinum toxin have on drooling?
3. Is quality of life influenced by the interventions?
 *  Does a reduction of drooling change the individual’s quality of Life
 *  Does a reduction of drooling influence the practical efforts by family and 
 caretakers in relation to drooling.
1.5.3. Patients
The inclusion of patients started in 2000, within nine months 53 patients were seen for 
intake. All subjects entered an intake period in which the diagnosis ‘cerebral palsy’ was 
confirmed. The inclusion criteria were tested (Table 1.3).
Eight children were not enrolled: the parents of three children choosed not to participate 
because of a long travel distance or the rather large number of study investigations 
that had to be fullfilled; five children were excluded because they did not satisfy the 
inclusion criteria.
Table 1.3: Inclusion and Exclusion criteria
Inclusion criteria:
Children (male and female) of pre-school and school age (aging 3 – 18 yrs)
Confirmed diagnosis of cerebral palsy (clinical picture, CT, MRI, EEG)
A score of 3 or higher on the Teacher Drooling Scale, indicating severe drooling (chapter 8, 
table 8.1)
All medication, taken to treat drooling, stopped at least 3 months before start of the study
Minimal bodyweight 8 kg
Informed consent obtained
Caretakers have high enough cognitive ability to participate in the study
Readiness to participate for al least 8 months
Exclusion criteria:
The child is enrolled in another medical study
Previous surgical procedures in the oral or nasal cavity interfering with saliva production
Treatment with BoNT for another indication in the previous 6 months
Known hypersensitivity to Botox“or any part of the formulation
The use of drugs that interfere with saliva secretion
Known systemic diseases (bronchial asthma, congenital heart failure, and myasthenia gravis)
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Thus 45 multiple complex handicapped children were included of whom 28 were male, 
17 were female. The age ranged from 3 to 16 years with a mean of 9 yrs and 5 mo with 
a SD of 3 yrs and 7 mo.
None of the participating children suffered from complicating diseases. Nine of the 
patients had a medical history with recurrent pneumonia. No ENT surgery had been 
performed to treat drooling. Some of the children had received ear tubes, which was 
no contra-indication to participate. Of the initial population, 35 patients suffered from 
ante- and perinatal brain damage caused by preterm birth or asphyxia; 5 patients had 
a brain malformation; 2 suffered from post-infectious cerebral damage; 1 was known 
to have brain damage resulting from profuse epileptic seizures; 2 patients suffered 
from undefined retardation. Concomitant diseases comprised hypothyroidism in one 
patient, and colitis ulcerosa in another. Epilepsy occurred in 19 subjects 12 of whom 
used anti-epileptic drugs.
Figure 1.8: 
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The patients demonstrated the following motor disorder: 1 patient hypotonia; 27 
spastic paresis; 17 mixed motor disorders with spastic and dyskinetic paresis. No 
patient exclusively showed athetosis or ataxia. Eight children were ambulant without 
aid and thirty-seven were (partially) wheelchairs bound.
Mental ability was determined for all patients based on available data at entry of the 
study. These data were collected from the institutions or schools that were attended by 
the children. Mental ability was scored on a 5 point scale according to the subdivision 
presented in table 1.4
Table 1.4: Scores of mental ability
 Level of developmental age Level of Intelligence quotient
I developmental age below 4 yrs 
II developmental age 4 yrs to 6 yrs IQ < 70
III developmental age 4 yrs to 6 yrs  IQ _ 70
IV developmental age 7 yrs or more IQ < 70
V developmental age 7 yrs or more IQ _ 70
The following distribution of mental ability was found in the population: ‘I’ in 22 
patients; ‘II’ in 9, ‘III’ in 2, ‘IV’ in 2, and ‘V’ in 10 patients.
Twenty-two children could not talk. None of the children attended a mainstream school. 
Twenty-nine went to special education schools and fourteen attended a daycare center 
for mentally retarded children.
1.5.4. Outline of the study
To treat drooling Botulinum Neuro Toxin Type-A (BoNT) has become in use over the 
past five years in children and adults with multiple complex neurological disorders. 
This PhD study was undertaken to provide scientific evidence for the effect of BoNT 
after injection in the salivary glands.
Drugs are widely used in the treatment of drooling. The anticholinergic drug scopolamine 
was chosen to serve as a reference for the effect of BoNT injections. The mode of action 
of anticholinergic agents can be understood from the fact that parasympathetic post-
ganglionic stimulation of the salivary glands, mediated by acethylcholine, is completely 
blocked at the muscarinic receptors. A systematic review has been performed to find 
evidence for the efficacy of anticholinergic drugs to treat drooling, which is described 
in chapter 2.
28 Chapter 1
In order to obtain reference data on saliva secretion a study was performed in healthy 
children. The results are described in chapter 3.
The collection of saliva from the mouth is difficult and subjected to bias especially in 
the investigation of children with severe handicaps. As described in the literature, the 
swab method has been used for investigations in healthy subjects. Chapter 4 describes 
the measurement of the salivary flow rate by the swab method in handicapped children. 
The quantification of the measurement error and biological variation are described.
The treatment of drooling by BoNT is a new challenge. As a prerequisite to start the 
present study, the injection technique for the salivary glands had to be safe and easy to 
perform. A pilot study was undertaken in order to evaluate the injection technique in 
sufficient detail, which is described in chapter 5.
In chapter 6 the first experiences with intra-glandular BoNT injections are presented, 
based on a case series.
The core of this thesis is described in the chapter 7 and 8. A detailed description of the 
physiological effect of scopolamine and BoNT on the secretory function of the salivary 
glands is described in chapter 7. The clinical relevance of the treatment modalities is 
outlined in chapter 8.
As mentioned in the introduction ‘anterior drooling’ should be distinguished from 
‘posterior drooling’. A case study is presented in chapter 9 to describe the effect of 
BoNT injections on posterior drooling. The consequences for some aspects of quality 
of life are described in chapter 10.
Chapter 11 provides the ‘general discussion’.
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Abstract
Objective: Drooling frequently occurs in children with multiple handicaps. The 
application of anticholinergic drugs is regarded as a potential strategy to treat drooling. 
The literature was studied to investigate the efficacy of anticholinergic drugs.
Design: A systematic review of the medical literature has been performed.
Setting: The study is part of a larger program investigating new options for the treatment 
of drooling, approved by the medial ethics committee of the University Hospital.
Intervention: A computer-aided search of original studies concerning the treatment 
of drooling has been carried out.  According to the rules of systematic reviews the 
methodological and statistical integrity of the identified studies were assessed with 
priori defined criteria. The articles were weighed for their separate contribution to the 
evidence synthesis.
Results: The search resulted in 64 reports of which 7 studies passed the screening and 
were subjected to further assessment and discussion by three referees. Because of 
the small number of reports and the methodological restriction within the studies, no 
meta-analysis could be performed.
Conclusion: No general conclusion can be made about the efficacy or average effect 
of anticholinergic drugs to treat drooling in children with multiple handicaps. There 
is some evidence that 3 anticholinergic drugs (Benztropine, glycopyrrolate, and 
Benzhexol hydrochloride) are effective in the treatment of drooling but it cannot be 
concluded that one drug is preferable.
Introduction
Drooling is a normal clinical manifestation of the growing child, but if it lasts after four 
years of age it is abnormal1-3. As noted in many articles, drooling occurs frequently 
in children with Cerebral Palsy (CP). There is rarely hypersalivation4 and drooling 
rather is the result of a defect in the oral phase of swallowing5. A lack of control in 
the coordinate mechanism of oro-facial, palato-lingual, and head-neck musculature 
leads to an excessive pooling of saliva in the anterior mouth3. Other factors such as 
spasticity or a decreased intra-oral tactile sensitivity predispose to drooling.
Drooling children frequently have a chronically irritated skin over the chin and the 
peri-oral region. In cool weather the dampness from saliva is chilling. The pooling of 
saliva in the oral cavity increases the risk of aspiration particularly in combination with 
gastro-esophageal reflux. There may be chronic loss of fluid and nutrients. 
Drooling is cosmetically unappealing and has a negative social effect that can be 
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detrimental to the emotional and behavioral development of the individual. The 
unsightly nature of the drooling and salivary spray when the child talks, sneezes or 
coughs can result in a degree of alienation6. Patients who are aware of the problem 
are less likely to interact with other children during normal peer activities. Drooling 
has been reported to be a significant problem in about 10% to 37,5% of patients with 
cerebral palsy2;7;8. Bachrach9 interviewed parents by means of a questionnaire that 
included questions regarding drooling. Thirty-four percent indicated it was sometimes, 
and 16% responded that it was often a problem. Caretakers often spend much time in 
suctioning and cleaning the children’s mouths and changing their clothes. Attempts 
to reduce drooling have included both invasive and non-invasive techniques10. The 
latter refers to behavioral techniques, speech therapy, oral sensory and motor training, 
orthodontic treatment11;12, anticholinergic drugs9;13-21, and (intra-ductal) radiation22;23. 
Surgical procedures include salivary gland excision24, salivary duct rerouting2;21;24-27 or 
a combination of these. Chordatympanic neurectomy has been performed to eliminate 
parasympathetic stimulation to the salivary gland28. The application of anticholinergic is 
regarded as a realistic possibility to treat drooling and many physicians are exploring the 
effect of these agents along with the prescription of physiotherapy and speech therapy, as 
the first choice of treatment9;11;13;14;16-20;29-32. In a narritive review of the literature Nunn10 
concludes that “the lack of a scientific approach to many of the studies cited makes it 
virtually impossible to conclude that any one approach is better than another”.
The objective of this study is to perform a systematic review of the literature to 
investigate the efficacy of anticholinergic drugs to treat drooling in children with 
multiple handicaps.
Material and methods
Search
Material for the review (articles about relevant studies published before June 2002) 
were identified by a systematic search in the bibliographic databases of Medline (from 
1966), Pubmed (from 1966), the Cochrane Library, and Current Contents (from 1996) 
using the keywords shown in table 2.1. The keyword “anticholinergic drug” appeared to 
be inadequate, because the studies in which the generic name for a specific drug was 
used would be excluded. The keywords were expanded by using the “explode function” 
present in Medline. References from the retrieved articles were checked. The retrieved 
articles were screened by title. If any uncertainty remained, printouts of the abstracts 
were checked.
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Table 2.1: The applied keywords for the literature search
Groups Pharmacological  Symptoms Treatment Population 
Keywords preparations
1.  Anticholinergic drug Drooling Treatment Child
2.  Anticholinergic drugs Drool* Treatments Children
3.  Anticholinergic drug* Hypersalivation Treatment* Child*
4.  Anticholinergic medication Hypersal* Intervention Infant
5.  Anticholinergic treatment Dribbling Interventions Infants
6.  Anticholinergic treatments Dribb* Intervention* Infant*
7.  Anticholinergic treatment* Sialorrhea Management Pre?school Child
8.  Cholinergic blocking Sialor* Management* Preschool Children
9.  Cholinergic blockings Ptyalism Therapy Pre?school Child*
10.  Cholinergic blocking* Ptyal* Therapy* Adolescence
11.  Cholinergic antagonist Saliva  Pediatric patient
12.  Cholinergic antagonists Saliv*  Pediatric patients
13.  Cholinergic antagonist* High salivary   Pediatric patient* 
  secretion
14.  Choline?asterase inhibitor High salivary   Juvenile 
  secretion
15.  Choline?asterase inhibitors Salivation  Juveniles
16.  Choline?asterase inhibitor* Salivary flow  Juvenil*
17.  Parasympaticolitics   
18.  Parasympaticolitica   
19.  Anti?muscarinic   
20.  Scopolamine   
21.  Scopoderm TTS   
22.  Hyosine   
23.  N-Methylscopolamine   
24.  Butylscopolammonium  
 bromide   
25.  Benztropine   
26.  Glycopyrrolate   
27.  Atropine   
28.  Pyridostigmine   
29.  Benhexolhydrochloride   
30.  Antisialorrhoic   
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Only patient related studies aimed at the treatment of drooling with anticholinergic 
drugs in multiple handicapped children and published in the English, German, Dutch, 
or French languages were included. Letters, abstract and ‘published presentations’ 
were excluded.
Table 2.2: Definitions and criteria for selection and inclusion of articles in the study
Definitions
* Child: a person up to the age of eighteen
* Drooling: “The unintentional loss of saliva from the oral cavity due to pyramidal or extra-
pyramidal impairment”
Criteria for inclusion of selected articles
* The study is patient related and aimed at the treatment of drooling with drugs
* The study has been performed as a clinical trial, cohort study, case series, case-references or 
case-control study
* The study population or relevant subgroup primarily concerns children of pre-school and 
school age
* The treatment of drooling has been evaluated with descriptions of the population (diagnosis 
and an indication of impairment and disability), the intervention and the outcome measure
* Published in the English, German, Dutch or French languages
Criteria for exclusion of selected articles
* Articles written in other languages that only provided an abstract in English
* Letters, abstract and published presentations without acceptable description of methodology, 
population and results
* Narrative reviews
Table 2.2  provides the definitions and the exact inclusion and exclusion criteria for the 
articles.  Three referees (PJ, PvT and JvL) independently analyzed all selected studies.
The publications were blinded with respect to author, source and results. Subsequently 
the level of methodological quality was assessed. The studies that passed the preliminary 
screening were subjected to a systematic review using a checklist with  priori defined 
methodological criteria. The checklist (Table 2.3) was constructed according to a 
system, originally developed for the evaluation of randomized controlled clinical trials 
(RCT’s)33-36.
Each criterion for internal validity (V1 - V7), external validity (V8 - V15) and the method 
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of data presentation (D1 - D5) was assessed and scored with a three level system: [3] 
sufficient, [2] moderate, [1] insufficient. In case a choice had to be made between sub-
items, only one of these could be filled in and the other sub-item was scored [0].
Table 2.3: Checklist for methodological evaluation of included articles
Internal validity (V1 -V7)
1 Randomization method presented
2a Homogeneity of the population at entry of the study concerning diagnosis, confounding 
factors, prognostic factors
2b Sub-group analysis done with respect to the mechanism for drooling if necessary
3  Description of a method to control for ‘adherence to therapy’
4  Description of a system for control of co-interventions (E.N.T.-surgery, behavioral therapy 
and  medication)  at entry and during the study
5  Standardized method of outcome measure fully described
6  Repeated measurements during the observation period according to a fixed protocol
7  Intention-to-treat analysis if applicable
External validity (V8 - V15)
8  Description of inclusion and exclusion criteria
9  Accurate description of the planned therapy or interventions
10  Check for co-intervention during the trial
11  Outcome rates correctly listed in the text
12  Description of relevant characteristics related to loss to follow-up and adequate 
management of dropouts
13  Presentation of the number of subjects ‘loss to follow-up’
14  Minimal follow-up period of 3 months
15  Control for side effects
Data Presentation (D1 - D5)
1  Adequate sample size
2  Presentation of the mean of the outcome measures
3  Presentation of the standard deviation of the outcome measures
4  Method of statistical analysis described in relation to the design used
5  Appropriate statistical analysis done
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This system implies a maximum sum score of 60 points for the 20 items on the 
checklist. However, some items were not applicable [NA] in view of the specific study 
design. In such a case the maximum sum score decreased accordingly.
Internal validity 
Randomization (V1) is a critical issue. The description of how randomization was 
achieved had to be made clear. It was not possible to verify whether the randomization 
procedure was actually properly executed as this is hardly ever mentioned in published 
work.
The homogeneity (V2) of the study population has been assessed. The item on 
homogeneity is subdivided into two sub-items (V2a and V2b). These items evaluate 
the comparability of the subjects within the population with respect to the underlying 
mechanism of drooling; it ought to be reflected in homogeneity for diagnosis and 
the resultant motor impairment. This item also investigates the homogeneity of the 
population under study with respect to confounding factors at entry of the study (age, 
stage of the disease, co-morbidity, and co-medication) that could influence salivary 
flow. In particular concurrent use of anticholinergic medication as well as caries, and 
peridontologic disturbances is of importance. A [3] was assigned if the population was 
well documented. In case incomplete data had been given a [2] was scored. In cases 
there was insufficient information to determine the degree of homogeneity; a [1] was 
scored. A V2a score of [2] or [3] satisfied the minimum requirements for homogeneity. 
Consequently sub-group analysis was not needed for this study and item V2b was 
scored as [0]. If V2a had a score of [1], sub-group analysis had to be performed. In case 
subgroup analysis had been carried out, the score for item V2a was transformed to 
[0].
Adherence to therapy (V3) had to be measured and indicated in the description of 
the study. Control for relevant intervention at entry and during the trial (V4) had to be 
described and to be controlled (i.e. surgery in the oral cavity, behavioral therapy and 
the application of medication aimed at reducing drooling).
A quantitative indication of the severity of drooling was always required. The accuracy 
of the applied severity or frequency scoring system was evaluated (V5).  A quantitative 
score or ratio-scale provided in absolute numbers (e.g. ml/min) was judged sufficient 
and consequently scored[3]. Semi-quantitative scores that used an ordinal scale such 
as the Teacher Drooling Scale37 are classified as moderate [2]. The use of dichotomous 
scales was considered to be insufficient [1]. Outcome measurements had to be repeated 
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at fixed intervals during a relevant period after start of the intervention (V6).
Randomized clinical trials had to meet the intention-to-treat principle (V7).
External validity
The description of inclusion and exclusion criteria for subjects (V8) in a study was 
considered to be essential. A thorough description of the planned therapy (V9) was 
obligatory. This item scored sufficient if a description was given. Co-interventions 
during the trial (V10) had to be described and the relevance with respect to the therapy 
had to be mentioned. The outcome measures such as ratio scales or the results of 
ordinary scales had to be described in the text (V11). In case the description was unclear 
or provided no meaningful information, this item was regarded as insufficient. 
The reasons for ‘lost to follow-up’ (V12) had to be given, and these cases needed to 
be managed adequately. This item also scored positive in case there were no dropouts 
during the study or if the description of the dropouts contained convincing arguments. 
The absolute number or the percentage of subjects ‘lost to follow-up’ (V13) needed to be 
mentioned. Based on the information provided, it was demanded that the percentage 
of lost to follow up could be calculated. 
The follow-up period had to be long enough (V14) to determine the usefulness of the 
anticholinergic drug treatment and possible side effects. This period was determined 
to be a minimum period of 8 weeks since it could be expected that side-effect  would be 
clear by that time. Side-effects of the therapy (V15) were regarded as a critical success 
factor. This criterion tested whether there had been sufficient control for side effects.
Data presentation 
The number of patients was judged in relation to the study design (D1). Outcome 
measurements had to be adequately reported with quantitative measures (absolute 
numbers or relative difference scores) with presentation of the Mean (D2) and Standard 
Deviation (D3).
The planned statistical analysis had to be described clearly in relation to the proposed 
research design (D4), and the article had to provide evidence the statistical analysis 
had indeed been conducted (D5). 
Results of the literature search
The primary search resulted in 64 articles. Of these retrieved articles 36 were excluded 
based on the contents of the abstract; 30 articles appeared to be irrelevant in relation to 
46 Chapter 2
the research questions of this review26;38-66. Two titles were listed twice in the primary 
search40;57.These duplicates were removed. One Japanese article was excluded67, as 
were 2 articles concerning ‘case reports19;68, and 1 narrative review1. The remaining 28 
articles were completely read. Seventeen articles without abstracts were rejected from 
the study because they were not relevant to the research questions25;69-84. One article 
was recognized as another narrative review31 and was excluded. Two articles did not 
concern children or problems related to CP29;32. One study had a retrospective design 
and was excluded9. Screening of the references of all articles did not bring up new 
articles. 
Sixty-four articles were retrieved in the primary search from which seven articles could 
be selected for further investigation.
The methodological quality of the seven selected articles was determined (Table 2.4). 
Three studies were randomized clinical trials (RCT)11;14;17, 3 were cohort studies13;18;20 
and 1 had an experimental design30.
In this review one RCT14, one study with a classical Virchow design30 and one cohort 
study18 were judged as methodologically adequate in relation to the study design 
that was used.  Two RCT17;11 and 2 cohort studies13;20 did not meet the proposed 
methodological criteria. In order to provide a complete overview of the available 
literature, these articles are also listed in table 2.4. 
For the methodological quality of the selected RCT’s the internal validity (table 4) was 
regarded as the most critical aspect, in particular homogeneity (V2). Randomization 
(V1), the ‘Intention-to treat analysis’ (V7), adherence to treatment (V3) and, the method 
of outcome measure (V5) were weighed as equally essential. Randomization and 
Intention-to-treat are items that are not applicable for cohort studies. To be qualified 
as an article with good internal validity, the studies had to satisfy the above mentioned 
criteria of internal validity with a minimum score of 12 points (out of 21) for RCT’s or 
8 points (out of 15) for cohort studies. The outcomes of the items on internal validity, 
external validity and data-presentation are listed in Table 2.4.
Three referees analyzed the selected articles. The scores for the methodological and 
statistical items were scored on prepared lists. Consensus about particular items was 
acquired by a thorough discussion. It has not been necessary to consult an other 
referee.
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Table 2.4: The methodological assessment of selected studies
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In the next section the separate articles are described with respect to the methodological 
quality and, the clinical relevance of the presented information. 
Camp-Bruno et al14 investigated the effect of Benztropine for the treatment of drooling 
in 27 subjects in a placebo controlled RCT. The scoring method of the severity and 
frequency of drooling was outlined in detail. Homogeneity of the population was rated 
insufficient because there has been no correction for age, while in the literature an 
influence of age until puberty on salivary flow has been described. Subgroup analysis 
was not performed. Control for adherence to therapy was considered sufficient. The 
criterion of the “intention to treat” principle was not satisfied. Of the 27 patients 7 
were later dropouts. In the opinion of the reviewers a percentage of 30% dropouts 
was too large. The adverse effects of three patients were described, data of the other 
four missed. The adverse effects were scored on an ordinal scale. Unfortunately the 
outcomes of the measurements were not presented. The internal validity of the study 
was good: 85,7% (18/21, meaning 18 out of a maximum of 21 points), although the 
“intention to treat” principal was not satisfied. The external validity was good: 83,3% 
(20/24), as was the way in which the data were presented: 100% (15/15). In conclusion 
this study could be used for the evidence synthesis.
The study by Bruno-Camp shows that in principal Benztropine can have a positive 
effect on drooling. On the other hand, one cannot make a statement about the average 
effect of the drug. During the study the population with 27 subjects was too small to 
compensate for a dropout percentage of almost 30%. Three of the 7 dropouts were 
certainly related to the treatment. With the results presented the question whether 
non-therapy related circumstances have influenced the outcome remains unanswered. 
A statement about the treatment and its adverse effect cannot be made because the 
study has a follow-up period of a few weeks. 
Mier et al11 performed a double-blind, cross-over study to evaluate the efficacy and 
dose-ranging of glycopyrrolate to treat drooling. For this purpose thirty nine children 
were enrolled. Randomization was not described and no information was given about 
the inclusion and exclusion criteria of the subjects. There was insufficient homogeneity 
in the population because there has been no correction for age. Sufficient information 
has been given about the mechanism of drooling, other medical conditions and, 
adherence to therapy. The criterion of the “intention to treat” principle was not 
satisfied. The scoring method of the severity and frequency of drooling was outlined in 
detail. Two dosage regimes for glycopyrrolate were used and sufficiently described. The 
results were presented in a clear way and sufficient statistical information has been 
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provided. Referring to the chosen design the number of patients included is enough to 
require adequate statistical power. The number of drop-outs (31%) is not acceptable. 
This seriously reduces the methodological value of the study in particular because the 
drop-outs appeared to be selectively related to the medication, together with the fact 
that the intention-to-treat principle was not satisfied. The score on internal validity 
was low to moderate: 52.3%, due to insufficient description of randomization and 
the study population. External validity scored 83,3% (20/24) and data presentation 
100% (15/15). Because of the score on internal validity this study could be used in the 
evidence synthesis to support primary evidence.
The authors conclude that children tolerating glycopyrrolate will demonstrate “marked 
improvement in drooling” at individual doses. Dosage guidelines are provided. In 20% 
of the cases adverse effects necessitated withdrawal of the glycopyrrolate.
Lewis et al17, investigated the effect on drooling of a trans-dermal application of 
scopolamine, in a placebo controlled RCT with a crossover design. A two-week 
period of scolamine was plotted against the same duration of placebo treatment. The 
homogeneity of the population was insufficient and no adequate subgroup analysis 
was carried out. The adherence to therapy was not described and the method of 
measurements insufficiently described. A five-level scale was used in which the 
amount of present drooling during therapy was compared to the usual situation for the 
particular patient. In this respect the patient was supposed to serve as his or her own 
control. The method was regarded as being insufficient because it was unclear how 
many people finally observed a particular child and in which way data were calculated. 
The “intention to treat” principal was not satisfied. Side effects were well documented. 
The method of statistical analysis was described in relation to the design used, but 
the analysis itself was not presented in sufficient detail. For example no means and 
standard deviations could be calculated.
Internal validity of this study was moderate: 57,1% (12/21). External validity scored 
79,2% (19/24) and data presentation 60% (9/15). The article could not be used in the 
evidence synthesis because of the low internal validity in combination with the way 
data were presented. 
The authors present a good overview of the possible side effect of scopolamine: pupil 
dilatation, dizziness, pruritus around the patch and, increased mouthing behaviors. 
One child experienced deterioration of a pre-existent refractory seizure disorder.
Owen et al30 investigated the effect of Benztropine on the salivary flow using the 
classical Virchow Design: a-b-a-b. Three patients were enrolled in this study. Salivary 
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flow was scored using an ordinal scale. A baseline period was introduced followed by a 
period of optimal dose finding. After a washout period the patient received medication 
or placebo (within-subject design). Using this design, follow-up was not required 
because it was not relevant in relation to the research question. The methodological 
quality of the study was correct. The a-b-a-b design in this case could only answer the 
question whether the salivary glands react to the application of Benztropine. From 
the results presented, one can conclude that the inter-individual variation was rather 
large. A general conclusion for a population could not be drawn because of the small 
number of patients. The study does not permit a judgment as to whether Benztropine 
is a useful therapy in the treatment of drooling in children with CP, in general. There 
was insufficient homogeneity in the population due to the great variation in age of 
the three participants. Subgroup analysis was not conducted although the diagnosis 
and potential confounders were mentioned, but in the discussion of the results 
these data were not related to a specific patient. Because of the chosen design, it 
was methodologically inadequate not to mention co-interventions. The performance 
of statistical analysis was insufficient since no information was given as to whether 
analysis was actually done. No results were reported. The internal validity score was 
moderate: 57,1% (12/21). The score on external validity was moderate: 66,6% (16/24) 
and more attention should have been paid to the data presentation: 60% (9/15). 
Because of the objective and the chosen research design this study could only be used 
as additional information to support the evidence.
The study by Owen indicates that the salivary glands would react to Benztropine with 
a positive effect on salivary flow. With the limited subjects included and the chosen 
research design, no conclusion can be made about the average effect of the drug in a 
certain population. 
Reddihough18 studied the effect of Benzhexol Hydrochloride (Artane) on drooling. 
During 3 months, 20 children 3 to 12 years of age were treated. The outcome measure 
was described in detail and well standardized. The authors provided the reader with a 
good indication how drooling was defined during the observations in a well-documented 
homogeneic population. Some criticism could be addressed to the wide spread in age 
of the participating subjects. Control for the adherence to therapy and co-intervention 
was insufficient. Inclusion and exclusion criteria were sufficiently described, as was 
the intervention. The outcome measures were listed in the text unfortunately as 
a description for the population as a whole. From the presented table with results, 
one could not conclude which data belonged to a particular patient. This might have 
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been of importance with respect to the differences in age. Results were presented as 
percentages of the median score of drooling before and during treatment. Statistical 
procedures were clearly presented. The score on internal validity was moderate: 66,6% 
(10/15) and external validity good:  75% (18/24). Data presentation scored 100% (15/15). 
The study by Reddihough, a cohort study, only provides additional information to 
support the evidence. In the evidence synthesis this study could be used as secondary 
evidence.
Following good clinical practice the problem of drooling is outlined together with the 
remark that ‘salivary flow is profuse in infancy, but decreases rapidly up to five years 
and then more gradually to puberty’. The article gives adequate information about the 
application of Benzhexol Hydrochloride and description of how the optimal dosage 
was achieved. No relation was found between the dosage and the age of the child. 
Drooling decreased in 17 out of 20 subjects. Because the study was of reasonable 
methodological quality, two conclusions are likely: a) Benzhexol Hydrochloride has a 
good effect on drooling, although the average effect remains unclear, b) the optimal 
dosage varies from 2x2mg up to 2x3 mg daily.
Blasco et al13 investigated the effect of Glycopyrrolate as a treatment for drooling in 
40 children. This was a cohort study that did not satisfy the minimal requirements for 
internal validity. The data about the homogeneity of the population were incomplete, 
no information was provided about potential confounding factors such as age, stage 
of the disease, co-morbidity, inflammation, and caries. The use of medication was 
made explicit and half of the population appeared to use a variety of drugs but no 
appropriate information was given as to whether these drugs could influence salivary 
flow. Adherence to therapy was not indicated, and the method of outcome measures 
was graded as insufficient since a dichotomous scale was used. All items for external 
validity but one were scored positive, unfortunately the outcome measures were not 
listed in the text. In the data presentation baseline measures were not mentioned. 
Internal validity scored low 40% (6/15), external validity 91,6% (22/24) and, data 
presentation 45,6% (7/15). Based on the data set presented in the article, together 
with the scores on internal validity no statement could be made about the efficacy of 
Glycopyrrolate on drooling.
Although this study cannot be used in the evidence synthesis, the information provided 
is of clinical importance. A short overview of the problem of drooling and the treatment 
possibilities were given. The use of anticholinergic drugs and in particular the dosages 
of Glycopyrrolate were presented. This is in line with the opening sentence of the 
52 Chapter 2
article in which the author stated that the objective of the study was to outline ‘the use 
of glycopyrrolate in the control of drooling in children and young adults with CP and 
related neurodevelopmental disabilities’.
In the study by Stern20 the effect of Glycopyrrolate to treat drooling was investigated 
in a population of 24 subjects. Although the mean age of the participants is given, it 
is not possible to determine whether more than 50 % of the population is under the 
age of eighteen. The outcome measures used have limitations. Parents were asked to 
complete a questionnaire ‘some time after the end of the trial’ in order to assess the 
effect of Glycopyrrolate. This uncertain time interval violated the quality of internal 
validity. The authors admit that the way, in which the questionnaires were completed, 
is open to discussion and criticism. Adherence to therapy was not described. The 
items on the inclusion and exclusion criteria, homogeneity and the performed 
intervention were satisfied.  The number of lost to follow-up was not indicated. The 
measurements before the start of the therapy were not listed in the text nor were the 
post treatment results given per patient. Insufficient insight was acquired in the effect 
of the intervention with Glycopyrrolate. Information about statistical analysis provided 
in the text was inadequate. Internal validity scored moderate: 66% (10/15), external 
validity: 75% (18/24) and, data presentation: 73,3% (11/15). As a case series the study 
could not be taken into account for ‘evidence synthesis’.
From a clinical point of view the authors provide a good overview of the mechanism 
of drooling in general and the treatment possibilities, even though this was not the 
purpose of the article. 
Evidence synthesis and discussion
Evidence synthesis
RCT’s can be considered to give primary evidence where-as cohort studies, referred 
to as pre-experimental design, can only provide additional information to support the 
outcome of the RCT’s. We performed an in-depth review of the medical literature in 
order to do a meta-analysis. Unfortunately only seven studies could be identified. In 
our review, articles subjected to a methodological assessment can be weighed for their 
contribution to the “evidence” that the application of anticholinergic drugs is indeed 
effective in the treatment of drooling. For the methodological quality of the selected 
RCT’s the internal validity (Table 2.4) was regarded as the most critical aspect.
The RCT by Camp-Bruno14 acquired sufficient points on internal validity even though 
the item ‘the intention to treat’ was graded as insufficient, but the methodological 
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assessment scores of [3] for randomization (V1) and homogeneity (V2a) compensated 
for the this. The other RCT’s11;17 did not satisfy the criteria for internal validity. Mier 
et al did not describe randomization and inclusion criteria and consequently scored 
moderate on internal validity. In conclusion 1 RCT can be weighed as a “high grade 
evidence”14 study, 1 as “moderate grade evidence”11, and 1 as a “low grade evidence” 
study17. In relation to the objective of this study the RCT by Camp-Bruno contributes 
most to the evidence. The experimental study with the Virchow design30 scored 12 out 
of 12 possible points on internal validity. Although not a RCT this study was judged to 
provide additional information to the primary evidence.
The cohort study by Reddihough18 was considered to be a “moderate informative” 
study. The other two cohort studies by Blasco and Stern13;20 were regarded as “less 
informative”.
Discussion
For many clinicians the application of anticholinergic drugs is regarded as a realistic 
possibility to treat drooling and is the first choice therapy. This systematic review 
investigated the literature for evidence of the effectiveness of anticholinergic drugs 
in the treatment of drooling in children with multiple handicaps. An overall problem 
in the studies found is that no single method of measurement of salivary flow and 
outcome presentation is available. We endorse the plea for the development of a 
‘golden standard’1. Another problem is that in the selected studies that no drug has 
been repeatedly evaluated. As an outcome of our study no statement can be made 
about the long-term effects of anticholinergic drug therapy because non of the studies 
describe a follow-up period greater than a few weeks. Adverse effects were reported in 
all studies. Only one study provided precise information to what extend side effects 
necessitate to end the therapy11. Frequently reported side effects comprise: irritability, 
restlessness and over-activity, disorientation, marked pupil dilatation, and constipation. 
Other, less frequently reported side effects are insomnia, headaches, epileptic seizures, 
vomiting, difficulty in initiating micturation, dry mouth and lips,  ‘picking and grasping’ 
movements, and epistaxis.
From the articles by Camp-Bruno and Owen, one can conclude that a daily dosage 
of 3 mg to approximately 3.8 mg Benztropine should be effective in the treatment of 
drooling. This implies that Benztropine could be used in the treatment of drooling, 
although, adverse effects should be thoroughly controlled and no indication of long-
term effects can be given. Reddihough provided additional information to support the 
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evidence of the effectiveness of anticholinergic drugs. A significant reduction in the 
mean score for drooling was found with a dosage Benzhexol Hydrochloride varying 
from 2x2mg up to 2x3 mg daily. Mier et al provided support for the primary evidence of 
the efficacy of anticholinergic drugs. They conclude a marked reduction of drooling in 
cases Glycopyrrolate was tolerated.
Conclusion
The objective of this study was to investigate the efficacy of anticholinergic drugs 
to treat drooling in children with multiple handicaps. We performed an in-depth 
systematic review of the medical literature in order to do a meta-analysis. Unfortunately 
only seven studies could be identified. Due to the methodological drawbacks within 
the studies, no general conclusion can be made about the efficacy or average effect 
of anticholinergic drugs to treat drooling in children with multiple handicaps. Future 
uniformity in measurements can help the interpretation of outcomes. Further research 
in larger populations with a longer follow-up period should be encouraged. Based on 
our study there is some evidence that at least 3 anticholinergic drugs (Benztropine, 
glycopyrrolate, and Benzhexol hydrochloride) are effective in the treatment of drooling 
but it cannot be concluded that one anticholinergic drug is preferable above the other. 
Because of the small number of reports and the methodological restriction within the 
studies, no meta-analysis could be performed.
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Abstract
Objective: To obtain reference data on the unstimulated salivary flow rate in healthy 
6 - 11-year-old boys and girls, for use in the treatment of drooling in mentally and 
physically handicapped children.
Methods: Under standard conditions unstimulated saliva was collected from 62 healthy 
children using the swab method. Flow rate was determined by calculating the increase 
in weight of cotton rolls placed in the mouth for 5 min. The influence of the variables 
age, gender and type of gland were evaluated.
Results: No significant difference was found between the flow rate in boys and girls or 
among the children in this age window. The swab method showed good reproducibility. 
The right and left parotid glands had equal flow rates of 0.15 mL/min. The flow rate 
in the floor of the mouth secreted by the submandibular and sublingual glands was 
0.32 mL/min. Conclusions: age and gender did not influence salivary flow rate and 
therefore needed not to be taken in consideration when measuring salivary flow rate 
in healthy children 6-11 years of age. The swab method appeared to be reliable, easy to 
carry out and well-tolerated by the group of school children that was studied.
Introduction
Accurate measurements of salivary flow rate (sialometry) are required in clinical and 
experimental protocols, for example to monitor the treatment of drooling. In people 
with neurological dysfunction drooling primarily appears to result from inadequate 
swallowing and lip-closure due to dysfunctional oral motor activity, and rarely from the 
excessive secretion of saliva1. 
Parotid gland secretion rates can be measured by intra-oral cannulation of Stenson’s 
duct or by using a Lashley cup or Schneyer’s device2,3. Measurements of the other 
major and minor salivary gland flow rates are not performed routinely because of their 
relative inaccessibility, although some devices have been described4-7. Techniques 
for measuring whole saliva are usually based on draining into a receptable (draining 
method), collection by aspiration (spitting method) or measuring the increase in weight 
of an absorbent material that is chewed or placed in the mouth (swab method)8. The 
latter method also enables evaluation of the functional status of the individual glands 
when the cotton rolls are placed at the glands’ orifices. 
Salivary flow rates can be measured under unstimulated or stimulated conditions. A 
range of stimuli can influence salivary flow; gustatory and masticatory stimuli are used 
most commonly. Unstimulated salivary flow is the flow that occurs in the absence of 
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any obvious stimulation. The swab method has proved to be a highly reproducible, non-
invasive and convenient method, even for the measurement of gustatory stimulated 
flow rates9.
It is important to be aware of the many factors that can influence salivary flow rate, in 
order to keep the sampling procedure as standardized as possible. Variables that may 
influence flow rate are medication, circadian rhythms10, prestimulation11, gender12-15, 
age10,12-15, gland size16,17, psychological effects18, and health30.  
Measuring salivary flow rates in young children or physically or mentally handicapped 
persons is a challenge. Little has been published about the applicability of the different 
methods to these groups. Unstimulated whole saliva flow rates measured with the 
draining or spitting method are thought to be unreliable in children of younger than 10 
years of age, as these methods depend on the full co-operation of the child who has 
to sit still for quite some time14,20. No research has been done into unstimulated flow 
rates with the swab method in children. 
Measuring flow rates in physically or mentally handicapped children is usually 
performed to quantify the drool volume. Non-invasive methods involve weighing 
drooled saliva collected either on a bib or in a plastic bag attached to the subject’s 
chin21. Evaporation of saliva over the collection period is not taken into consideration 
and it can be difficult to achieve effective adherence of tape to a damp chin. Another 
method is to count the number of bibs or changes of clothing a subject undergoes 
during a given period of time. However, the decision and timing of when to change a bib 
or clothing is difficult to standardise. Sochaniwkyj developed an individually-adjusted 
collection device that is held against the subject’s chin by elastic straps attached to 
an orthodontic head bonnet. This system is unable to collect highly viscous saliva or 
saliva that does not fall from the lips into the collection system; consequently, such 
secretions will not be measured22. Apart from direct contact methods using devices, 
an observation method was proposed by Rapp to evaluate leaked saliva. He described 
the ‘Drooling Quotient’ to obtain quantitative measures of the percentage of drooling 
in time-sampling observations23.
To our knowledge, the swab method has not been used in the evaluation of drooling 
in mentally and physically handicapped children. We performed a study to evaluate 
salivary flow rate in healthy primary schoolchildren using the swab method. The aim 
of the study was to obtain reliable reference data on normal salivary flow rate in boys 
and girls ranging in age from 6 to 11 years, for use in the treatment of drooling. The 
influences of age and gender on salivary flow rates were investigated. 
 Salivation in healthy schoolchildren 67
Materials and methods
Subjects
Sixty-two healthy children were recruited from two primary schools. The population 
comprised 34 boys and 28 girls, ranging in age from six to 11 years. Levene’s test 
for Equality of Variances showed equal distribution of age (t=-0.67; df=60;p=0.51) 
in the boys (mean age 8.03 years, SD 1.83) and the girls (mean age 8.32 years, SD 
1.54). Subjects taking medication that would influence the quantity and quality of the 
salivary secretion were excluded. None of the children reported complaints suggestive 
of salivary gland dysfunction or displayed evidence of intra-oral soft tissue disease. The 
parents gave informed consent. 
Salivary Collection Method
Saliva was collected under standardized conditions according to the method described 
by Poth24. Three dental cotton rolls, of exact known weight, were placed in the mouth 
that had previously been dried with sterile gauze. One roll was placed under the tongue 
at the orifices of the ducts of the sublingual and submandibular gland, while the other 
two rolls were placed in the upper vestibules at the opening of each parotid gland duct. 
The children were asked not to chew on the cotton rolls. At the end of a 5- minute 
collection period, the cotton rolls were removed and immediately weighed. A duplicate 
of the test was performed after a 15-minute interval. Unstimulated salivary flow rates 
were calculated in mL/min for the right parotid, left parotid and submandibular plus 
sublingual glands. As the Specific Gravity of saliva is 1.0 volume and weight were used 
interchangeably. 
The cotton roll placed in the floor of the mouth absorbed the secretion of the two 
submandibular and sublingual glands. The sublingual glands are known to contribute 
about 5% of the saliva. Using this method, sublingual and submandibular salivas were 
collected together and are referred to as the submandibular flow rate. To control for 
diurnal and inter-examiner variation, all samples were collected in the morning by the 
same examiner, after a 1 h fast from food or drinks.  
Statistical Analysis
Between-variable correlations were tested: flow rate versus age, flow rate versus gender, 
right parotid versus left parotid flow rate, parotid versus submandibular flow rate. Test-
retest reliability was calculated. Statistical analyses were performed using (One-way) 
ANOVA’s or paired t-tests.
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Results
All the children could easily perform the test and no one had to be withdrawn from 
the study. For technical reasons, only one measurement was performed in two of the 
6 year-olds. 
Addition of the left parotid, right parotid and submandibular flow rates resulted in the 
whole saliva flow rate. The flow rates of unstimulated saliva per age group for each 
gland are shown in Table 3.1.
Table 3.1: Mean unstimulated salivary flow rate (ml/min) per age group
Gland  Age in years (number of subjects)
 6 (n=10) 7 (n=14) 8 (n=10) 9 (n=10) 10 (n=10) 11 (n=6)
SM 0.32 0.34 0.30 0.31 0.36 0.30
Par R 0.22 0.14 0.14 0.12 0.20 0.12
Par L 0.25 0.13 0.13 0.12 0.18 0.12
Whole  0.78 0.60 0.57 0.55 0.74 0.54
SM= submandibular (i.e. flow rate of right and left submandibular and sublingual glands),  
Par R= right parotid, Par L= left parotid, Whole= whole saliva 
Gender
The mean whole saliva flow rate obtained during the first measurement, rated 0.69 
mL/min (range 0.22-1.26 mL/min; SD = 0.32) for the boys (N = 33) and 0.54 mL/min 
(range 0.14- 1.30 mL/min; SD = 0.30)for the girls (N = 28). No significant differences 
excited between the flow rates of boys and girls during the first measurement (One-
way ANOVA: F = 3.12; df = 1,59; p = 0.08),  This was confirmed in the whole saliva flow 
rates during the second measurement (F = 0.64; df = 1,59; p = 0.43).
Age
Comparison of the mean unstimulated whole saliva flow rates between age groups did 
not reveal any significant differences (ANOVA: first measurement F = 0.29; df = 1,59; 
p = 0.60, second measurement F = 1.83; df = 1,59; p = 0.18). In addition, there were no 
age-related differences between the flow rates of the right parotid (F = 1.21; df = 6,53; 
p = 0.32) and left parotid gland (F = 2.03; df = 6,53; p = 0.08). Further analysis of the 
different age groups according to the Duncann procedure (post hoc test), again, did 
not reveal any significant differences.   
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Test-Retest reliability
The mean values of the whole salivary flow rates obtained during the first and second 
measurements were not significantly different. Test-retest reliabilities after comparing 
the results of the two collection samples were, however, significant for all three glands 
(Table 3.2). 
Right versus left parotid values
There appeared to be no significant difference in mean flow rate between the right and 
the left parotid glands (paired samples test: t = -0.117; df = 60; p = 0.91, correlation 
0.84). 
Table 3.2: Test-Retest reliability
Gland 1st measurement 2nd measurement Correlation Significance 
 (ml/min) ± SD (ml/min) ± SD 
SM 0.31 ± 0.12 0.33 ± 0.11 0.72 t=-1.5; df=59; p=0.15
Par R 0.15 ± 0.13 0.16 ± 0.12 0.75 t=-1.023; df=59; p=0.31
Par L 0.16  ±0.11 0.15 ± 0.13 0.81 t=0.38; df=59; p=0.70
Whole 0.62  ± 0.32 0.65 ± 0.31 0.83 t=-1.14; df=59; p=0.26
Correlation between the first and second measurement, Significance of the difference between the two 
measurements calculated with a paired t-test. 
SM= submandibular (i.e. flow rate of right and left submandibular and sublingual glands), Par R= right 
parotid, Par L= left parotid, Whole= whole saliva.
Parotid versus submandibular flow rate
There was a high correlation (first measurement: 0.54, second measurement: 0.66) 
between the combined flow rates of the right and left parotid gland (0.31 mL/min; SD 
= 0.24) and the submandibular flow rate (0.31 mL/min; SD = 0.12). Subjects with a 
higher parotid flow rate also demonstrated a higher submandibular flow rate. 
Discussion
The level of unstimulated parotid, submandibular and whole saliva flow rates were 
independent of gender or age. These results are in accordance with those of Andersson 
whose unstimulated whole saliva was of the same order in boys and girls of 10 years 
old, whereas 13-year-old boys had higher flow rates than girls14. Shannon & Feller did 
not find any significant differences in unstimulated parotid flow rates between boys and 
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girls ranging from 3 to 16 years12. In contrast, Lopez established a sex-related difference 
in unstimulated whole saliva flow rate: males, aged 5 - 77 years, had higher flow rates 
than females of the same age. Comparison with the present study is impossible, 
because of the extremely wide age distribution of the participating persons25. It has 
been suggested that the lower flow rates in females can be explained by to the smaller 
size of their salivary glands15. However, no representative material for comparison with 
respect to the salivary gland size in children is available in the literature. Our results 
showed that in the treatment of drooling until puberty, no gender effect has to be taken 
into consideration. 
In this study, no age-related decline or increase was noted in the unstimulated salivary 
flow of boys and girls between 6 to 11 years of age, although a relatively high flow rate 
was found in the 10-year-olds (Table 3.1). It is unclear why a larger number of the 10 
year-olds had whole saliva flow rates of more than 1 mL/min compared to the other 
age groups. Reviewing the test diary revealed that one of these children had lost a 
molar 1 day prior to the measurement, one was suffering from a clinically non-relevant 
common cold, and two children were shedding their teeth; the latter was a common 
feature in all the age groups. 
Andersson measured equal unstimulated whole saliva flow rate in 10 and 12-year-olds 
and Kavanagh in 12 and 13-year-old children13,14. Andersson compared the flow rates of 
children to those of adults using the spitting method. In agreement with Lourie (1943) 
he suggested general high salivary activity in children of school age that decreased with 
increasing age due to maturation of the autonomic nervous system. However, Becks 
and Shannon & Feller found that unstimulated parotid flow rate increased significantly 
with increasing age in children ranging from 3 to 16 years12. This is in contrast with 
our findings. No other reports have been published on the unstimulated salivary flow 
rate in children of comparable age to those in the present study. According to our 
results age is not an important factor when measuring salivary flow rate up to the age 
of puberty.
The swab method applied in this study to determine salivary flow rate showed good 
reproducibility and reliability, independent of age or gender in boys and girls aged from 
6 years and onwards. All the individuals were able to complete the procedure. In some 
cases the collection period had to be limited to 4 min, because the cotton rolls were no 
longer tolerated. Three children reported transient cramp in their cheek. 
In conclusion, the swab method was reproducible, easy to carry out and well-tolerated, 
even in a group of well-instructed 6-year-old children. In the case of a small oral cavity, 
we recommend to reduce the size of the cotton rolls. 
 Salivation in healthy schoolchildren 71
Reproducibility was not effected by age, gender or the type of salivary gland. Although it 
was easier to position the two cotton rolls in the buccal cavity than the one sublingual, 
and the former seemed to stay in place better during the 5-minute collection period, 
the flow rates at the different sites were equally reproducible.
Subjects with a higher parotid flow rate also had a higher submandibular flow rate. An 
increase in parotid flow rate caused by chewing on the cotton rolls can be ignored as a 
source of methodological error, because chewing does not stimulate the submandibular 
glands. 
Other authors found higher flow rate values during the second testing session11,14,15. 
They believed that the children were more familiar with the procedure, which led to 
better co-operation and diminished negative influence of stress on the secretion rate. 
In this study, although we found some variation between the first and second testing 
sessions, there were no significant differences. This is in accordance with the study by 
Crossner10.
The unstimulated whole saliva flow rates obtained using the present set-up were 
somewhat higher than those measured with various methods that have been published 
over the past 50 years (Table 3.3). Differences between the present values and those 
reported by others can be explained by the dissimilarity in subjects, collection 
conditions and devices. Comparing the research using the swab method, only Lopez’ 
study comprises, besides adults, children of the same age as the present study does. 
The low values found in that study may have been due to the participation of seniors 
and the fact that the subjects kept their eyes closed during sampling to avoid the 
influence of visual stimuli.
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Table 3.3: Unstimulated whole salivary flow rate 
Author Method N Age Gender Flow rate  
     (mL/min)
Becks (1939) ND 40 9-48 M+F 0.22-0.66
Becks & Wainwright (1943) ND 661 5-95 M+F 0.25-0.40
Peck (1958) swab 16 adults M 1.42 
    F 1.29
Andersson (1972) spitting 296 10 47 M / 53 F 0.39 / 0.38 
   13 47 M / 49 F 0.46 / 0.33
Dawes (1973) draining 7 adults M+F 0.46
Gutman (1974) spitting 22 6-76 M+F 0.09-0.96
Navazesh & Christensen draining 17 18-32 M+F 0.47 
(1982) spitting    0.47 
 suction    0.54 
 swab    0.52
Heintze et al. (1984) draining 629 15-74 M / F 0.36 / 0.26
Ben-Aryeh et al. (1984) spitting 31 26 M + F 0.47 
  30 69 M + F 0.29
Percival et al. (1994) spitting 116 20-80 M / F 0.50 / 0.33
Watanabe et al. (1995) draining 30 5 M + F 0.26
Lopez (1996) draining 159 5-77 M + F 0.23 
 swab    0.31
Kavanagh et al. (1998) draining 43 12-13 M + F 0.46-0.82
Present study  swab 60 6-11 M + F 0.46
M= male, F= female, ND= not described
Our unstimulated parotid flow rates were higher than those reported in the literature 
(Table 3.4).  Shannon & Feller were the only authors who measured unstimulated 
parotid flow rate in children using a collection cup; they found flow rates of 0.03-
0.04 mL/min12. Perhaps the swab method used in our study stimulated the parotid 
glands through oral tactile stimuli by the examiner or chewing on the cotton rolls by 
the subject, although manipulation of the oral musculature was prevented as much as 
possible and the subjects were instructed not to chew on the foreign object placed in 
their mouth.
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Table 3.4: Unstimulated parotid flow rate
Author Method N Age Flow rate (ml/min)
Shannon (1967) ND 4589 17-22  0.04
Dawes & Chebib (1972) Lashley cup 31 young adults 0.05-0.07
Dawes (1973) Lashley cup 7 adults 0.07
Dawes (1975) ND 9 adults 0.04-0.06
Shannon & Feller (1979) Cup 33 3- 6   0.03  
  54 7 - 8 0.03 
  64 9 - 10 0.04 
  56 11-16 0.04 
Heft & Baum (1984) Carlson- Crittenden cup 85 23-81 0.04-0.06
Moret et al. (1993) Curby collection device 30 19-25 0.10
Present study  Swab method 60 6-11 0.15
ND= not described
When we compared our results to the stimulated parotid flow rate described in the 
literature, our finding of 0.15 mL/min was much lower (Table 3.5). Thus it can be 
concluded that the swab method causes little or no stimulation. With higher parotid 
flow rates, the proportional contribution of the parotid glands to whole saliva volumes 
increases. In this study the parotids accounted for 50% of the unstimulated whole 
saliva, whereas others mentioned 21% to 26%26,27. Malpani used a non-invasive 
scintigraphic method to quantify unstimulated secretions from individual salivary 
glands and found the fractional output rate of the submandibular glands to be three 
times higher than that of the parotid glands28. Thus our results imply that the parotid 
glands made a relatively higher contribution to the whole saliva. An explanation for this 
dissimilarity might be the presence of remnant saliva in the floor of the mouth after 
removal of the cotton swab.
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Table 3.5: Stimulated parotid flow rate
Author Method N Age Flow rate (ml/min)
Ferguson et al. (1973) Lashley cup 27 adults 1.22
Shannon et al. (1974) ND 368 17-22  1.01
Dawes et al. (1978) ND 30 19-39 0.25-0.98
Ahlner & Lind (1983) swab method 150 15-80 Par R: 1.28 
    Par L: 1.32
Baum (1981) Carlson- Crittenden cup 208 23-88 0.71-0.96
Heft & Baum (1984) Carlson- Crittenden cup 85 23-81 0.62-0.84
Nederfors & Dahlof (1993) Carlson- Crittenden cup 29 29-43 1.50
Percival et al (1994) Lashley cup 116 20-80 0.59 (M)/ 0.45 (F)
M= male, F= female, Par R= right parotid gland, Par L= left parotid gland
Copious secretions can overflow the swabs. Measured secretions would then be 
underestimated, because of saliva losses. This was observed in only four children. To 
avoid overflow in patients examined on the suspicion of hypersalivation, the collection 
period can be reduced.  Still, our finding of 0.32 mL/min for both the submandibular 
glands (and sublingual glands) is similar to those reported in other research in which the 
flow rates of both, or only one submandibular gland are measured in adults (Table 3.6).
The subjects investigated by Sheebny, Enfors and Malpani were adults26-28. In children, 
the parotid glands in the unstimulated condition may be more highly active than in 
adults. 
Measuring salivary flow rate with a Lashley cup is a very precise method that can 
easily be carried out by a co-operative patient. Unfortunately, it is of no practical 
use for young children, or especially for the mentally and physically handicapped. In 
conclusion, the swab method proved to be reliable, well-tolerated by young children 
and suitable for use in a clinical setting. However, possible oral stimulation must be 
taken into consideration, which might impede comparison with results obtained with 
other methods. This study showed that the variables age and gender do not influence 
the salivary flow rate in a group of healthy 6 to 11-year-old children.
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Table 3.6: Unstimulated submandibular / sublingual flow rate
Author Method N age  Flow rate (ml/min)
Schneyer (1955) device which  ND young adults  0.15 M 
 separately collects SM  
 (right + left) and SL saliva 
Enfors (1962) Device 54 20-59 0.10
Dawes (1975) Device 9 young adults 0.16
Pedersen et al. (1985) device using suction 58 18-35  0.07 M/ 0.05 F 
 with micropipette  >66  0.01
Coudert et al. (1986) device with two collection  34 adults 0.16 
 cups and vacuum system
Tylenda et al. (1988) device using suction with  90 26-39 0.15 M/ 0.21 F 
 micropipette  40-59 0.23 M/ 0.12 F 
   >60 0.13 M/ 0.15 F
Oliveby et al. (1989) silicone device 5 26-38  0.11
Atkinson et al. (1990) Device 298 22-72   0.11 F
Ship et al. (1991) Device 102 20-90   0.11 M/ 0.10 F
Moret (1993) Coudert’s device 30 19-25  0.25
Wolff et al. (1997) device using suction 10 25-81  0.17  
 with vacuum pump
Truelove et al. (1967) Device 25 5-32  ND
Ferguson (1974) Truelove’s device 15 adults 0.26
Present study swab method 60 6-11 0.32
Research under market line measured flow rate of both submandibular glands. Above the market line only 
one gland is measured.  
M= male, F= female, ND= not described, SM= submandibular gland, SL= sublingual gland
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Abstract
Objective: to investigate the applicability of the swab method in the measurement 
of salivary flow rate in multiple handicapped drooling children; to quantify the 
measurement error of the procedure and the biological variation in the population. 
Study design: cohort study. Methods: in a repeated measurements design, baseline 
series of salivary flow rates were obtained from 45 children. The within-subject 
standard deviation (SW) was calculated to express the measurements error according 
to a procedure introduced by Bland and Altman. Results: 224 samples (mean=0.40 
ml/min., SD=0.19 ml/min.) were obtained and analyzed. The results of this study 
indicate that consistent scores were obtained at subsequent measurements and good 
parity existed between the two measurements of salivary flow rate at each session. 
The SW could be estimated (0.11 mL/min), which was applied to quantify the specific 
variation of the salivary flow rate in our population. Conclusion:  according to Bland 
and Altman, the within-subjects standard deviation (SW), being a quantification of the 
measurement error and biological variation, was found to be a useful tool to evaluate 
the obtained baseline salivary-flow rate measurements. The swab method can well 
be used to evaluate salivary flow rates in drooling children with cerebral palsy, during 
interventional studies that aim to reduce the saliva production.
Introduction
Drooling in multiple handicapped children is predominately caused by a disturbance in 
oral motor control1. It is generally accepted that handicapped children do not produce 
a greater amount of saliva compared to healthy subjects. The evaluation of drooling 
is difficult, because saliva secretion varies from moment to moment within a subject. 
Besides, the level of salivary flow at which a person demonstrates drooling, may differ 
among patients.
Rating scales are used to investigate the severity and frequency of drooling. The 
Teacher drooling scale (TDS), the drooling severity scale, and the drooling frequency 
scale are examples (Table 4.1)2;3. Visual analogue scales (VAS), which investigate the 
parents’ opinion, are also applied4. The Drooling Quotient (DQ) is a semi-quantitative 
observational method (expressed as a percentage) comprising two 15-minute periods 
of observation separated by a 30-minute break5;6. In terms of objectivity, the cannulation 
of the salivary ducts is referred to as the ‘gold standard’7. 
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Table 4.1: Drooling Rating Scales 
Scale Teacher Drooling scale# Drooling Severity Scale Drooling Frequency scale
1 No Drooling Never drools  Never drools 
  Dry 
2 Infrequent drooling Mild Occasionally drools 
 Small amount Only lips wet 
3 Occasional drooling Moderate Frequently drools 
 Intermittent all day Wet on lips and chin 
4 Frequent drooling Severe Constantly drools 
 But not profuse Clothing becomes wet 
5 Constant drooling Profuse 
 Always wet Clothing, hands, tray and  
  objects become wet 
#Thomas-Stonell N, Greenberg J. Dysphagia: 1988.
During this direct investigation technique, parotid secretion is collected by using special 
devices that cover the orifices of Stenson’s ducts. These procedures have serious 
practical limitations in non-cooperative subjects. Direct flow rate measurements from 
other major and minor salivary glands are not routinely performed because of their 
relative inaccessibility. Weighing of bibs in which spilled saliva has been collected, is 
also described8. The application of functional salivary gland imaging, using technetium 
scanning, has been suggested7. The exposure of young patients to radiation has to be 
carefully weighed and is probably contra-indicated for a non-life threatening condition 
like drooling.
In sialometry dental cotton rolls can be used, placed at the orifices of the ducts of the 
salivary glands9. The outcome of this swab method is the increase in weight of the 
absorbent material in a fixed time interval, transformed to either g/min. or mL/min. 
The swab method has proved to be a highly reproducible, non-invasive and convenient 
method even to measure gustatory stimulated flow rates10. The swab method can be 
applied to evaluate the salivary flow in a population under varying conditions (e.g. 
stimulated versus unstimulated saliva production). So far the observations were 
mainly conducted in healthy adult subjects11.
The magnitude of the measurement error, introduced during the swab method, 
is influenced by the biological variation of saliva production within the subject and 
between subjects. In addition, the measurement procedure itself will cause variation 
despite its standardization for example by creating an oral stimulus when inserting the 
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dental rolls. Measuring salivary flow rates in physically or mentally disabled children 
remains a challenge. In particular, this is true for a group of drooling children.
In principle, the results of therapies that aim to reduce the salivary flow (anticholinergic 
drugs and Botulinum toxin) can be evaluated by the swab method. However, application 
of the procedure has its limitations. In the event surgery is executed, such as the 
rerouting of Wharton’s duct, the swab method is useless because after the operation 
there is no orifice left to place the cotton roll.
To our knowledge there are no decisive data about the applicability of the swab method 
for multiple disabled children. In recent literature some preliminary reports have been 
published on this subject7;12. The objective of this article is to present data of repeated 
salivary flow measurements from the submandibular glands, using the swab method, 
in a population of drooling children with cerebral palsy (CP). The measurement error 
and biological variation in the population will be quantified by the within-subjects 
standard deviation (SW), according to the method designed by Bland and Altman. 
Clinicians would be able to use this specific information to evaluate the results of 
interventions undertaken to treat drooling in a group of handicapped children.
Patients and method
Patients
A score of 3 or higher on the TDS (Table 4.1) was demanded for children to be enrolled 
in the study.  
Forty-five children were included; 28 male; 17 female; age 3-16 years (mean 9.5, SD 
3.7). All entered a qualification period in which inclusion and exclusion criteria were 
assessed (Table 1.3). 
Eight were ambulant without aid; 37 had wheelchairs; 22 could not talk; 29 attended 
a special education school; 14 went to a daycare center for mentally handicapped 
children. 
Repeated measurements of salivary flow are reported in this study.
Procedures
For all children, salivary flow measurement sessions were scheduled with an interval 
of several days. At each session, 2 repeated measurements of salivary flow rate, 
separated by a 30-minute interval were carried out. In this manner, 3 or 4 pairs of 
repeated measurements were obtained from each child. Patients were evaluated in the 
morning, at least one hour after a meal, while they were awake and were positioned 
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erect. Prior to the assessment the mouth was cleaned and dried by gauze. Using the 
swab method, dental cotton rolls (Salivette®, Sarstedt BV, Etten-Leur, The Netherlands) 
were positioned at the orifices of the ducts of all major salivary glands, in order to collect 
saliva from the left parotid and right parotid (Stenson’s duct), the submandibular 
glands (Wharton’s duct), and the sublingual glands. The dental rolls were placed in a 
fixed order as quick as possible, starting in the upper region of the mouth. The endings 
of the Stenson ducts were covered to prevent saliva from leaking into lower parts 
of the oral cavity. In this way saliva was obtained separately from the different oral 
regions. The submandibular and sublingual ducts have a close anatomical relation 
so that separate measurements could not be obtained. The compound measurement 
of these glands is simply referred to as submandibular salivary flow (SubFl). During 
a 3 to 5-minute period, the cotton rolls absorbed sufficient saliva so that an increase 
in weight could be measured and the rolls were not over-saturated. The rolls were 
weighed before and after the procedure using an electronic device that was sensitive 
to 0.01 gram.
We scored the physical condition of each patient at all measurement moments in 
relation to flu, and oral or airway pathology. These conditions can influence saliva 
production and are regarded as ‘confounders’. The remarks made by the speech 
therapist were checked with respect to the child’s condition. Based on these findings 
some data were marked as ‘outliers’. These data (explained outliers) were eliminated 
from the database.
Analysis
Analysis of data was restricted to the submandibular flow rates. It is generally accepted 
that the submandibular glands produce 60 - 70% of the secreted saliva at rest, meaning 
that one does neither eat nor drink.
If parity existed between subsequent measurements using the swab method, the 
difference between these two measurements is expected to be approximately zero 
irrespective of the magnitude of the measurements. A rank correlation (Kendall’s tau) 
was calculated to assure that the spread of the differences of pairs of observation could 
be regarded as a non-systematic (random) process. To use the procedure as suggested 
by Bland and Altman, it was required that the variation of differences was independent 
of the magnitude of the mean. To visualize this, scatter diagrams were plotted of the 
absolute values of the difference against the mean of these scores.  In this way, it was 
determined whether or not only random error was found in the data.
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As mentioned above, the differences of pairs of observations in one patient should 
be zero. This is also true for the mean differences of the group. If the mean difference 
(all patients of a certain measurement moment) is significantly different from zero, 
we would not be able to use the data. We therefore calculated the mean within-subject 
difference for all patients at each session. 
The method, described by Bland and Altman, to quantify the measurement error by the 
use of a repeated measures design was applied13;14. 
Central in this concept is the within-subject standard deviation (SW) calculated as:
 i=N
 SW:√Σ  (d2)
  i=1 N
In this formula d2 (the square of the standard deviations) actually represents the 
variance of the scores and d2/N is in fact the mean within-subject variance15. The 
mean within-subjects variance can be calculated using a one-way ANOVA (available in 
various computer programs) to determine the ‘residual mean square’. The SW, in turn, 
is calculated by taking the square root.
Results
Of all observations, 22 were identified as explained outliers13. Thirteen of these 22 
outliers were taken during the first session and were produced by 22% of the patients. 
Considering the remarks made by the speech therapist, the first session seemed to be 
influenced by factors as anxiety and uncontrollable intra-oral sensory stimuli resulting 
in refusal to allow the dental rolls to be placed. The first session most likely should be 
regarded as a learning curve. Patients refusing the dental rolls during the first session 
did cooperate fully in the following sessions. Therefore, the data of the 2nd, 3rd and 
4th sessions are regarded as the most representative data and were used for further 
analysis.
The means and standard deviation of SubFl at the separate session are shown in 
Fig. 4.1 and tabulated in Table 4.2. It was concluded that the calculated means of the 
salivary flow rates were in the same range during the entire study.
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Figure 4.1: Mean submandibular flow at each measurement
The remaining 9 of the 22 outliers, produced by 5 children, were randomly spread. On 
one occasion the parents of the child reported fatigue because of exhausting school 
activities the same morning, one child had an epileptic seizure the day before the 
assessment, one child had a cold, one child liked to chew on the dental rolls possibly 
influencing the outcome, and the last child liked to chew on the rolls but also had a 
cold. These conditions were assumed to explain the deviation in sufficient detail.
Table 4.2: Mean submandibular flow at each measurement
Session*  2;1 2;2 3;1 3;2 4;1 4;2  Overall
Mean  .39 .36 .41 .39 .46 .40  .40
SD  .16 .17 .21 .19 .25 .23  .19
*Number indicating session and measurement
After discounting the first session and eliminating the outliers mentioned above, 224 
samples remained for further analysis (mean=0.40 ml/min., SD=0.19 ml/min, table 
4.2).
To determine SW the first step of the Bland and Altman procedure was taken. Off all 
pairs of salivary flow measurements, the within-subject differences between the two 
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measurements at each session were calculated and graphically depicted. Figure 4.2 is 
the scatter diagram of the second session with the separate within-subject differences 
of each patient plotted against the mean of the two scores13-15.
Figure 4.2: Within-subject differences against the mean (2nd measurement session)
Values below zero occurred in cases the second measurement was higher than the 
first. With the exception of two cases, most differences were clustered around zero. The 
estimated rank correlation showed no significant relation between the magnitude of 
the mean and the differences of the SubFl values (Kendall’s tau 0.41; non-significant). 
From this, it was concluded that the spread of the differences of pairs of observation 
could be regarded as a non-systematic (random) process.
In addition, the mean difference for each of the four sessions was calculated (range 
0.01 to 0.05 mL/min). The result supported the fact that the differences of repeated 
SubFl measurements of all patients at one particular session approximated zero. 
The above-mentioned steps were needed to allow calculation of the within-subjects 
standard deviation.
Using a computer aided ANOVA, the SW for the sessions “2 through 4” was calculated 
(SW[2-4]  = 0.11 mL/min).
Discussion
The objective of this study was to investigate the clinical applicability of the swab 
method in a population of multiple handicapped children. This was executed by 
quantifying the measurements error and biological variation of the salivary flow rate 
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by means of the within-subjects standard deviation (SW) in a repeated measurements 
design. Salivary flow rates were obtained from the submandibular glands by the swab 
method. Utilizing the absorbent properties of dental rolls, 224 samples were collected. 
The outcome of the swab method was the increase in roll weight (mL/min.) before 
and after the collection of saliva from individual oral regions. The results of this study 
indicate that consistent scores were obtained at subsequent measurements.
Taken the population into account, it was expected to meet considerable variation 
with-in and between subjects. The degree of the variation in repeated measurements 
represents biological variation over time, as well as error in the measurement procedure 
itself. According to Bland and Altman, this variation can be quantified by means of 
the within-subjects standard deviation (SW), which is expressed as 1 x SW, 2 x SW or 
1.96√2 x SW. The last option equals 2.77xSW and is used to determine the limits of 
agreement13. Calculation of the SW in baseline observations offers a clinically relevant 
way to delineate the population before treatment. The SW expresses to what extent the 
parameter (in this case salivary flow rate) will vary in a repeated measurement design, 
assuming standardized conditions. In addition, it gives the clinician a tool to decide 
whether an intervention in the treatment of drooling leads to a real improvement; 
a decrease in salivary flow rate greater than SW. The SW represents an entity based 
on data of the entire population and should not be applied to an individual subjects. 
The SW is specific for each population and is to be calculated for every new research 
program. In particular, interventional studies aiming to reduce the salivary secretion 
from the salivary glands (e.g. Botulinum toxin, anticholinergic drugs) may benefit 
from this approach. Regarding the upcoming interest in the Botulinum toxin in the 
treatment of drooling, it is foreseeable that many research programs on this subject will 
be undertaken in the next years. In addition, it should be mentioned that salivary flow 
measurement by the swab method is of limited meaning in some surgical procedures. 
For example the salivary flow from the submandibular gland cannot be accurately 
measured after relocation of Wharton’s duct.
Drooling in handicapped children is a serious clinical problem. The description of 
the different treatments to reduce or to redirect the salivary flow rate is beyond the 
scope of this article. No treatment option available is universally successful. It seems 
to be an incurable problem and treatment aimed at reducing salivary flow is a good 
approach in many cases, which can be assessed by the swab method. An experienced 
speech therapist should carry out the swab method and the child must accept the 
dental rolls. In general, the first session ought to be regarded as a learning curve. 
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If the measurements are part of a research program at least two pairs of repeated 
measurements should be available in order to calculate the SW.
To be conclusive about the result of any intervention the clinician has to decide at 
what point the treatment can be considered to be effective. For clinical practice the 
SW indicates a minimal change in the salivary flow rate in order to be sure that the 
outcome cannot be attributed to sources of error.
In relation to the mean of our population (0.40 mL/min.) a positive change of 1 x SW 
(0.11 mL/min.) or more, as a result of therapy, would mean a decrease of salivary flow 
of 25%. We concluded that an improvement of (more than) 1 x SW implicated a notable 
change in the salivary flow compared to baseline.
In conclusion, the swab method can be applied to measure salivary flow rates in a group 
of drooling handicapped children. According to Bland and Altman, the within-subjects 
standard deviation (SW), being the quantification of the error in the measurement 
procedure and the biological variation, was found to be a useful tool to evaluate the 
obtained salivary-flow rate measurements.
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Abstract
Objective: The aim of this article is to present backgrounds, the procedure, and technique 
of bilateral ultra-sound guided, single dose injections of Botulinum neurotoxin type-
A (BONT) into the salivary glands in patients suffering from severe drooling. Study 
design: Clinical trial.
Methods: Initially, an in-vitro study was performed to determine the volume of the dilution 
of BONT required for optimal spreading and to gain insight in the spreading pattern of 
the fluid in the submandibular gland. Subsequently, patients with severe drooling were 
included in a clinical study. Salivary flow was measured under standardized conditions, 
and BONT was injected into the submandibular glands with the patient under general 
anesthesia and with ultrasound guidance as an outpatient procedure or during a short 
stay at the daycare unit.
Results: BONT for each gland should be diluted in a volume of 1 to 1.5 mL of saline to 
achieve adequate spreading within the gland and to diminish the risk of diffusion into 
surrounding structures. With ultrasound guidance, separate structures surrounding 
the glands and structures within the glandular parenchyma are well recognized and 
injection errors can be avoided.
Conclusion: With the procedure described, it is possible to accurately inject BONT 
directly into the glandular parenchyma and to visualize spreading of the fluid in the 
glandular parenchyma. It is found to be a safe method that guarantees an optimal 
clinical effect and avoids potentially harmful side effects. We recommend ultra-sound 
guidance if injections of BONT into the salivary glands are considered. 
Introduction
Drooling is an important clinical, social, and emotional issue for people with severe 
neurological disease such as cerebral palsy in childhood and Parkinson’s disease or 
amyotrophic lateral sclerosis (ALS) in adults1;2. 
Salivation is mediated through the autonomic nervous system in which the salivary 
glands function under a complex parasympathetic and sympathetic neural control. 
Parasympathetic nerves provide the main drive for glandular secretion. Sympathetic 
impulses appear to evoke specialized responses that tend to modulate the composition 
of the saliva. Nerve endings within the parasympathetic postganglionic system secrete 
acetylcholine, and blocking these receptor sites inhibits nervous stimulation to the 
salivary glands. The application of Botulinum toxin type-A (BONT) to treat drooling is 
still experimental and subject to research. Because of the pharmacological properties 
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of BONT, it has been postulated that BONT might reduce salivary flow from the 
salivary glands3. BONT is applied to diminish the salivary flow rate, to reach a balance 
between the quantity of secreted saliva and the swallowing capacity of the particular 
patient. The main goal of the treatment is to reduce drooling1. However, the injection of 
BONT into the surrounding structures of the salivary glands could lead to unintended 
clinical effects. For example, deposition of BONT in the muscles can cause paresis 
with disturbance of deglutition. Before the intra-glandular treatment can be tested, the 
injection procedure must first be evaluated.
The aims of the present report are to present an in-vitro study and to demonstrate 
the technique and results of the in-vivo injections into the submandibular glands in 
children with severe drooling.
The theoretical possible adverse effects of unintended injections into the surrounding 
structures of the glands are discussed for the submandibular glands as well as for the 
parotid gland.
Material and method
In vitro study
An in-vitro study was performed in order to determine the anatomical distribution 
of injected fluid into the submandibular glandular parenchyma and to determine 
the volume to which dilution was needed to obtain optimal spreading. A normal 
submandibular gland was obtained from a surgical procedure in which the gland 
had to be removed as part of a radical neck dissection. Immediately on removal, the 
parenchyma of the isolated gland was injected. Two injection sites representing a 
realistic in vivo approach were chosen and injected with an increasing volume up to 
1.5 mL Omnipaque (140 mg/mL). Omnipaque was used because it is a water-soluble 
contrast medium with the same viscosity as a BONT solution. The application enabled 
X-ray investigation of the gland at several stages of injected volumes.
In vivo study
Children with cerebral palsy and with severe drooling who visit our specialized 
interdisciplinary outpatient clinic could be included in our clinical trial to treat drooling 
with BONT. The inclusion criteria (Table 1.3) had to be satisfied: (1) no medical condition 
contra-indicating therapy with BONT, (2) no prior injection with BOTOX® for any other 
indications within 6 months before entrance in the study, (3) no known hypersensibility 
to BOTOX® or any ingredients of the formulations, (4) no use of anticholinergic drugs, 
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and (5) a score of three or higher on a drooling severity scale and frequency scale 
severity scale or a score of 3 or higher on the TDS (Table 4.1 and 5.1)4.
Written informed consent was obtained from the parents or caretakers. The Hospital 
Ethics in Human Research Committee approved the study.
Table 5.1: Questionnaire-based scoring system for drooling severity and frequency (Thomas-
Stonell N, 1988)
Drooling severity Drooling frequency
1 Dry Never drools 1 Never drools
2 Mild Only lips wet 2 Occasionally drools
3 moderate Wet on lips and chin 3 Frequently drools
4 Severe Drools to extent the clothing becomes damp 4 Constantly drools.
5 Profuse Clothing, hands, tray and objects become wet
Measurements
All subjects were evaluated with repeated salivary flow measures from both the 
submandibular/sublingual glands and the left- and right-side parotid glands before 
and at regular intervals up to 24 weeks post BONT injections. Absorbent cotton rolls 
positioned at the orifices of the salivary ducts were weighed sequentially before and 
after the procedure of saliva collection1. Patients were evaluated while awake and sitting 
erect. The interval between the investigation and the last meal was at least 1 hour.
Medication
Botulinum toxin-A (Allergan BV, Nieuwegein, the Netherlands) in a total dose of 30 U 
up to 50 U was used. BONT was diluted with saline up to 1.0 mL or 1.5 mL per gland. 
One single dose of BOTOX® was injected in the submandibular gland at each side 
divided over two sites per gland using a 25 G needle (Spinocan®). 
BoNT injection procedure
The aim of our clinical study was to reduce salivary flow rate in order to reach a new 
balance between the quantity of secreted saliva and the swallowing capacity of the 
child. Therefore, only the submandibular glands were injected (see also: Fig. 1.2). 
The submandibular glands produce approximately 60 to 70% of the saliva when a 
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person is not eating or drinking. The activity of the parotids increases during gustatory 
stimulation, a function with which we did not want to interfere.
The children were given injections under general anesthesia because injections under 
local anesthesia could be too painful and frightening and would induce restlessness. 
Because the injections should be localized to the gland, movement of the patient could 
also disturb the procedure. All injections with BONT for this indication were performed 
as an outpatient procedure with some hours of recovery and monitoring at the daytime 
care-unit.
Ultra-sound guidance during the injections was performed at each occasion. The salivary 
glands were sonographically examined using a commercially available ultrasound 
system (SAL 250, Toshiba medical systems cooperation, Tokyo, Japan) equipped with 
a high-resolution, 7.5-MHz small-parts transducer. The transducer is positioned in 
such a way that injection with the needle is possible along the longitudinal axis of the 
transducer (Fig. 5.1), providing a quick and easy-to-perform visualization of the needle 
in the gland. Furthermore, ultrasound was used to position the needle at two different 
injection sites per gland, as well as to monitor and guide the spreading of the fluid 
throughout the gland.
Figure 5.1: Ultra-sound guided injection into the submandibular gland
  
The needle positioned along the longitudinal axis of the 
transducer.
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Results
In vitro study
A selection of the sequential X-rays taken during the in vitro study is shown in Fig. 
5.2. The submandibular gland has been injected with Omnipaque®. The X-ray images 
show the result of injections in the ventral and dorsal margin of the gland. From the 
first injection site, several small volumes of Omnipaque®, (up to 0.75 mL) were effused 
into the gland showing the fluid to spread along the interlobular septa (see also: Fig 
1.3) and reaching about half of the parenchyma. 
More volume from the same injection site did not enlarge the spreading area. After the 
second injection the entire glandular parenchyma was filled up homogeneously. Based on 
this observation, it could be concluded that the BONT for each gland should be diluted 
in a volume of approximately 1 mL to 1.5 mL of saline to achieve adequate spreading of 
the formulation in the glandular parenchyma. Furthermore, solutions should be injected 
into the salivary glands at two injection sites per gland or in one deeper injection with 
separate small effusions while withdrawing the needle. In theory, the latter procedure 
may be more traumatic to the gland and may give a higher risk of bleeding.
Figure 5.2. In-vitro injections into the submandibular gland (Omnipaque®).
1 = 1st injection site, 2 = 2nd injection site.
In vivo study
Figure 5.3 shows an ultrasound image of the needle still penetrating the left-side 
submandibular gland from the ventral-medial side during injection of BONT. Figure 
5.4 shows the submandibular gland as a homogenous hyperechoic structure before 
injection. After injection the fluid is seen as hypoechic changes in the gland. This 
indicates the spreading of the formulation throughout the parenchyma.
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Figure 5.3. Ultra-sound image of the submandibular gland 
 
(1) during injection of BONT, the needle (2) penetrating from the ventral-medial side.
In our clinical study, 44 patients were injected according to the above-mentioned 
procedure, representing 88 submandibular glands. Under ultrasound guidance, we 
had no difficulty in localizing and identifying the submandibular gland. Besides, it was 
always possible to puncture the glands and visualize the needle in the parenchyma, 
as well as to monitor the spreading pattern of the fluid throughout the parenchyma 
(Fig. 5.4). The majority of the patients showed a positive effect of the BONT injections. 
The presentation of these data is beyond the scope of the present report, but the data 
indicate that the effusion of the medication was intra-glandular. These findings are in 
accordance with the results of an earlier reported case-series that showed a reduction 
of the salivary flow rate from the submandibular glands after BONT injection1.
In 88 submandibular gland injections we registered no side effect or complication of 
the ultra-sound-guided procedure. Following ultrasound-guided injection of a salivary 
gland we never observed any clinical relevant diffusion of BONT into the surrounding 
structures.
Since we performed the study as a daytime-care procedure, parents were asked to 
report every noted possible side effect. In a few cases the children complained of a 
temporary swelling of the submandibular gland that was experienced as uncomfortable 
at deglutition during a period of a few hours. Other side effects such as thickening of 
the saliva could be ascribed to the anti-cholinergic effect of the BONT itself.
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Figure 5.4: Ultrasound images of the submandibular gland
  
A B
(A) Before BoNT injection, (B) After BONT injection.
Discussion
At present, more than 50 possible indications for the application of BONT are described5. 
Bushara has suggested the hypothesis of using BONT injected into the parotid glands 
to treat sialorrhoea in patients with amyotrophic lateral sclerosis3. In the treatment of 
drooling Jost reported that BONT had been effective for about 4 to 7 months in five 
patients with Parkinson’s disease who received intra-parotid injections2. Several other 
studies have confirmed the positive effect for patients with Parkinson disease6;7. In 
a preliminary investigation we found support for the assumption that BONT may be 
useful in the treatment of drooling in children with cerebral palsy1.
Seven structural similar but immunologic distinct exotoxins are produced by clostridium 
botulinum of which Type A is widely known for its clinical application. Botulinum toxin 
type-A is a protein and potent neurotoxin, and appropriate care should be exercised 
during its preparation and use. When injecting BONT into massive structures such 
as the calf muscle, it is sufficient to locate the injection site by manual palpation of 
the muscle and perform EMG-control. When smaller anatomical structures are to be 
injected with BONT, it is necessary to prevent the distribution of the medication from 
the injection site into the surrounding structures.
Sonography, when performed by an experienced examiner, can be used to evaluate 
many structures and conditions in the head and neck area. When a salivary gland is 
punctured for cytology or injection, ultrasound guidance offers an elegant and effective 
method to ensure that the needle is positioned in the glandular parenchyma to avoid 
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lesions or effusion of the formulation in the vascular structures or the surrounding 
tissues.
If the parotid gland has to be injected, it is recommended to approach only the superficial 
part, which represents the larger part of the gland that lies close to the masseter muscle. 
With ultrasound guidance an erroneous injection into the masseter muscle, which 
would result in weakening of jaw closure, can be avoided. After ultrasound-guided 
injection of a salivary gland we never observed any clinical relevant diffusion of BONT 
into the surrounding structures. Tan et al recently reported a recurrent dislocation of the 
temporomandibular joint (TMJ) after BONT treatment for sialorrhoea in amyotrophic 
lateral sclerosis8. The authors describe the injection technique in which they manually 
palpate and locate the portion of the parotid gland lying between the ascending ramus 
of the mandible and the mastoid process. The depth of the injection was about 1 cm and 
possibly superficial enough to allow the toxin to spread in the surrounding structures. 
As an explanation of the TMJ dislocation, it is speculated that diffusion of the BONT 
into the masseter muscle could have caused weakness. That might have contributed 
to the clinical complaints. The specific function of the masseter muscle is to close the 
jaw by elevating the mandible, but it also stabilizes the TMJ as a counterpart of the 
posterior belly of the digastric muscle and the lateral pterygoid muscle. When, for any 
reason, the masseter muscle becomes flaccid and the elevation of the jaw becomes 
weaker, the posterior belly of the digastric muscle, together with the lateral pterygoid 
muscle, can bring about a moment over the TMJ and force it into anterior dislocation. 
To prevent an unintended deposition of BONT in the periglandular tissues, which 
could produce the above-mentioned side effects, the intra-glandular injections must 
be performed with an imaging procedure. It has been noted that anterior dislocation of 
the TMJ can be treated by injection of the lateral pterygoid muscle with BONT9.
Under ultrasound guidance, Stenson’s duct, emerging from the anterior border of the 
parotid gland, is well recognizable.  This is also the place were the buccal branches of 
the facial nerve radiate outwards along with the duct and the transverse facial artery. 
BONT should not be injected in this region.
The approach of the deeper part of the parotid gland can be complicated by injections in 
the posterior part of the digastric muscle, the retromandibular veins, the maxillary and 
superficial temporal arteries or, the external carotid artery. Although ultrasound cannot 
adequately visualize the deeper part of the parotid in detail, the above-mentioned 
structures can be delineated well.
The Facial nerve is situated between the superficial part and the deeper part of the 
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parotid gland and should not be injected. On a transversal sonographical image 
this site is approximately located between the mastoid bone and the ramus of the 
mandible.
The submandibular gland is smaller than the parotid. There are no major structures 
located within the parenchyma, although some submandibular lymph nodes are within 
the capsule. The submandibular gland, situated between the corpus of the mandible 
and the medial pterygoid muscle on its lateral margin and the mylohyoid muscle on 
the medial side, is hard to locate accurately by palpation. The dorsal margin is grooved 
by the facial artery and has a close relation with the posterior belly of the digastric 
muscle. The inferior margin is located directly on the anterior belly of the digastric 
muscle. If this gland is to be injected with BONT, ultrasound guidance is needed to 
avoid penetration of the surrounding muscles. This might cause weakness of opening 
of the jaw (medial pterygoid muscles, the posterior belly of the digastric muscle) or 
restriction of the elevation of the oral floor and tongue during deglutition (mylohyoid 
muscle, the ventral part of the digastric muscle).
Because of the pharmacological properties of BONT, it has been postulated that BONT 
might reduce salivary flow from the salivary glands3. It is obvious that injections of 
BONT in the periglandular structures will result in a diminished effect on the salivary 
flow reduction and, consequently, on drooling.
The possibilities of identifying structures in the head and neck region with ultrasound 
techniques are well documented10-12. The possibility of using ultra-sound to “guide” 
BONT injection in the salivary glands in the treatment of sialorrhoea has already been 
mentioned in the literature13;14.
Conclusion
With the procedure described, it is possible to accurately inject BONT directly into 
the glandular parenchyma and to visualize spreading of the fluid in the glandular 
parenchyma. It is found to be a safe method that guarantees an optimal clinical effect 
and avoids potential harmful side effects.
The available literature suggests that there is an indication to treat drooling with 
injections of BONT into the salivary glands1;2;6;7;13-15. Based on our study we recommend 
performing the injection procedure under ultra sound guidance.
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Abstract
Drooling beyond the age of four years is pathological, particularly if it occurs in children 
with neurological and developmental impairment and disability. Considering the 
therapeutic spectrum of Botulinum toxin-A and in view of the innervation of the salivary 
glands, we postulated that intraglandular injections into the submandibular glands with 
Botulinum Toxin type-A could reduce the secretion of saliva and consequently decrease 
drooling. Three patients with cerebral palsy and severe drooling were selected and 
evaluated over a 4-month period. Under ultrasound guidance, one dose of Botulinum 
toxin type-A was injected bilaterally into the submandibular glands. Saliva secretion 
was measured at baseline and repeated four times during the following 4 months. 
In the three patients, maximal salivary flow rate of the sublingual and submandibular 
glands was reduced 51 to 63 %. The time of the maximal effect differed among the 
three children. The parents reported a satisfactory reduction of drooling throughout 
the whole study period. No objectionable disturbances of oral functions were observed. 
There was a mild transient thickening of saliva in one of the patients.
Conclusion: The application of Botulinum toxin type-A to the submandibular gland is 
a promising technique to reduce salivary flow rate and probably an alternative in the 
treatment of drooling in children with cerebral palsy.
Introduction
Drooling can be an important clinical, social, and emotional issue, and beyond the age 
of 4 years it is pathological and a clinical expression of a defect in the oral phase of 
swallowing8. Lack of control in swallowing coordination may lead to excessive pooling 
of saliva in the anterior oral cavity. Factors that predispose drooling in children with 
cerebral palsy include the degree of spasticity, a low swallowing frequency, a diminished 
intra-oral tactile sensitivity, and constant tongue thrusting 20. Drooling in cerebral palsy 
also worsens if there is moderate or severe mental retardation. It has been reported to 
be a significant problem in 10% to 37,5% of patients with CP 11;22.
Salivation is mediated through the autonomic nervous system with the salivary 
glands functioning under a complex parasympathetic and sympathetic neural control. 
Parasympathetic nerves provide the main drive for the secretion of fluid by the glands. 
Sympathetic impulses appear to evoke specialized responses that tend to modulate the 
composition of the saliva. The treatment of drooling has been extensively described in 
the literature. The methods available for the management of drooling comprise both 
surgical and non-surgical options 1;2;4;6;12;13;15. Surgical options in the treatment of 
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drooling are denervation of the salivary glands by transtympanic neurectomy, rerouting 
or ligation of the salivary duct of either the submandibular or parotid gland, and excision 
of one or more salivary glands 1;7;9;11;12;16. Nerve endings of the parasympathetic 
postganglionic neurons system secrete acetylcholine, and blockade of these receptor 
sites inhibits nervous stimulation to the salivary glands. Anticholinergic drugs can be 
used to decrease saliva secretion. Unfortunately, due to the systemic application of the 
drugs a wide range of side effects are known2;4;6;13;15. No treatment option is universally 
successful, and each method has potential complications4.
From canine studies, Shaari demonstrated that both Botulinum Toxin types A and D 
reduced the neural evoked production of saliva from submandibular glands18.
Botulinum toxin type-A has the following mechanism. It binds to “SNAP-25” (25 kDa 
synaptosome-associated protein), a cytoplasmic protein involved in the fusion of 
synaptic vesicles with the presynaptic membrane. This ultimately disrupts the secretory 
pathway for acetylcholine and causes chemodenervation10. The process of denervation 
is reversed as the nerve end regenerates and re-innervates the target organ. Bushara 
has suggested the hypothesis of using Botulinum toxin injected into the parotid glands 
to treat sialorrhea in patients with amyotrophic lateral sclerosis5.
In view of the pharmacological properties of Botulinum toxin type-A, we expected that 
injections into the submandibular glands with Botulinum toxin type-A would reduce the 
secretion of saliva and consequently diminish drooling. This study presents the results 
of a single dose injected bilaterally into the submandibular glands with Botulinum 
toxin type-A of three children with cerebral palsy who suffered from severe drooling. 
Subjects and method
Three children with cerebral palsy and suffering from severe drooling were recruited 
from our outpatient clinic. Inclusion criteria (Table 1.3) were: 1) no medical condition 
contra-indicating therapy with Botulinum Toxin, 2) no recent (< than 6 months) 
injection with Botulinum toxin for other indications,  3) no known hypersensibility to 
BOTOX® or any ingredients of the formulation, 4) no use of anticholinergic drugs, 5) 
no previous surgical procedures in the oral or nasal cavity to reduce the production of 
saliva, and 6) a score of 3 or higher on the drooling severity and frequency scale or a 
score of 3 or higher on the TDS (Table 4.1 and 5.1). The characteristics of the patients 
are listed in Table 6.1.
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Table 6.1: Patients characteristics
Patients 1 2 3 
Sex male male Female
Age (years) 13  11 13
Weight (kg.) 45 26 23
Clinical Picture Quadriplegia Quadriplegia Quadriplegia
Motor expression Spasticity/Chorea Dystonia Spasticity/Athetosis
Mental state Mild retardation Moderate retardation Severe retardation
To classify the patients and delineate the severity of the problem, drooling was scored 
by means of the ‘Questionnaire-based Semi-quantitative Assessment of Drooling 
Severity and Frequency’ during the first outpatient visit21. All three patients had the 
highest score (five) on the severity scale. This score reflects that clothing; hands, tray, 
and objects become wet due to drooled saliva. Patient 1 scored three on the frequency 
scale, indicating frequent drooling. The other two patients scored four, indicating 
constant drooling.
We used Botulinum toxin type-A (BOTOX®; Allergan Benelux BV, Nieuwegien, The 
Netherlands) in a dose dependent on the child’s weight. A total dose of 30 U was 
used for a body weight up to 15 kg, 40 U for children weighing 15 to 25 kg, and 50 U 
when the body weight exceeded 25 kg. These dosages were in accordance with the 
suggested pediatric dosing in the treatment of spasticity17. The Botulinum Toxin was 
diluted with 1.5 mL saline for each gland. From an in vitro study we noticed this to be 
sufficient to reach all parts of the glands. Our aim was to reduce salivary flow rate at 
rest in order to reach a new balance between the quantity of secreted saliva and the 
swallowing activities of the child. Therefore, we choose to inject the submandibular 
glands because these glands produce approximately 60 to 70% of the saliva whereas 
the parotid glands secrete about 20 -25% of the total amount of saliva when a person is 
at rest. Furthermore, the activity of the parotids increases during gustatory stimulation. 
One single dose of Botulinum toxin was injected bilaterally divided over two sites 
per gland by using a 25 G needle (Spinocan®). The injections were performed under 
general anesthesia with ultrasound guidance to precisely locate the needle within the 
submandibular gland.
Saliva secretion was measured from the submandibular/sublingual gland as well as 
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the left and right parotid gland. For this purpose, absorbent cotton rolls were used and 
positioned at the orifices of the salivary ducts. The orifices of the submandibular and 
sublingual ducts have a close anatomical relation so that separate measurement could 
not be obtained. The cotton rolls absorb sufficient saliva during a limited 5-minute 
period. The rolls were weighed before and after the procedure using an electronic scale, 
which was sensitive to 0.01 g. The increase in weight collected during a fixed time can 
be converted into mL saliva/min. Patients were evaluated at least one hour after a meal 
while awake and sitting erect. Before the injection each patient was screened by the 
speech therapist to determine base-line salivary flow rate. In the follow-up period the 
children were examined and salivary flow rate was measured at 2, 4, 8 and 16 weeks 
after the injections.
Before and after Botulinum Toxin injection, the parents were asked to complete forms 
containing questions about drooling, eating, drinking and daily care as a reflection of 
the quality of life.
The study has been approved by the Hospital Ethics in Human Research Committee.
Results
The data of the salivary flow rate on consecutive measurement moments were recorded 
and are shown in Fig. 6.1. In all three cases, the salivary flow rate was substantially 
reduced on the first control visit 2 weeks after injection. The maximal salivary flow 
rate of the compound samples of the sublingual and submandibular glands showed 
a reduction of 51 to 63 %. The time of the maximal effect differed among the three 
children. In patient 1 and 3 reduction of the initial amount lasted throughout the study 
period of 16 weeks, whereas patient 2 had maximal reduction at 4 weeks.
The quality of life data collected during the follow-up period will be briefly described. 
Relevant observations from the parents are included in the clinical description. The 
clinical observations varied among the patients. Patient 1 had only mild mental 
retardation and his awareness that he drooled less might have ameliorated his 
swallowing coordination. He did not drool at all during the follow-up period. Patient 
2 showed a moderate change. The salivary flow was reduced to a maximum of 51% 4 
weeks after the injection. In this patient, the saliva secretion increased again before the 
third control visit at eight weeks following injection. He drooled less and his parents 
were satisfied for the whole period, because it meant that he could attend school, using 
only one bib. Although patient 3 never stopped drooling during this study, there was an 
impressive reduction. In the questionnaires the parents responded that there was also 
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a major reduction of drooling during the night when the pillow only became damp. This 
result was probably related to the favorable recumbent posture in combination with 
the reduction of saliva secretion of 61% and 63 % found at 4 and 8 weeks respectively 
after injection. For all patients, the left and right parotid glands showed no change 
in secretion activities during the 16 weeks following the single dose. There were no 
objectionable disturbances of oral function observed in all three patients. Patient 3 had 
a mild, transient thickening of saliva, which was treated for three days with a mucolytic 
drug.
Figure 6.1: Submandibular salivary flow (mL/min), left and right side together
 
 
 
 
Discussion
This study investigates the effect of a single dose of Botulinum toxin type-A on reducing 
salivary flow rate in 3 children with cerebral palsy. In all 3 children the maximal reduction 
was greater than 50 %.
Generally the effect of Botulinum toxin in the treatment of spasticity lasts about 3 to 4 
months19. In the treatment of drooling, Jost describes that Botulinum toxin had been 
effective for about 4 to 7 months in five Parkinson patients treated with intra-parotid 
injections14. Our study shows that the submandibular gland reacted similarly. For 
only one patient the reduction in salivary flow rate was less than 4 months. Possible 
explanations are: 1) inappropriate injection site, 2) a disproportion between the injected 
volume of diluted Botulinum toxin and the size of the glands, or 3) a short lasting effect 
of the Botulinum toxin.
Patient 2 reacted relatively short, possibly related to a quick induction of nervous 
sprouting. The parents of this patient reported they were satisfied about the lesser 
amount of drooling during whole the study period. In our patients, general anesthesia 
was used to perform the procedure. However, it is conceivable that if one gets more 
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familiar with the technique of intraglandular injections under ultrasound guidance, 
the injections can be done with just sedation instead of anesthesia. We intended to 
diminish salivary flow rate from the submandibular glands and leave the parotid glands 
to produce saliva when the person eats and drinks.
This study supports the hypothesis that injections with Botulinum toxin type-A into 
the submandibular glands will decrease salivary flow rate for an acceptable period. 
The duration of the effect appears to vary. Questions remain about several subjects 
such as the most appropriate dose, the effect of Botulinum toxin injections on the 
composition of saliva, and the duration of the effect. Further research is required to 
evaluate the effectiveness of intraglandular application of Botulinum toxin in either the 
parotid glands or in the submandibular glands. A comparative prospective study with 
a larger number of patients is needed together with a relevant quality of life study.
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Abstract
Background: To investigate the effectiveness of Botulinum neurotoxin type-A (BoNT) 
in reducing salivary flow rate in children with Cerebral Palsy (CP) suffering from 
severe drooling. During a controlled clinical trial, single-dose BoNT injections into the 
submandibular salivary glands were compared to scopolamine treatment.
Methods: Forty-five school-aged children were included. Salivary flow rates from all 
major glands were obtained at baseline and compared to measurements during the 
interventions. Basic statistics consisted of analysis of difference scores.
Results: Compared to baseline, the mean decrease in submandibular flow was 24.7 % 
during scopolamine and 42.4 % following BoNT injections. The difference scores were 
statistically significant with maximum reductions 2, 4 and 8 weeks following BoNT. Of 
all children, 94.9 % responded during scopolamine. Response rates for BoNT varied 
from 69.2% two weeks to 48.7% twenty-four weeks after injection, the end of the 
study. Four patients discontinued scopolamine therapy because of side effects. Only 
incidentally mild side effects were reported from BoNT.
Conclusion: Intra-glandular BoNT injections significantly reduce salivary flow rate in the 
majority of drooling CP children demonstrating high response rates up to 24 weeks. 
The procedure is simple to perform, effective and safe when ultrasound guidance is 
used. This is the first controlled trial comparing the efficacy of Botulinum toxin to 
another anticholinergic agent. The anticholinergic effect of BoNT exceeds that of 
scopolamine. Since anticholinergic drugs are frequently contra-indicated because of 
side effects, BoNT injections offer an alternative in the treatment of drooling. BoNT 
could be beneficial to a broader group of patients, both children and adults, if a 
reduction of salivary flow is needed in the treatment of drooling.
Introduction
The efficacy of Botulinum toxin (BoNT) injections in the salivary glands to treat drooling 
is promising1-3. For safe injections and optimal results ultrasound guidance is needed. In 
addition, anesthesia is required when children are treated4,5. From the pharmacological 
profile of BoNT an appreciable anticholinergic effect can be expected6,7. In particular, 
type-A toxin cleaves SNAP-25, an enzyme involved in the release of acethylcholine at the 
presynaptic membrane of parasympathetic nerves. However, its capability to reduce the 
salivary flow rate has not yet been established. Uncertainty still exists about the efficacy 
and duration of the effect. Preliminary reports, presenting case series or small cohort 
studies, describe different techniques for evaluation1-3,8. The reader cannot conclude 
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whether the use of BoNT would be an improvement over other interventions. BoNT is 
an anticholinergic agent. The use of other anticholinergic drugs to treat drooling has 
been reported repeatedly in the literature and an extensive clinical practice exists in the 
application of this medication.
The objective of this study was to investigate the effectiveness of BoNT to reduce 
salivary flow rate in drooling children with cerebral palsy (CP). A controlled clinical 
trial has been performed in which BoNT injections of the submandibular glands were 
compared to treatment with scopolamine. The results of quantitative measurements 
of salivary flow rates are summarized. The nill hypothesis that ‘there would be no 
difference in effectiveness of flow reduction between scopolamine and BoNT’, was 
tested.
Method and material
Patients
Fifty-three consecutive patients with the diagnosis CP were screened in the outpatient 
clinic between January 2000 and November 2001. Forty-five severely drooling children 
were included, according to the criteria as tabulated in Table 1.3.
All drugs used were carefully evaluated to assess their influence on saliva secretion. 
Continuous use of anticholinergic drugs or benzodiazepines was not allowed. In 
particular clonazepam was a reason for exclusion. Throughout the study no change 
in medication was allowed. Medication to treat drooling had to be stopped at least 
three months prior to participation. All possible adverse effects and risks related to the 
study were explained to the parents and written informed consent was obtained. The 
Hospital’s Human Research Committee approved the study.
Design
In this controlled “open-label” clinical trial, salivary flow rate measurements from 
all major salivary glands were performed during scopolamine application that were 
compared to the results of BoNT injections into both submandibular glands. An 
independent observer assessed the primary outcome parameter (salivary flow rate) 
blinded for the status of the participating patients. This was achieved by varying 
baseline measurements among the patients according to a predetermined schedule.
In view of side effects the protocol anticipated that some of the patients might not 
complete the scopolamine period. If scopolamine was used less than 48 hours, the 
subject was considerate a dropout. If scopolamine was discontinued after 48 hours, 
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the subject remained in the study provided a salivary flow measurement was obtained 
within the first 24 hours after discontinuing the therapy.
Procedures
Scopo-derm TTS® 1.5 (Novartis Consumer Health BV, Breda, the Netherlands), a sticky 
plaster containing 1.5 mg of the anticholinergic drug scopolamine, was placed behind 
the ear for a maximum of 10 to 14 days. After clear instructions, parents were asked 
to fill out a daily form to register side effects. Assessment was scheduled on the tenth 
day with the plaster still in place. After a washout period of 2 to 4 weeks, the child was 
admitted for outpatient treatment. Under general anesthesia a single dose of Botulinum 
toxin (Botox®, Allergan, Nieuwegein, the Netherlands) was injected bilaterally in the 
submandibular glands, using a 1 ml syringe. The total dosage, divided between the left 
and right gland, depended on the child’s weight: 30 U for children weighing less than 
15 kg, 40 U for children with a body weight between 15 and 25 kg, and 50 U for children 
weighing more than 25 kg. On injection, each dose was fractionated and divided over 
minimally three sites in the gland.  To locate the glands, ultrasound guidance was 
performed using a system (SAL 250: Toshiba medical sysytems cooperation, Tokyo, 
Japan) equipped with a 7.5-MHz transducer4. The submandibular glands were injected 
as it is generally accepted that these glands produce 60 to 70% of secreted resting 
saliva9. Saliva produced during eating and drinking is mainly produced by the parotid 
glands with which we did not want to interfere.
Follow-up measurements were planned at 2, 4, 8, 16, and 24 weeks after BoNT. Parents 
were asked to register side effects in a diary.
Prior to the assessment the mouth was cleaned and dried by gauze. In order to 
measure salivary flow rate the ‘swab method’ was used during which absorbent 
cotton rolls (Salivette®, Sarstedt B.V, Etten-Leur, the Netherlands) were placed directly 
at the orifices of the submandibular, sublingual, and parotid glands for a 5-minute 
period. The procedure was always executed by the same speech therapist in the same 
environment. Patients were evaluated in the morning after at least 1 hour of starvation 
and while awake and sitting erect. Special attention was paid to the body posture with 
the head in an upright position. The flow rate was calculated by the formula: Salivary 
flow rate [mg/min] = (weight increase of rolls [mg] / time of collection [min]). Since 
the specific gravity of saliva is 1.0 the results were converted to ml/min. The procedure 
was repeated after 30 minutes. The mean of the two measurements was the outcome 
parameter.
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Because of the close anatomical relation between the sublingual and submandibular 
glands, separate flow rates could not be obtained. The compound salivary flow from 
these two glands is referred to as submandibular flow (SubFl). The salivary flow from 
the right parotid (PaRFl) and the left parotid gland (PaLFl) were also assessed. The 
‘total salivary flow’ (TSFl) was the summation of SubFl, PaRFl and PaLFl.
Statistics
A power analysis was performed to calculate the required number of patients. 
Approximately 40 subjects were needed to reach a power of 80% with an alpha of 0.05. 
The difference between the two episodes of treatment had to be at least 1 SD. Assuming 
a dropout percentage of 7%, the inclusion of 45 subjects would have sufficient power. 
Because of the complexity of the design and vulnerability of the patients, missing data 
were inevitable. For this reason data were adjusted by ‘last observation carried forward’ 
(locf) and by a ‘worst case scenario’ (wcs) system. In the wcs procedure all missing 
data were replaced by baseline values. In this way the difference in potential effect for 
both therapies was “reduced” by introducing a bias towards zero.
A MANOVA was executed to identify patterns of response using a within-subjects 
design with the subsequent measurement moments as the variables. In addition, 
paired samples t-tests were done for SubFl as well as TSFl data to analyze difference 
scores in flow rate.
In order to quantify the measurement error of the swab method, the within-subjects 
standard deviation (SW) was estimated from repeated baseline measurements of 
each patient that were performed under standardized conditions10. The biological 
variation and the between-subjects variation in salivary flow rate and the error in the 
measurement procedure itself influence the magnitude of the SW. For the clinician, the 
SW clarifies whether a change in flow rate is the result of measurement error alone or 
the outcome of an applied intervention. In this study, success to either scopolamine 
or BoNT treatment was defined as a decrease in SubFl of more than 1.0 SW. For all 
statistics a level of significance with a p-value ≤ 0.05 was obligatory.
Results
Forty-five children were included (Fig.7.1), 28 male, 17 female, age 3-17 years (mean 9.5, 
SD 3.7). No child had to be excluded because of use of medication. Of all patients, 21 
did not use medication, 4 patients incidentally used benzodiazepines to treat epileptic 
seizures, and 2 patients stopped medication that was given to treat drooling. None 
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of the subjects had Botulinum toxin before. By the end of the trial six dropouts had 
occurred: 4 patients could not fulfill the scopolamine period, 1 changed anti-epileptic 
medication, and 1 did not attend the required measurements because of intercurrent 
illness not related to the trial. The results of 39 patients were analyzed according to an 
“intention to treat model”.
Figure 7.1: Flow diagram of subject’s progress through phases of the trial
There were no missing values in the baseline data. Of all other measurement, 21 
missing values representing 6.7% of the total, were estimated as follows (number of 
missing/number of patients): scopolamine (4/39); washout (1/39); BoNT-2 (2/39); 
BoNT-4 (9/39); BoNT-8 (2/39); BoNT-16 (2/39); BoNT-24 (1/39). Primary analyses 
were done with the locf data. Descriptive statistics of the consecutive measurement 
moments are tabulated (Table 7.1).
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Table 7.1: Descriptive statistics at baseline and subsequent follow-up measurements
 Mean SD Median
Baseline .41 .22 .37
Scopolamine .31 .18 .28
Washout .40 .22 .37 
BoNT-2 .24 .15 .22
BoNT-4 .25 .18 .20
BoNT-8 .23 .15 .20
BoNT-16 .27 .19 .24
BoNT-24 .28 .16 .28
Compared to baseline, the mean salivary flow rates of SubFl as well as TSFl decreased 
during scopolamine application and after BoNT injections, as is shown in Fig. 7.2. 
Figure 7.2: Mean Salivary Flow at subsequent measurement moments (Locf data)
 
locf = last observation carried forward, SubFl: Submandibular flow (-〇-), TSFl: Total Salivary Flow(-◊-),  
SA: Scopolamine application, BI: BOTOX Injection,  
Baseline: Measurement at baseline, Scopol: Measurement during scopolamine application, Washout: 
Measurement after Washout, BoNT-X: Measurements at subsequent moments (Wks) following BoNT 
injections. 
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With the SubFl at each moment in time defined as the within-subjects variable a 
MANOVA, with a repeated measurements design was executed to evaluate the pattern 
of response of the assessments during the trial (Hotelling’s trace: F=13.83; df (7.32); 
p < 0.001). An effect over time was found as depicted in the Fig. 7.2 and described in 
further detail by analysis of difference scores (Table 7.2). 
The procedure was repeated for the TSFl (Hotelling’s trace: F=7.892; df (7.32); p < 
0.001). Because the between-subjects variation was larger for the TSFl data, a natural 
log-transformation was done to stabilize the variance and patterns over time. A 
MANOVA was executed (Hotelling’s trace: F=15.029; df (7.32); p < 0.001). Because the 
graphical pattern showed great resemblance to the original TSFl data it was concluded 
that the curves in the 
Table 7.2: Mean change of submandibular flow as a result of interventions (N = 39)
Locf data (mL/min.)
Measurements Mean change from  p value Mean change from  p value 
 baseline (SD)  washout (SD)
Scopolamine 0.10 (0.16) 0.001
BoNT-2 0.17 (0.17) 0.001 0.16 (0.16) < 0.001
BoNT-4 0.16 (0.19) 0.001 0.15 (0.20) < 0.001
BoNT-8 0.19 (0.16) 0.001 0.17 (0.17) < 0.001
BoNT-16 0.14 (0.15) 0.001 0.12 (0.20) 0.001
BoNT-24 0.13 (0.17) 0.001 0.11 (0.21) 0.002
N: number of patients, Locf: last observation carried forward, 
SD: Standard deviation, BL: Baseline, 
BoNT-X: Measurements at subsequent moments (wks) following BoNT injections
Fig. 7.2 were comparable. Compared to baseline, the TSFl changed in the same 
direction over time as the SubFl with reduction during scopolamine application, return 
to baseline level during washout, and a second decrease in salivary flow rates following 
BoNT injections.
If the washout period was chosen properly the salivary flow rates after ‘washout’ 
of scopolamine should be in the same range as baseline measurements. A paired 
samples t-tests was performed to calculate the difference between baseline SubFl (locf 
data) and washout (mean difference = 0.0119 mL/min; SD = 0.2165; 95% confidence 
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interval of the difference -0.0582 to 0.0821; p = 0.733). No significant difference was 
found, indicating that the length of the washout period was sufficient. This finding 
minimizes the probability of a carry-over effect from scopolamine treatment to the 
BoNT injection period.
Compared to baseline SubFl showed a mean reduction of 24.7 % during scopolamine 
and a mean reduction of 42.4 % 2 weeks after BoNT. Table 7.2 presents the differences 
and significance between baseline measurements and the measurements after 
treatment. The greatest reductions in salivary flow were achieved 2, 4, and 8 weeks 
following BoNT. The SubFl appeared to increase slightly after BoNT-8 but remained 
significantly different from baseline.
Further analyses of SubFl were performed to investigate the mean differences between 
the individual BoNT assessments and scopolamine (Table 7.3). BoNT measurements 
2, 4 and 8 weeks after injections, showed significantly greater reduction compared to 
scopolamine. Between the eighth and the sixteenth week after BoNT this significance 
disappeared.
Table 7.3: Mean change of submandibular flow between interventions (N = 39)
Locf data (mL/min.)
 Mean change from  p value 
 scopolamine to BoNT (SD)
Sc: BoNT-2 0.0725 (0.13) 0.01
Sc: BoNT-4 0.0607 (0.15) 0.14
Sc: BoNT-8 0.0828 (0.13) < 0.001
Sc : BoNT-16 0.0371 (0.15) 0.129
Sc : BoNT-24 0.0258 (0.16) 0.327
N: number of patients, Locf: last observation carried forward, SD: Standard deviation, BL: Baseline, BoNT-
X: Measurements at subsequent moments (wks) following BoNT injections Sc: Scopolamine.
Analysis of “worst case scenario” data did not lead to different results comparing 
baseline to both treatments. However, no significant difference in salivary flow 
reduction could be found comparing scopolamine to BoNT.
In this study the within-subjects standard deviation (SW) of the baseline measurements 
was 0.11 ml/min (see: methods), which is acceptable regarding the mean SubFl of 
0.40ml/min. Success to scopolamine, was achieved in 94.9 % of the children. Success 
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rates for BoNT were: BoNT-2 (69.2%), BoNT-4 (64.1%), BoNT-8 (61.5%), BoNT-16 
(48.7%) and BoNT-24 (48.7%). McNemar test was used to compare the response rate 
after scopolamine to the response rate 2 weeks after BoNT (p = 0.002). In favor of 
scopolamine, there appeared to be a significant difference in the number of patients 
that responded according to our definition.
Adverse effects during application of scopolamine were reported in 82.2% of cases. Side 
effects due to scopolamine became apparent within the first three days of administration 
and several patients complained of more than one symptom. Five patients (11.1%) had 
‘mild’, fourteen patients (31.1%) had ‘moderate’, and 18 patients (40%) had severe 
side effects. Most often reported adverse effects were xerostomia in 66.7% of cases, 
restlessness 35.6%, somnolence 35.6%, blurred vision 20%, and confusion in 20% of 
cases. No morbidity was seen in relation to the general anesthesia. Following BoNT 
injections, incidental side effects were reported. Two patients (5.1%) had a transient 
flu-like syndrome lasting for less than 2 days. Another 2 patients complained of mild 
difficulty of swallowing. This was ascribed to local swelling, which subsided in a few 
hours. In one case moderate difficulty with swallowing developed after one week and 
was present for 10 days. It was theorized that this could be the result of diffusion 
of Botulinum toxin into the surrounding muscles, which would explain the one-week 
interval for the symptoms to develop. However, when one considers the physiological 
action and the process of re-innervations, it is difficult to understand how the problem 
could disappear within 10 days.
Discussion
Persistent drooling is a serious medical and social problem. The general opinion still 
is that neither conservative therapy (speech therapy, behavioral therapy, drugs) nor 
surgical interventions are universally successful11-13. Intra-glandular Botulinum toxin 
injections in the salivary glands have been suggested in the past few years2,3,14,15.
This is the first controlled clinical trial that evaluated the reduction of the salivary flow 
rate by comparing the efficacy of Botulinum toxin to another anticholinergic agent. 
The effect of BoNT on the reduction of submandibular salivary flow exceeded that of 
scopolamine. Compared to baseline, the mean reduction following BoNT injections 
was 42.4% versus 24.7% during scopolamine. This reflects the explicit anticholinergic 
effect of BoNT.
The number of responders was calculated according to our definition of therapeutic 
success. Success rates were high with the outcome in favor of scopolamine 
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(scopolamine: 94.9%, BoNT_2: 69.2%). In theory the difference in response rate can 
be explained in several ways: 1) the reaction to BoNT may be dose related. We did not 
investigate this because dose finding was not an aim of this study, 2) BoNT (or part 
of it) was not injected in the gland. However, ultrasound guidance assured adequate 
delivery and 3) immunity existed for BoNT. We did not rule out this possibility. However, 
the risk of neutralizing anti-BoNT type-A antibodies was low because none of these 
patients had previously been treated with Botulinum toxin.
Unless the above-mentioned, the number of responders to BoNT remained well 
throughout the 24-week duration of the study. This long-term reduction of the salivary 
flow from one of the major salivary glands is a promising finding since Botulinum toxin 
is known to work for 9 to 12 months in other conditions involving the autonomous 
nervous system, for example hyperhidrosis16,17.
The study was executed as an “open label” trial because the applied interventions could 
not be blinded. The possibility of a carry-over effect necessitated a strict sequence in 
the treatment order: scopolamine prior to Botulinum toxin. The washout period of 
scopolamine appeared to be sufficient at analysis of the results.
Using the swab method for salivary flow measurement, oral stimuli by the dental rolls 
cannot be avoided which may partly explain the between-subjects variation in both the 
SubFl and the TSFl. The capability to react to intra-oral tactile stimuli with a higher 
level of secretion is more explicit in the parotids. This probably is a reason why TSFl, 
including the parotids, showed a greater variation. Nevertheless, the data of SubFl 
and TSFl demonstrated a similar trend, which is in line with the fact that the parotids, 
the sublingual and the minor salivary glands have a limited contribution to the non-
stimulated saliva production.
A complete blockage of SubFl was not achieved. This might be explained by the 
fact that parasympathetic innervations as well as ortho-sympathetic innervations 
stimulate salivary secretion. In canine studies it was demonstrated that after 
complete anticholinergic blockage of the glands with atropine, a maximum of 76% 
of submandibular salivary flow reduction was achieved7. Therefore, it is not likely that 
in man full blockage of salivary flow would be achieved, by applying anticholinergic 
treatment.
Averse reactions to scopolamine occurred in 82.2% of cases. In approximately 9 % of 
cases, treatment had to be terminated due to side effects, which explained 4 out of 
6 dropouts from the study. BoNT injections were given under general anesthesia of 
which the potential risks should not be neglected. This should be weighed against the 
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possible adverse effects that are to be encountered when using scopolamine (or other 
anticholinergic drugs) for a longer period. Following BoNT only mild side effects were 
registered. However, a temporary disturbance in swallowing was reported in 7.6 % of 
cases that required no additional measures.
No decisive conclusion could be drawn from the literature regarding the optimal 
effective dosage of BoNT for injection into the salivary glands. Determining the 
optimal effective dose was not an objective of the present study. The dosages used in 
this study, appearing to be effective, were derived from existing guidelines for intra-
muscular injections and are far within the safety limits of Botox®18. The volume in 
which the BoNT should be diluted was based on the findings of an in-vitro study 
regarding the spread of BoNT in the gland after injection4. Recent reports mention 
successful treatment of drooling using lower dosages of Botox®2,3. Taking this into 
account it is not likely that too low dosages were used in our study. 
Considering the side effects as observed of scopolamine, BoNT injections are more 
favorable when salivary flow reduction is needed in the treatment of drooling. Although 
temporary, salivary flow reduction following BoNT injections is of satisfying duration 
for the responders. A disadvantage is the need for anesthesia in the treatment of 
children. Surgery, providing a definite solution, also has to be considerate as a potential 
alternative. Further research is needed to investigate the long-term outcome of BoNT 
injections into the submandibular glands also in combination with the parotid glands. 
Dose-finding studies are warranted. The technique of intraglandular BoNT injections 
has to be compared to surgical interventions. In this respect it seems of great 
importance to define age groups or specific diagnoses in both children and adults that 
form particular indications for one or the other approach.
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Abstract
Objective: To investigate the clinical effectiveness of Botulinum neurotoxin type-A 
(BoNT) to reduce drooling in children with cerebral palsy (CP).
Methods: A controlled clinical trial was performed in which the results of single-
dose BoNT injections in the submandibular glands were compared to treatment 
with scopolamine. Forty-five children who had CP and experienced severe drooling 
were enrolled. Drooling severity was measured at baseline, during application of 
scopolamine and at different intervals after BoNT injections up to 24 weeks, using the 
Drooling Quotient (DQ), the Teacher Drooling Scale (TDS) and Visual Analog Scales 
(VAS).
Results: Drooling was reduced during scopolamine application as well as following 
BoNT injections. Compared with baseline, the mean DQ showed a significant decrease 
throughout the study. Greatest reductions were achieved 2 to 8 weeks after BoNT 
injection. No significant differences were found between scopolamine measurements 
and those up to 24 months after BoNT injection. Using VAS, parents recorded the 
effect on drooling in which significant differences were found between baseline VAS 
score and all follow-up assessments. According to our definition of “success to 
therapy”, demanding a 2-point decrease on the TDS, 61.5 % of patients responded 
to BoNT injections. Analysis of the DQ demonstrated a response rate of 53% of the 
patients to scopolamine and 48.7% to BoNT until 24 weeks after BoNT injections, the 
actual duration of this study. As a reaction to scopolamine, 71.1% of the patients had 
moderate to severe side effects. Only non-severe, incidental side effects were reported 
following BoNT injections.
Conclusions: During scopolamine application as well as following intra-glandular BoNT 
injections, a clinically relevant reduction of drooling was achieved in children with CP, 
demonstrating maximum effect 2 to 8 weeks after injections. This is the first controlled 
clinical trial that confirmed a significant effect of BoNT injections in the treatment of 
drooling. General anesthesia was needed for all children. BoNT injections show fewer 
and less serious side effects than transdermal scopolamine treatment. 
Introduction
Drooling is an important clinical problem in ~ 10% to 38% of cerebral palsy patients1-3. 
Insufficient control of the coordinate mechanism of orofacial, palatolingual, and head 
and neck musculature results in excessive pooling of saliva in the anterior part of the 
oral cavity and unintentional saliva loss4. Hypersalivation is generally not the case 
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in children with CP. Direct saliva collection can be performed by the swab method 
in which absorbent cotton rolls are placed directly at the orifices of the glands for 5 
minutes. The flow rate can be calculated by the formula: Salivary flow rate [mg/min] = 
(weight increase of rolls [mg] / time of collection [min])5;6.
The clinical evaluation of drooling severity and frequency is difficult because of within-
subjects fluctuation during the day and a large between-subjects variation. Several 
systems have been used and advocated for assessment of the extent of drooling,. 
Since its introduction, various modifications of the Drooling Quotient (DQ) have 
been used7;8-13. The DQ is a validated semi-quantitative, direct observational method 
(see: methods)7;14. Rating scales such as the Teacher Drooling Scale (TDS) have been 
designed to assess drooling severity and frequency. The TDS is a useful tool for out-
patient visits15. 
The management of drooling remains a problem. Despite effective treatment 
modalities to diminish saliva production drooling may persist. Many factors contribute 
to the saliva passage from the oral cavity to the esophagus, such as the child’s mental 
abilities, the cognitive awareness of social norms, an intact swallowing mechanism, 
oral sensibility, lip closure, and the ability to hold the head in an upright position. 
In addition, variables that may influence salivary flow rate are medication, circadian 
rhythms, prestimulation, gender, age, psychological effect, and general health16-21. 
The effective reduction of saliva production is relevant to the patient only when the 
treatment leads to a clinically apparent diminished drooling.
Conservative treatments as well as surgical procedures all have their limitations22. 
Recent reports suggested Botulinum neurotoxin type-A (BoNT) injections into the 
salivary glands as an option for treatment of drooling6;9;10. These reports are case 
series and small cohort studies lacking the power to prove the efficacy of BoNT 
injections. Ellies et al studied a larger population and concluded that the BoNT effect 
lasted for ~ 2 to 3 months23. From the pharmacological profile of BoNT, an appreciable 
anticholinergic effect can be expected. In particular, type-A toxin cleaves SNAP-25, 
an enzyme involved in the release of acethylcholine at the presynaptic membrane of 
parasympathetic nerves. In this way, a temporary denervation of the target organ is 
established. Botulinum toxin is known to give clinically relevant results for 9 to 12 
months in other conditions involving the autonomic nervous system, for example 
hyperhidrosis24;25. Although BoNT has been suggested for clinical use in the treatment 
of drooling, uncertainty remains about the clinical effect and duration.
In this study, a controlled clinical trial on the treatment of drooling has been 
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performed in which BoNT injections in the submandibular glands were compared 
with scopolamine treatment. Difference scores of semi-quantitative measurements 
of drooling (Drooling Quotient; Teacher Drooling Scale; Visual Analog Scales) were 
analyzed. The null hypothesis that ‘the effect on drooling would not differ between 
scopolamine and BoNT’ was tested.
Method and material
Patients
Forty-five children with the diagnosis CP were recruited from the outpatient clinic and 
enrolled in the study between January 2000 and November 2001. Consecutive subjects 
were included during a qualification period in which inclusion criteria and exclusion 
criteria were examined (Table 1.3).
A score of 3 or higher on the TDS (Table 8.1) was mandatory to be included in the 
study15. All drugs used were carefully evaluated to assess their influence on saliva 
secretion.
Table 8.1: Teacher drooling scale
1 No drooling
2 Infrequent drooling; small amount
3 Occasional drooling; intermittent all day
4 Frequent drooling; but not profuse
5 Constant drooling; always wet
Drugs to treat drooling had to be stopped at least three months before participation. 
Throughout the study, no medication that could influence the severity of drooling 
was allowed. No requirements were set with regard to the child’s level of mental 
development.
Possible adverse effects and risks related to the interventions during the study were 
explained to the parents. Written informed consent was obtained. The Hospital’s 
Human Research Committee approved the study.
Study Design
The study was executed as a controlled, open-label, clinical trial. The difference 
between the 2 episodes of treatment had to be at least 1 SD. Drooling evaluation (see 
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Procedures) was performed during baseline, scopolamine application, and after BoNT 
injections into the submandibular glands. The sequence of interventions had a fixed 
order: scopolamine before BoNT. This was chosen because the washout period of 
scopolamine is known, whereas the duration of the supposed effect of BoNT needed to 
be determined. An independent employee assessed the primary outcome parameters 
blinded for the status of the participating patients, which was achieved by varying the 
number of baseline measurements among the patients according to a predetermined 
schedule.
In view of side effects of scopolamine, the protocol anticipated that some of the patients 
might not complete the scopolamine period. When scopolamine was used for <48 
hours, the patient was considerate a dropout. When scopolamine was discontinued >48 
hours after start, the patient remained in the study, provided a control measurement 
was obtained within the first 24 hours after discontinuation of the therapy.
Patients returned for follow-up measurements at 2, 4, 8, 16 and 24 weeks after BoNT 
injections. Patients had to have undergone at least 1 of the scheduled investigations 
at 2, 4 or 8 weeks. At least 3 of 5 visits within the first 24 weeks after BoNT injections 
had to be conducted.
If a patient was excluded during the use of scopolamine or during the washout period, 
it was planned to contact the parents by telephone after 2 and 4 weeks to check for 
adverse effects or other complaints. Dropouts after the BoNT injections were to be 
contacted monthly until 24 weeks post injection.
Procedures
A scopolamine patch (Scopo-derm TTS®, Novartis Consumer Health BV, Breda: 
The Netherlands) was placed behind the ear and changed within every 72 hours. An 
assessment was scheduled on the 10th day with the 4th plaster in situ being applied 
no longer than 48 hours before. After a washout period of 2 to 4 weeks, the child 
was admitted for outpatient treatment. Using general anesthesia for all patients, a 
single dose of Botulinum toxin (Botox®, Allergan, Nieuwegein: The Netherlands), 
reconstituted with 0.9% sodium chloride solution, was injected bilaterally in the 
submandibular glands using a 25 G needle (Spinocan®) and a 1 mL syringe. Weight-
dependent dosages were injected in each gland: 15 U/gland for children who weighed 
<15 kg, 20 U/gland for children with a body weight of between 15 kg and 25 kg, and 25 
U/gland for children who weighed >25 kg. On injection, each dose was fractionated 
and divided over minimally 3 sites in the gland.  Ultrasound guidance was performed 
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using a system (SAL 250: Toshiba medical systems cooperation, Tokyo, Japan) 
equipped with a 7.5-MHz transducer. Only the submandibular glands were injected. It 
is generally accepted that these glands produce 60 to 70% of secreted resting saliva 
when the individual is not eating or drinking26. Saliva that is produced during eating 
and drinking is produced mainly by the parotid glands, with which we did not want to 
interfere. The sublingual glands, contributing up to 5% to the total saliva production, 
were not treated.
After BoNT, parents were asked to register all possible side effects in a diary. These 
were discussed during outpatient visits.
Assessment of drooling
The DQ and VAS served as the primary outcome measures for this study. The TDS, 
scored on an ordinal scale, was used to give supportive evidence for the efficacy of 
BoNT.
The DQ was scored according to its original design during two periods of 10 
minutes separated by a 60 minute break7. An episode of drooling was defined as 
new saliva present on the lip margin or dropping from the chin12. Every 15 seconds 
(40 observations in 10 minutes) the presence or absence of drooling was assessed. 
Patients were evaluated at least one hour after a meal while awake and sitting erect. 
Two speech therapists were especially trained to execute the measurements. Separate 
observations were made during different activities: 1 with the child watching TV and 1 
during an activity, as chosen by the child, that demanded a higher level of concentration 
or physical effort. The mean of the 2 observations was used for analysis to provide an 
outcome on a numerical scale.
The DQ was expressed as a percentage estimated from the ratio of observed drooling 
episodes and the total number of observations (DQ [%] = 100 X number of drooling 
episodes/40)8.
DQ assessments were made at baseline, during the use of scopolamine, at washout 
after ending scopolamine therapy, and at regular intervals after BoNT injections (2, 4, 
8, 16, and 24 weeks).
After receiving specific instructions, parents filled out Visual analog scales (VAS) in 
order to investigate therapy results as experienced in the home situation. Scales of 
exactly 10 cm without visible subdivisions were presented on which the average degree 
of drooling severity during the 10 to 14 days before assessment had to be indicated. 
A mark at the left end represented severe drooling; a mark at the right end meant 
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no drooling. An independent employee scored the VAS with a ruler in millimeters, 
resulting in a number ranging from 0 to 100, which was handled as a parametric 
variable. VAS assessment was made at baseline, during the use of scopolamine and at 
regular intervals after BoNT injections (4, 8, 16, and 24 weeks).
The TDS (Table 8.1) was used to assess the degree of drooling by interviewing the 
parents or caregivers during outpatient visits15. Assessments of TDS were made at 
baseline and after BoNT injections (8 and 24 weeks). Before analysis of the data, a 
significant reaction to therapy was defined as a 2-point improvement on the TDS 
(range 1-5, Table 8.1). The outcome after BoNT injections is only used to support the 
findings in the DQ and VAS data.
Statistics
A power analysis was performed before start of the study. Approximately 40 subjects 
were needed to reach a power of 80% with an alpha of 0.05. The difference between 
the 2 episodes of treatment had to be at least 1 SD. Assuming a dropout percentage 
of 7%, the inclusion of 45 subjects was sufficient. Because of the complexity of the 
design and vulnerability of the patients, missing data were inevitable. For this reason 
data were adjusted in 2 ways: 1) by carrying the last observation forward (clof) and 
2) by a worst-case scenario (wcs) system. In the wcs procedure all missing data were 
replaced by baseline values. In this way the effect difference between the therapies was 
“reduced” by introducing a bias towards the null. The outcomes of both approaches 
were compared.
All statistical procedures were carried out with SPSS/pc+(tm) (version 9.0; SPSS, Inc, 
Chicago, IL). Data analysis included descriptive statistics; multivariate analysis of 
variance (MANOVA) of repeated measurements to identify patterns of response over 
time, using a within-subjects design with the measurement moments as the variables; 
and paired-samples t tests to analyze differences of paired observations (DQ and VAS) 
at subsequent measurements. In addition, success of therapy for either scopolamine 
or BoNT was defined as a decrease in DQ of at least 50% of the patient’s baseline 
value. Frequency analyses were performed to determine the percentage of responders 
in the population. A Wilcoxon signed-ranks test was used to analyze changes in TDS 
(ordinal scale). For all statistics a level of significance with a one-sided p-value ≤.05 
was mandatory.
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Results
Forty-five children were included; 28 boys and 17 girls (age: 3-16 yrs; mean: 9.5; SD: 3.7). 
Eight were ambulant without aid, 37 had wheelchairs, 22 could not talk, 29 attended 
a special education school, and 14 went to a daycare center for mentally handicapped 
children. Thirty-four children had a mental retardation with a developmental level <6 
years as determined by psychological investigation.
None of the subjects was treated with Botulinum toxin before. By the end of the trial, 6 
dropouts had occurred: 4 patients could not fulfill the scopolamine period, 1 changed 
anti-epileptic medication, and 1 did not attend the required measurements because 
of an intercurrent illness not related to the trial. The results of 39 patients could be 
analyzed.
DQ
In the first instance, analyses were executed with ‘clof’ data. Descriptive statistics of 
the consecutive measurement moments showed that, compared with baseline, the 
mean DQ decreased during scopolamine application as well as after BoNT injections, 
which is shown in Figure 8.1. 
Figure 8.1: Mean drooling quotient in time
 
Sc = Application of Scopolamine; BTX = Injection of Botulinum Toxin 
BoNT = Botulinum toxin; BoNT-X = interval in weeks after injections; DQ = Drooling Quotient
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With the DQ at each moment in time defined as the within-subjects variable, a 
MANOVA with a repeated measurements design was executed to evaluate the pattern 
of response during the trial (Hotelings trace: F=12.79; df (7.00); p = .000).
An effect over time was found as depicted in the Fig 8.1 and described in additinal 
detail by analysis of difference.
Univariate analyses were executed to further analyze interval difference scores. To justify 
the length of the washout period, we compared the DQ values at baseline with the 
measurements after washout of scopolamine, using a paired-samples t test. The mean 
change in DQ from baseline to washout value was estimated to be -1.60 which was a 
non-significant difference (t = -0,464; df (38); p =.32, 1 tailed). This finding minimizes 
the probability of a carryover effect from scopolamine treatment to BoNT, indicating 
that the length of washout after scopolamine application was sufficient. 
Changes in DQ (expressed as differences), SD, and p values between baseline and the 
subsequent measurements are tabulated in Table 8.2. All DQ measurements showed 
a significant decrease (mean differences ranging: 15.5 to 21.7; p ≤.05, based on paired-
samples t tests).
The greatest reduction was achieved 2 weeks after BoNT injections (BoNT-2: mean 
difference score 21.7; SD 18.3; p =.000). The DQ increased slightly after BoNT-2. At the 
end of the study, though, a significant reduction of drooling was still found, implying 
an ongoing effect.
Table 8.2: Mean differences between baseline and follow-up measurements
    DQ                VAS
 Difference (SD) Significance# Difference (SD) Significance#
Bl / scopolamine 17.7 (21.2) 0.000 -34.3 (30.9) 0.000
Bl / BoNT-2 21.7 (18.3) 0.000
Bl / BoNT-4 16.1 (18.9) 0.000 - 30.1 (22.8) 0.000
Bl / BoNT-8 20.0 (20.5) 0.000 - 22.1 (23.9) 0.000
Bl / BoNT-16 15 .5 (19.1) 0.000 - 20.5 (24.9) 0.000
Bl / BoNT-24 15.7 (16.4) 0.000 - 13.5 (25.7) 0.002
Bl = baseline; BoNT = Botulinum toxin; BoNT-X = interval in weeks after injections; DQ = drooling 
quotient; VAS = Visual Analog Scale. 
#paired-samples t tests, one-sided p-value ≤.05
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During additional analysis, scopolamine measurements were compared with the 
measurements after BoNT injections up to 24 weeks (Table 8.3). 
Table 8.3: Mean differences between scopolamine and BoNT measurements
    DQ                 VAS
 Difference (SD) Significance# Difference (SD) Significance#
Sc / BoNT-2  4.1 (16.5) 0.131 
Sc / BoNT-4 - 1.6 (19.2) 0.604 4.2 (31.3) 0.405
Sc / BoNT-8 2.4 (21.7) 0.502 12.2 (30.9) 0.018
Sc / BoNT-16 - 2.2 (21.8) 0.528 13.7 (32.9) 0.013
Sc / BoNT-24 - 2.1 (20.2) 0.529 20.7 (39.9) 0.002
Sc = scopolamine; BoNT = Botulinum toxin; BoNT-X = interval in weeks after injections; DQ = drooling 
quotient; 
#with paired samples t-tests, one-sided p-value ≤ 0.05
No significant differences were found (mean differences; -2.2 to 4.1; p > 0.05, based on 
paired-samples t tests). Analysis of “worst case scenario” data did not lead to different 
results comparing baseline with both treatments. 
According to our definition of success to therapy, patients could be assigned as a 
responder if baseline DQ decreased by 50% or more during the interventions. Analysis 
of frequencies was done. During scopolamine, 53% of the patients were recognized as 
responders. Response rates to BoNT were as follows: BoNT-2, 64.1%; BoNT-4, 43.5%; 
BoNT-8, 53%; BoNT-16, 41%; and BoNT-24, 48.7%.
VAS
The analysis of the VAS showed an effect over time. With the VAS at each moment in 
time defined as the within-subjects variable, a MANOVA with a repeated measurements 
design was executed to evaluate the pattern of response during the trial (Hotelings 
trace: F = 16.55; df (5); p = .000). Fig 8.2 shows the course of the mean scores at the 
subsequent measurement moments.
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Figure 8.2: Mean VAS in time
 
 
 
 
 
 
VAS = Visual analog scale; BoNT = Botulinum toxin;  
BoNT-X = interval in weeks after injections
The degree of reported drooling by the parents declined substantially when baseline 
numbers (VAS: 19.3; SD: 13.4; range: 2-61) were compared with measurement during 
scopolamine application (VAS: 53.6; SD: 13.4; range: 0-96). Measurements scored 
by the parents after BoNT demonstrated good results with a maximum reduction at 
BoNT-4 (VAS: 49.3; SD: 24.5; range: 8-93). The VAS score at BoNT-4 was in the same 
range as during scopolamine application, revealing no significant difference (mean 
difference: 4.2; SD: 31.3; t -0,842; df = 38; p = .20, 1-tailed). Analyses of VAS difference 
scores were performed, using paired-samples t tests to compare baseline values with 
the results after therapy (Table 8.2). All differences were significant, indicating that 
parents reported diminished drooling throughout the study. In addition, scopolamine 
VAS scores were compared with all subsequent BoNT measurements (Table 8.3), using 
paired-samples t tests. No differences were found meaning that the outcomes of both 
therapies as reported by the parents were in the same range.
TDS
Patients had to score 3 or higher on the TDS to be included in the study. At start of the 
study 94.9% of the patients had a score of 5 with the remaining 5.1% having a score 
of 4.  A success to therapy was defined as a 2-point improvement on the TDS (see 
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methods). The Wilcoxon signed-ranks test was used to analyze changes in TDS over 
time. Compared with baseline, a significant decrease was observed at BoNT-8 (Z = -
4.8; p = .000, 1-tailed) and BoNT-24 (Z = -4.1; p = .000, 1-tailed). The TDS is an ordinal 
scale; as such, the outcome can only provide supportive evidence. To confirm the 
outcome, the TDS should show changes in the same direction as the VAS (Fig 8.3).
The curve shows that at baseline, all patients were severely drooling (mean: 4.9). 
Drooling diminished after BoNT injections. At BoNT-8, the mean score decreased to 3, 
indicating occasional drooling. At BoNT-24, the mean TDS score equaled 3.8.
Figure 8.3: Mean TDS in time
 
 
 
 
 
 
 
 
TDS = Teacher drooling scale; BoNT = Botulinum toxin; BoNT-X = interval in weeks after injections
The TDS was also used to define success to therapy (see Methods). An analysis of 
frequency of scores on the TDS was made to provide insight into parents’ recognition 
of the BoNT therapy effect. Eight weeks following the BoNT injections, TDS scores were 
as follows: 1, 15.4%; 2, 28.2%; and 3, 17.9%. This indicates that 61.5 % of the patients 
were good responders according to our definition. 15.4 % of the children changed only 
slightly (score: 4). Twenty-three percent of the cases, representing 9 patients, did not 
show improvement compared to their initial score. Eight (20.5%) patients  remained 
at score 5 and 1 (2.5%) patient at score 4. None of the parents reported an increase in 
drooling severity as a result of therapy.
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None of the patients showed improvement between BoNT-8 and BoNT-24. TDS 
frequency scores at BoNT-24 were as follows: 1, 5.1%; 2, 15.4%; 3, 15.4%; 4, 20.5%; 
5, 43.6%. At 24 weeks following BoNT injections, 35.9% of the parents still reported 
a good effect, whereas 43.6% of the children had returned to baseline value, among 
them the 20.5% who did not react to therapy at all.
Side effects
Parents scored the extent of side effects on a 4-point scale (0 = no side effect; 1 = mild, 
not every day/occurring sometimes; 2 = moderate, present every day; 3 = severe side 
effect, constantly present). Side effectsas a result of scopolamine became apparent 
within the first three days of administration, and several patients complained of >1 
symptom. Adverse effects during application of scopolamine were reported in 82.2% 
of cases. Five (11.1%) patients had mild, 14 (31.1%) patients had moderate, and 18 
(40%) patients had severe side effects.
Most often reported adverse effects were xerostomia (66.7%), restlessness (35.6%), 
somnolence (35.6%), blurred vision because of pupillary dilatation, and confusion 
(20%). Four out of the 6 dropouts from the study had to end their participation 
because of adverse effects to scopolamine. In all 4 cases, restlessness, apparent in 
their movement performance, and confusion were the main reasons to terminate 
scopolamine use. After BoNT injections, incidental side effects were reported. Two 
(5.1%) patients had a transient flu-like syndrome lasting for <2 days. Another 3 patients 
complained of mild difficulty with swallowing. 
Discussion
This is the first controlled, clinical trial evaluating the treatment of drooling in children 
with CP by comparing the efficacy of 2 different anticholinergic agents: bilateral single-
dose BoNT injections into the submandibular glands and transdermal scopolamine. 
A positive clinical effect from intra-glandular BoNT injections as well as scopolamine 
application was found. Scopolamine was expected to have a greater effect on 
drooling because of its systemic availability, influencing the submandibular glands, 
the sublingual glands, and the parotid glands apart form all minor glands within the 
mucosa of the oral cavity. As chosen during this trial, BoNT is injected only focally into 
the submandibular gland. Nevertheless, the short-term effect on drooling by intra-
glandular BoNT injections was of the same magnitude as that of scopolamine. This 
outcome is compatible with the concept that the submandibular glands produce a large 
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part of resting saliva. In addition, it underlines that BoNT has a strong anticholinergic 
effect in the target glands.
The outcomes of clinically relevant parameters (DQ and VAS) were in accordance with 
each other, showing a reduction in drooling following both interventions. The parents’ 
reports about their child’s drooling at home (VAS scores) showed significant change. A 
similar positive effect was demonstrated in the reduction of DQ after BoNT injections 
up to 24 weeks, the end of the study. Response rates, as analyzed in the DQ data, were 
high. Of all patients, 53% responded during scopolamine, 64.1% responded 2 weeks 
after BoNT injections, and 53% responded 8 weeks after injections. After 24 weeks, 
48.7% of the patients still responded to BoNT. Success to therapy was also defined 
as a 2-point decrease of the TDS as compared with baseline. Eight weeks after BoNT 
injections, 61.5% of the patients could be registered as responders according to the 
TDS approach. At the end of the study (BoNT-24), 35.9% of the patients were still 
responding to the BoNT injections.
The outcome of success to therapy as described with the DQ is based on an objective 
observation expressed on a numerical scale. The result of the TDS is a subjective 
expression on an ordinal scale. Still, the results of both observations on BoNT are 
congruent. Comparable outcomes on drooling in BoNT studies have been reported in 
observational studies9;10.
Transdermally applied scopolamine and oral anticholinergic agents like glycopyrrolate 
and benztropine have been widely investigated in the treatment of drooling8;15;27-34. 
Lewis et al randomly assigned patients to a 2-weeks use of scopolamine patches and 
placebo patches using a cross-over design31. Success to therapy was recorded in 80% 
of patients. Blasco performed a prospective open-label study in which 90% of the 
patients had reduced drooling in response to glycopyrrolate, based on the subjective 
reports by parents28. Bachrach investigated the results of glycopyrrolate among 37 
patients in a questionnaire based cohort study27. Parents were asked to describe the 
amount of drooling before medication had begun and while their child was taking the 
medication, using a five-point scale. A significant improvement was present in 95% 
of cases. Mier et al used increasing dosages of glycopyrrolate in a placebo-controlled 
clinical trial32. According to their definition of success to therapy, 81% of patients 
responded to the highest dosage. The abovementioned success rates all exceeded the 
53% responders found in the present study. An explanation for this difference could 
be that the definitions of response (a 50% reduction or more of the DQ, in our study) 
used in the studies are not be interchangeable.
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Disadvantages of systemic anticholinergic drugs are the many side effects. Severe 
side effects were observed in 40% of cases. Symptoms like xerostomia, restlessness, 
somnolence, blurred vision, and confusion were apparent in this study, necessitating 
ending the therapy in 7% of the participants. In this way, 4 of 6 dropouts were due 
to scopolamine. It was theorized that side effects are probably even underscored 
in this study population, taken into account the patients’ inability to present their 
complaints clearly. Besides, scopolamine was applied for a relatively short period. 
Thus, continued use of scopolamine in a dosage large enough to treat severe drooling 
seems undesirable. 
Side effects due to anticholinergic therapy are also described in other studies. 
Lewis et al (1994) reported two-third of his population to have pupillary dilatation 
and ~ 27% demonstrated pruritus or increased mouthing behavior as a reaction to 
scopolamine31. Applying glycopyrrolate (Blasco, 1996), 32.5% of the patients had 
adverse effects of which behavioral changes (13%) were specified in a percentage28. 
Mier et al reported that adverse effects were common, affecting 69% of the children 
taking glycopyrrolate32. The identified side effects ranged from 10 to 23%, comprising 
behavioral changes, facial flushing, nasal congestion, constipation, vomiting, diarrhea, 
dry mouth, urinary retention, and blurred vision. Seven of 36 participants withdrew 
from the study because of side effects. Although side effects seem to be common in 
relation to the use of anticholinergic drugs, the intensity and the occurrence of central 
effect may vary, depending on the drug of choice.
BoNT led to temporary complaints about swallowing in 2 cases. This was ascribed 
to local swelling in 1 patient. In another case moderate difficulty with swallowing 
developed after 1 week and remained for 10 days. It was theorized that this might have 
been the result of diffusion of BoNT into the surrounding muscles. Other authors 
explicitly noted that no side effect were seen following BoNT injections23.
BoNT, when accidentally injected next to the salivary glands, will influence neural 
activity at the neuro-muscular junction as well. To avoid side effects and achieve 
optimal results, ultrasound guidance is strongly recommended5;23;35;36. Although easy 
to perform, BoNT injections are to some extend invasive. General anesthesia could be 
regarded as a disadvantage. In this respect it most be emphasized that other authors 
perform the procedure without anesthesia23.
As chosen in our protocol, only the submandibular glands were treated. However, 
it must be realized that there may exist indications to treat the parotids as well, for 
example excessive drooling during eating and drinking.
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To our knowledge, this is the first controlled clinical trial in the treatment of drooling, 
evaluating the effect of scopolamine application and intra-glandular BoNT injections 
into the submandibular glands. Both treatments significantly reduced drooling 
compared with baseline. The outcome of both therapies is in the same range and, no 
significant differences were found between DQ measurements during scopolamine 
and BoNT. A disadvantage in the treatment with scopolamine is the high percentage 
of observed adverse reactions, whereas BoNT injections need general anesthesia in 
children. The BoNT effect is temporary, although longer duration might be expected 
especially after recurrent treatment because of supposed hypotrophy of the glands after 
long denervation. Referring to the demands about the diagnosis and TDS, as stated in 
the inclusion criteria, the generalizability of this study is limited to comparable groups 
of patients. Further research is needed to investigate BoNT therapy in other groups 
and to compare it to other interventions to treat drooling, such as surgery. Considering 
the social burden to the affected children it is relevant to develop clinical guidelines 
to distinguish types and age groups of drooling patients in order to optimize the 
treatment modalities that are specifically effective.
In conclusion, during scopolamine application as well as after intra-glandular BoNT 
injections a clinically relevant reduction of drooling was achieved in children with 
CP, demonstrating maximum effect 2 to 8 weeks after injections. Analysis of the DQ 
demonstrated a response rate to scopolamine of 53% and of nearly 50% until 24 weeks 
post BoNT injections, the actual duration of this study. Additional research is warranted 
to optimize selection of patients in an effort to maximize the therapeutic effect.
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Abstract
Background: anterior drooling and posterior drooling are two distinguished phenomena. 
The latter refers to saliva that is spilled over the tongue through the faucial isthmus. 
Posterior drooling in children with cerebral palsy may lead to salivary aspiration and 
pneumonia. The objective of this study was to evaluate the effect of Botulinum toxin 
on posterior drooling. 
Method: the mechanism of posterior drooling and the consequences are described 
and illustrated by the case report of a severely drooling 9-year old boy with cerebral 
palsy. He was treated by repeated bilateral intra-glandular Botulinum toxin injections in 
the submandibular glands. Salivary secretions were measured from all major salivary 
glands to obtain information about the flow rate from each oral region. In addition, the 
degree of drooling was assessed by an observational method, and by means of Visual 
Analog Scales that were completed by the parents. Video fluoroscopic swallow studies 
were done to evaluate the situation before and after treatment. 
Results: the salivary flow rate from the injected glands was substantially reduced. Visible 
anterior drooling diminished substantially. From the clinical course after injections a 
reduction of posterior drooling became clear. Episodes of recurrent pneumonia, as 
were seen before treatment disappeared for 7 to 12 months. 
Conclusion: Injections with Botulinum toxin may become to play an important role 
in the treatment of posterior drooling, although further research in a larger group of 
patients is needed.
Introduction 
Impairment in swallowing can result in drooling, which has been reported in about 10 
to 37.4% of cases of children with cerebral palsy (CP)1;2. These children often have a 
poor synchrony of lip closure, demonstrate an open bite, score lower on tests for oral 
sensation, and have a lower frequency of conscious swallowing3-7.
The mechanism of drooling is explained by disturbances in the phases of normal 
swallowing: 1) the oral ‘preparatory’ phase, 2) the oral phase, 3) the pharyngeal 
phase, and 4) the esophageal phase. The preparatory and oral phases are completely 
voluntary, the pharyngeal phase has both voluntary and involuntary components and 
the esophageal phase is fully involuntary8. 
The oral preparatory phase is needed to form a bolus. The length depends on the 
composition and texture of the food. The oral preparatory phase becomes important 
when spoon-feeding starts, normally at four to six months of age. Lip closure is needed 
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to hold the bolus in the mouth and the soft palate is brought in a lowered position, to 
prevent the bolus from entering the pharynx before a swallow is initiated. The larynx and 
pharynx are at rest and there is an open airway enhancing nasal breathing. The onset 
of the oral phase starts with elevation of the tongue of which the anterior part contains 
the bolus. The tongue carries the bolus in posterior direction by peristaltic movements, 
making sequential contact with the hard and soft palates.  On the average, the length 
of the oral phase is about 0.5 seconds. The voluntary control of swallowing ends when 
the bolus reaches the posterior pharyngeal wall and continues into the pharyngeal 
phase of swallowing. The initialization of the pharyngeal swallow reflex occurs when 
the bolus appears in the space between the soft palate and the tongue, or when the 
bolus accumulates in the valleculae. This results in elevation of the soft palate, which 
closes the nasal-pharynx. The larynx closes to protect the airway in combination with 
relaxation of the upper esophageal sphincter. The pharyngeal phase of swallowing 
continues automatically in the esophageal phase of swallowing.
Drooling is the unintentional loss of saliva from the mouth, known as anterior 
drooling9;10. However, anterior drooling has to be distinguished from posterior drooling 
which refers to saliva that is spilled over the tongue through the faucial isthmus. Under 
physiological conditions this initiates the pharyngeal phase of swallowing, during which 
the larynx closes to protect the airways followed by relaxation of the upper esophageal 
sphincter. Whenever the trigger to swallow is impaired or missing pooled saliva may 
lead to posterior drooling mostly apparent from an alarming congested breathing, 
coughing, gagging, vomiting, and at times aspiration into the trachea. Unrecognized 
and “silent” pneumonia can occur11;12. The risk of posterior drooling can be enhanced 
by the fact that many disabled children are taken care of in a supine position for a 
substantial part of the day.
A complex interaction exists between gastro esophageal reflux and salivary flow rate. 
In healthy subjects exposure of the distal esophagus to acid results in an immediate 
increase of saliva secretion. The possible function of this is that swallowed saliva 
plays a role in the defense of esophageal mucosa to acid-induced injuries. Reflux in 
children with CP causes stimulation of pH-sensitive receptors in the mucosa of the 
distal esophagus which activates the esophageal-salivary reflex leading to an increase 
of salivary flow rate with resultant drooling13;14. The same mechanism may also cause 
deterioration of posterior drooling. In addition, chronic gastro esophageal reflux itself is 
a well-known clinical entity causing chronic aspiration of gastro-intestinal contents15-17. 
Up to 60% of severely impaired children aspirate18;19.
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Botulinum neuro-toxin (BoNT) injections in the salivary glands in the treatment of 
anterior drooling demonstrate promising efficacy20-24. 
This case-report summarizes the results of repeated bilateral single-dose BoNT 
injections into the submandibular glands in a patient with CP with severe drooling, 
aspiration, and recurrent pneumonia. The primary treatment intention was to decrease 
salivary flow in an effort to reduce anterior as well as posterior drooling.
Patient and methods
The patient
A male (9 yr and 4 months of age; diagnosis CP; quadriplegic spastic athetosis; 
wheelchair dependent) was referred to our outpatient clinic because he constantly 
drooled in a manner that clothes, furniture, and objects became wet. He used to 
withdraw from peer activities because of his drooling.
Detailed characteristics of the patient are tabulated in table 9.1. 
Table 9.1: Characteristics at entry of the study
Gender Male
Age at entry of the study 9 years; 4 months
Birth A term; vacuum extraction; Apgar: 4-4-5; Intra-cerebral bleeding
Diagnosis Cerebral palsy; Quadriplegia; Epilepsy; Mental retardation
Movement disorder Spastic/dyskinetic movement disorder; Ashworth score 4  
 (arms and legs)
Unsupported sit Not possible
Head balance Insufficient
Mobility Wheelchair bound
Activity of daily living Dependent
Feeding Feeding and swallowing problems; Percutaneous gastro-stoma  
 (at age 3 yr)
Oral motor performance Hyper-tonicity
Hyper-reflex activity Slow uncoordinated tongue movements; tongue trusting activities
Increased swallowing time Hyper sensibility
Insufficient lip closure Mal occlusion
Speech Anarthria; use of ‘my voice’ computer aided communication
Drooling Profuse Anterior and Posterior Drooling; TDS score of 5
General health Chronic distal esophagitis; gastro-esophageal reflux;  
 Recurrent pneumonia
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In the 2 years prior to consultation episodes of pneumonia had occurred averagely 7 
times a year. He had gastro-esophageal reflux and was mainly fad by a percutaneous 
endoscopic gastrostomy (PEG). Stasis of saliva in the oral cavity and hypopharynx 
was always present. Congested breathing resulted in restless sleep during which he 
choked on his own saliva. He used an anticholinergic drug to reduce the discomfort 
of drooling.
Assessments
The oral anatomy, sensitivity, reflex activity, and oral-motor skills were assessed (Table 
9.1).
To measure salivary flow rate the ‘swab method’ was used during which absorbent 
dental cotton rolls (Salivette®: Sarstedt B.V, Etten-Leur, The Netherlands) were placed 
directly at the orifices of the larger glands for a 5-minute period. The salivary flow rate 
for each separate salivary gland was calculated by the formula:
Salivary flow rate [mL/min] = (weight increase of dental rolls / time of collection). The 
assessments were conducted by the same speech pathologist, always in the morning 
following 1 hour of starvation. The procedure was repeated 30 minutes later. The mean 
of the two measurements was used as the result for the study.
Because of the close anatomical relation between the sublingual and submandibular 
glands, separate flow rates could not be obtained. The compound salivary flow from 
these two glands is referred to as submandibular flow (SubFl). 
The drooling quotient, visual analogue scales, and the Teacher Drooling Scale (TDS) 
were used to assess the degree of drooling25.
The TDS rates anterior drooling on a 5-point scale. A score 5 indicates ‘constantly wet 
and saliva leaking on clothes and furniture’, 3 means ‘occasionally drooling’, and 1 
indicates ‘no drooling’.
The drooling quotient (DQ), an observational method, was scored according to its 
original design during two periods of 10 minutes separated by a 60-minute break. An 
episode of drooling was defined as new saliva present on the lip margin or leaving 
the chin. Every 15 seconds (40 observations in 10 minutes) the presence or absence 
of drooling was assessed. Evaluation took place at least one hour after a meal while 
awake and sitting erect. The DQ was expressed as a percentage estimated from the 
ratio of observed drooling episodes and the total number of observations (DQ [%] = 
100 X number of drooling episodes/40)26. The mean of both observations was used 
for analysis providing an outcome on a numerical scale.
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Visual analog scales of exactly 10 cm without visible subdivisions were presented to 
the parents. The average degree of drooling severity had to be indicated concerning 
the two weeks before assessment. Scoring, measured with a ruler in mm. resulted in 
a numerical outcome.
The patient was indicated for bilateral Botulinum toxin injections in the submandibular 
glands. Only the submandibular glands were injected. It is generally accepted that 
these glands produce 60 - 70% of secreted resting saliva, when the individual is neither 
eats nor drinks. The parotids respond explicitly during eating and drinking, producing 
much serous saliva, with which we did not want to interfere. 
The patient was followed in our clinic for several years and repeatedly received BoNT 
injections (Fig. 9.1).
Figure 9.1: Scheme of BoNT injections
  1st injection ----------------- 2nd injection ---------------------------------------------- 3rd injection
                >      Interval      <              >                       Interval                  <
                       7 months                                           12 months
Two weeks before the third injection and 4 weeks after this intervention Video 
fluoroscopic swallow studies (VFSS) were performed to assess the efficacy of 
swallowing.
Intervention
Under general anesthesia a single dose of 50 Units Botulinum toxin (Botox®: Allergan, 
Nieuwegein, The Netherlands) was injected bilaterally in the submandibular glands, 
using a 25 G needle (Spinocan®) and a 1 ml syringe. The total dosage was divided 
between the left and right gland. On injection, each dose was fractionated and divided 
over minimally three sites in the gland.  To locate the glands, ultrasound guidance 
was performed using a system (SAL 250: Toshiba medical systems cooperation, Tokyo, 
Japan) equipped with a 7.5-MHz transducer.
The patient returned for follow-up measurements (Flow, DQ, VAS) at 2, 8, 16, and 24 
weeks after the 1st BoNT injection and at 4, 8, 18, and 28 weeks after the 2nd injection. 
In addition, parents filled out extended questionnaires concerning items that could 
possibly be influenced by a change in salivary flow. Parents were also asked to register 
side effects of the BoNT injections in a diary.
164 Chapter 9
Results
The first BoNT treatment was given at the age of 9 years and 6 months. In the months 
following injection the flow from the submandibular gland, as investigated by the ‘swab 
method’ decreased (Figure 9.1, Table 9.2).
Figure 9.2: Submandibular salivary flow rate before and after 1st BoNT injections
 
Subm=submandibular; BoNT-x=time interval in wks after BoNT injections
Table 9.2: Assessment of salivary flow rate and drooling before and after treatment
 Base B12 B18 B116 B124 Base B24 B28 B218 B228 
 I     II
SubFL 0.59 0.31 0.31 0.28 0.38 0.38 0.11 0.22 0.30 0.28
DQ 46 6 4 2.5 7.25 24 7.5 12.5 16 7
B=Botulinum neuro-toxin; B1x=time interval in weeks after first BoNT injections; B2x= time interval in 
weeks after second BoNT injections; SubFL=submandibular salivary flow rate; DQ=drooling quotient
The TDS scored 5 at baseline. Eight weeks after the 1st injections TDS decreased to 2, 
indicating ‘sometimes drooling’.  In accordance with this the DQ was reduced by 91.3% 
(from 46 to 4). The outcome of the VAS assessments showed a similar trend: according 
to the parents’ opinion drooling was severe at baseline (VAS: 13) whereas it improved 
substantially 8 weeks after BoNT injections to mild drooling (VAS: 78). Approximately 
6 months after the BoNT injections (control visit 24 weeks) parents reported that, 
to their opinion, drooling had started to increase (VAS: 34). The SubFL and DQ had 
increased slightly although a substantial difference still existed compared to baseline 
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(Table 9.2). Based on the registrations of SubFL, DQ and VAS a good impression 
was obtained about anterior drooling and the results after BoNT administration. In 
addition, it became clear that his posterior drooling as was present before the BoNT 
injections, improved. Two weeks after treatment parents reported his breathing to be 
improved because of less stasis of saliva in the oral cavity. During the entire control 
period he slept better, his condition improved, and he had no pneumonia. Although 
the controls of anterior drooling remained fairly good, parents reported congested 
breathing again after 7 months, which had been absent after BoNT treatment and for 
which no objective test or observational study, existed. Based on the clinical picture, 
suggesting the recurrence of posterior drooling, a second BoNT treatment was 
executed. The results of the follow-up measurements are presented in Table 9.2.
The symptoms of posterior drooling disappeared again after the 2nd injection and the 
pulmonary condition improved. During an outpatient visit, 10 months after the second 
treatment, pneumonia was reported. A third BoNT treatment was executed 12 months 
after the second injection. 
VFSS’s were done before and after the third injection in order to visualize the probable 
false route of saliva into the trachea and to gain better insight in the mechanism of 
swallowing.
The first VFSS was made some weeks before the 3rd BoNT injection when he was 
recovering from an episode of pneumonia. To conduct the study the patient received 
3 mL thickened liquids (barium contrast). On analysis of the videos, the oral stage of 
swallowing showed poor and insufficient bolus formation. The tongue demonstrated 
inadequate peristaltic movements with limited transport of the bolus. The onset of the 
pharyngeal phase of swallowing was delayed and pooling occurred in the valleculae and 
pyriform sinuses. Following 3 attempts to swallow, the material was partially spelled 
over into the trachea (Figure 9.3). 
Residual contrast medium was seen after the first swallowing actions and extended 
efforts were needed to clear the pharynx. There was no immediate cough or gag 
response to the aspiration which resulted in silent aspiration. The second VFSS was 
taken 12 weeks after the 3rd BoNT injection. His tongue movements were stronger 
and he showed no refusal to swallow. In contrast to the first study, the onset of the 
pharyngeal phase was not delayed. Pooling in the valleculae still occurred but was 
followed by an efficient swallow act, during which no aspiration was observed and less 
residual contrast medium was seen.
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Figure 9.3: Video fluoroscopic swallow study prior to 3rd BoNT injection
 
 
 
 
 
 
#: Aspirated liquid.
Discussion
Our patient was repeatedly treated with BoNT injections bilaterally in the submandibular 
glands because of posterior as well as anterior drooling. With intervals of respectively 
7 and 12 months he was treated three times with a total of 50 U Botox. The technique 
required ultrasound guidance and anesthesia for safe injections27. From the 
pharmacological profile of BoNT intra-glandular injections are expected to give an 
anticholinergic effect because it blocks the secretion of acetylcholine at the terminal 
nerve endings. 
The results showed a marked decrease in submandibular salivary flow following the 
first injection (Figure 9.2) as well as a reduction in drooling (Table 9.2). The change 
in anterior drooling could be evaluated by investigation of the TDS, DQ and VAS 
scores. Posterior drooling was evaluated indirectly by a change of clinical symptoms 
like congested breathing, swallowing difficulties, and aspiration with associated 
pneumonia.
A recurrence of the salivary secretion from the submandibular glands was foreseeable 
since Botulinum toxin has a temporary effect. However, a striking finding was the longer 
time interval of the results after the second BoNT injection. It is hypothesized that 
hypotrophy of the injected salivary glands may arise due to long lasting denervation 
by BoNT.
Parents reported an improvement in eating after the first injections. From the 
#
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questionnaires it was concluded that ‘fear to swallow’ decreased, oral intake increased, 
and he gained more body weight. It was concluded that the diminished salivary flow rate 
caused less episodes of aspiration in particular during the night. The patient trusted 
himself more to swallow. In addition, there might have been less congestion of saliva at 
the faucial isthmus resulting in a decrease of defensive coughing relieving pharyngeal 
irritation. The vicious circle of irritation, with avoidance or refusal to swallow tended to 
return when the salivary flow from the submandibular glands increased again. Based on 
this experience video fluoroscopic swallowing studies were executed before and some 
weeks after the third BoNT injection. The patient had a bad condition during the first 
assessment and clearly demonstrated aspiration. The results of this study supported 
the parents’ conviction that swallowing and deglutition were negatively influenced 
during episodes of diminished general health, e.g. during recurrent pneumonia. It was 
registered that the episodes of pneumonia decrease impressively after BoNT injections 
and, along with this, his physical condition improved. The conditions resulted in 
less irritation and pain during deglutition, a better swallowing mechanism, and the 
disappearance of aspiration. The VTSS 12 weeks after treatment showed an efficient 
swallow act without aspiration.
In conclusion: Posterior drooling in children with cerebral palsy can play an important 
role in the clinical picture as it can lead to (silent) aspiration. In the case we described 
in this article, BoNT injections in the submandibular glands resulted in a substantial 
reduction of submandibular salivary flow rate. From the clinical course after injections 
a reduction of posterior drooling was clear with the absence of recurrent pneumonia 
as the most important finding.
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Abstract
Aim: to investigated the effect of treatment of drooling on Quality of Life. Methods: a 
questionnaire was developed containing items that were recognized as representative 
for Quality of life of drooling children and their families. Parents were asked to fill in the 
lists. Forty-five severely drooling children (mean age 9 years and 5 months, SD 3.7, 28 
male and 17 female) were monitored before and after receiving medication to reduce 
the salivary flow.
Results: Anticholinergic agents effectively reduced salivary flow. Drooling diminished 
substantially, which was accompanied by a significant reduction in care-taking actions, 
making daily care less demanding. The number of damages to communication devices 
and computers decreased. Conclusion:  In addition to the evaluation of primary variables 
such as the salivary flow rate, investigation of items of Quality of Life provides useful 
information about the outcome of drooling treatment, which can also be applied to 
surgical procedures.
Introduction
Drooling in children with cerebral palsy (CP) is primarily due to oral motor dysfunction 
resulting in inefficient and infrequent swallowing and poor lip closure1;2. It is a significant 
problem in 10-37,5% of patients with CP 3;4. The evaluation of the effects of interventions 
is mostly directed to the salivary flow. However, during some studies parents also 
answered open-end questions concerning the severity of drooling to determine the 
outcome of an intervention5-7. After reviewing these studies, it was concluded that 
Quality of Life (QoL) is only roughly investigated in relation to drooling. 
QoL research employs questionnaires that are either generic (e.g. the Child Health 
Questionnaire)8 or condition specific (e.g. the questionnaires for children with cancer, 
asthma, etc). QoL assessment in children with CP is relatively recent9-11. So far, no 
validated questionnaires are available addressing specific problems such as drooling 
in children with CP. 
An open-label controlled clinical trial during which patients were treated subsequently 
with scopolamine and Botulinum toxin (BoNT) has been conducted at the University 
of Nijmegen. A positive effect on salivary flow rate was seen for both anticholinergic 
agents (accepted for publication: Neurology/June 2004). The reduction in salivary flow 
rate was strongly related to a significant reduction in drooling (accepted for publication: 
Pediatrics/March 2004). 
The objective of this study was to evaluate changes in aspects of QoL as a result of 
drooling treatment. The impact of drooling on daily life was investigated before and 
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after treatment, which was made operational by questionnaires, especially developed 
for this study, containing items of daily situations and daily care recognized as relevant 
aspects of QoL.
Method
Patients
Forty-five severely drooling patients with the diagnosis CP, recruited from the outpatient 
clinic, were included in a controlled, clinical trial evaluating the effect of intraglandular 
BoNT (Botox®, Allergan, Nieuwegein, the Netherlands) injections into the submandibular 
glands on drooling compared with the effect of application of transdermal scopolamine 
patches. Inclusion criteria comprised: boys and girls; pre-school and school age; 
diagnosis of CP; a score of 3 or higher on the Teacher Drooling Scale (Table 4.1). 
The latter comprises a 5-point scale to score the degree of drooling: 1) ‘No drooling’, 
3) ‘Occasional drooling on and off all day’, 5) ‘Constant drooling, always wet’.
All drugs used were carefully evaluated to assess their influence on saliva secretion. 
Continuous use of anticholinergic drugs or benzodiazepines was not allowed. In 
particular clonazepam was a reason for exclusion. Throughout the study no change 
in medication was allowed. Medication to treat drooling had to be stopped at least 
three months before participation. All possible adverse effects and risks related to the 
study were explained to the parents and written informed consent was obtained. The 
Hospital’s Human Research Committee approved the study.
Data collection
Parents may serve as excellent proxy for their children when assessing health related 
QoL12. For this study, a detailed questionnaire, to be filled in by the parents, was 
developed to evaluate the impact of drooling on items of daily life. The prerequisite for 
the items was that an expert team, consisting of a speech therapist, clinical pediatric 
psychologist and physician in rehabilitation medicine, reached consensus that the 
selected items reflected relevant aspects of QoL. The parents of three children who 
participated in a pilot study were invited to comment on the preliminary version of 
the questionnaire, which resulted in some adjustments13. The questionnaire contained 
open-end as well as multiple-choice questions. In addition, parents scored several 
visual analogue scales (VAS) to give their opinion about some statements about 
drooling and its consequences. 
The data from two sections of the questionnaire (see appendix) are presented: the 1st 
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containing questions about drooling severity assessed for specific daily situations or 
activities (each item had a score range from 1 indicating ‘no drooling’ to 9 indicating ‘very 
severe drooling’, the 2nd section containing open-end and multiple-choice questions 
about practical consequences for daily care that were supposed to be influenced by 
drooling itself or possibly could improve after treatment of drooling.
Parents received detailed spoken instruction how to score, which was also written in 
the introduction of the questionnaire. The questions concerned the situation of the 
two weeks before assessment. Assessments were made at baseline, during the use of 
scopolamine, and 4, 8, 16, and 24 weeks following BoNT injections. 
Data handling
Missing values occurred because of incomplete response, non-interpretable answers, 
or unanswered questions. Prior to data analysis, missing values were imputed by using 
the method of ‘carrying the last observation forward’ (CLOF), meaning that missing 
data after scopolamine and BoNT injections were replaced by the last available score 
on the same item. Missing values at baseline were estimated by imputing the mean (in 
case of a numerical score) or the median (in case of a ordinal score) of all participating 
children.
Statistical Analysis
From all investigated items, we identified those situations for which the parents of at 
least 50% of the children scored ‘severe drooling’ at baseline (Table 10.1). To evaluate 
the severity of drooling in these situations over time, we used an analysis of variance 
technique for repeated measurements with the scores of the degree of drooling as the 
dependent variable.
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Table 10.1: Patients scoring 7, 8 or 9 on a 9-point drooling severity scale for specific items
Condition Ns Nd (%Nd) Condition Ns Nd (%Nd)
Level of activity    Body position 
demanding activity 29 33 (88) unsupported sit 26 33 (79)
strenuous activity 28 32 (88) prone position 25 33 (76)
intensive movement 24 25 (96) supported sit 24 35 (69)
relaxed, watching TV 21 33 (64) supine position        6 30 (20)
walking 11 17 (65) 
sleeping 4 28 (14)
Sensorimotor factors    Mood, physical condition 
eating 20 34 (59) enthusiastic 27 33 (82)
drinking 19 26 (73) tired 25 32 (78)
certain tastes or foodstuffs 16 21 (76) sick 19 29 (66)
after brushing teeth 13 29 (45) cries 18 27 (67)
teething 12 15 (80)    
talking 9 17 (53) 
smell of food  9 19 (47)
    Medical factors   
    broncho/pulm. reactions 14 16 (88)
    using medication 9 18 (50)
    after taking medication  8 17 (47)
Ns  =  number of severely drooling children,  
Nd  =  number of drooling children,  
%Nd  =  percentage of Nd-children drooling severely 
In order to evaluate the effect size for these items Cohen’s d was calculated by 
comparing the mean baseline score of all patients to the mean at follow-up. The effect 
size was defined ‘large’ in cases Cohen’s d exceeded 0.814.
To evaluate changes in daily parental care, analysis of variance techniques for repeated 
measurements were used for each individual item and Cohen’s d was estimated. Non-
parametric tests were conducted on appropriate items, such as damage to clothing, 
toys, books, furniture, communication aids, electric devices, or computers.
 Quality of life 177 
 
A p-value equal to or of less than 0.05 was demanded for all tests. Because of multiple 
testing in tests of within-subjects effects, we used a Bonferroni correction (i.e. 0.05/
number of tests).
Results
Forty-five children were included ranging in age from 3 to 16 years, mean 9 years and 
5 months, SD 3.7, 28 male and 17 female. Eight children were ambulant without aid, 
37 children were wheelchair bound. Twenty-two children could not talk. None of the 
children attended mainstream schools: 29 attended a special education school, and 14 
attended a daycare center for mentally handicapped children. Thirty-four children were 
retarded with a developmental age below six years as determined by psychological 
investigation. No child had to be excluded because of use of medication. Of all 
patients, 21 did not use medication, four patients incidentally used benzodiazepines 
to treat epileptic seizures, and two patients stopped medication that was given to treat 
drooling. None of the subjects had Botulinum toxin before.
A response-rate of 85% was achieved (199 out of the initial 234 lists were returned).
The outcome of baseline investigations
Table 10.1 presents the specific conditions for which severe drooling, was scored. Each 
cluster of items starts with the condition most frequently scored. Because some of 
the items were not applicable for an individual child the actual percentage of involved 
children are given.
In particular, severe drooling occurred during strenuous activities that demand a higher 
level of concentration, such as during walking and sports. On the other hand severe 
drooling was observed in situations during which insufficient attention was paid to the 
need to swallow, such as watching television.
Severe drooling influenced the care and attention given to the child. For example, 18 
children were told to swallow averagely 25 times per day, and 26 children had their mouth 
and chin wiped averagely 73 times per day. Thirty-one wore bibs or a shawl, which had 
to be replaced seven times a day. In thirty-one children clothes were redressed every 
day of which 16 repeatedly. Five children wore terry cloth wristbands. Parents ran nine 
(range 2-25) loads of wash averagely per week. They also reported damage to clothing 
(77%), toys (44%), books (44%) and furniture (46%) that was ascribed to drooling. 
In addition, communication aids (n = 9), electronic communication devices (n = 8), 
computers (n = 10), and audio equipment (n = 6) were damaged. Forty-one percent of 
the parents reported curtailing the child’s play with objects that could be damaged.
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The outcome of repeated measure analyses: daily situations 
A MANOVA with a repeated measurements design was executed for those items on 
which 50% of the sample, representing at least 19 children, demonstrated severe 
baseline drooling. For nearly all situations a significant change was recorded after 
intervention (Table 10.2).
Table 10.2: Drooling in daily situations 
Situation Multivariate Tests of Within- Effect-size: Cohen’s d  
 Tests Subjects Effects    
 HT2 (p) F (df1, df2) p*
    Sc B4 B8 B16 B24
Concentrated activity 1.65 (0.002) 5.4 (5, 110) < 0.001 5.530 4.009 4.880 4.331 3.254
Strenuous activity 1.48 (0.002) 7.2 (5, 115) < 0.001 6.580 4.491 5.532 4.848 3.235
Intensive movement 1.40 (0.056) 4,5 (5, 75) 0.001 4.530 3.785 4.535 4.755 3.437 
(sports) 
Relaxed, watching TV 1,23 (0.008) 6,4 (5, 110) < 0.001 4.350 3.846 3.939 4.623 2.287
Eating 2.21 (<0.000) 6.1 (5, 120) < 0.001 4.647 3.675 3.728 4.290 2.441
Drinking 1.57 (0.009) 3.4 (5, 95) 0.007 2.956 2.460 3.099 2.404 1.475
Unsupported sit 1.56 (0.001) 6.7 (5, 120) < 0.001 5.053 5.106 5.690 5.246 3.613
Prone position 2.82 (<0.001) 6.9 (5, 110) < 0.001 4.648 5.103 4.548 4.330 2.004
Supported sit 1.86 (<0.001) 8.2 (5, 145) < 0.001 6.472 5.555 6.087 5.613 4.489
Is enthusiastic 1.13 (0.009) 6.2 (5, 115) < 0.001 6.029 4.397 4.763 4.058 2.684
Is tired 0.91 (0.046) 6.2 (5, 100) < 0.001 4.350 4.191 3.994 4.191 2.218
Is sick 1.91 (0.248) 0.8 (5, 45) 0.561 -0.339 0.434 0.761 1.449 -0.443
multivariate tests with repeated measurements as factor (Hotelling’s Trace (HT2)),  
tests of within-subjects effects (F-values (degrees of freedom) and p-value) and effect size Cohen’s d 
comparing mean baseline scores to mean scores during Scopolamine treatment (Sc) and 4, 8, 16 and 24 
weeks after BoNT injection (B4, B8, B16 and B24).  
*Significance is reached when p<0.004 
However, multivariate tests did not reach significance for the items ‘intensive 
movement’ (Hotelling’s trace = 1.40; p = 0.056) or ‘is sick’ (Hotelling’s trace=1.91; 
p=0.248). In all other daily situations, drooling severity decreased significantly during 
scopolamine application and 4, 8, 16, and 24 weeks after BoNT injection (Fig 10.1). 
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Figure 10.1: Mean drooling severity scores in specific situations
Drooling severity scores at baseline (BL), scopolamine treatment (Sc), and 4, 8, 16 and 24 weeks after 
BoNT injection (B4, B8, B16 and B24). Specific situation: unsupported sit (♦), eating (■), concentrated 
activity (▲), enthusiastic (x). 
Except for ‘is sick’, Cohen’s d exceeded 0.8 in all comparisons, indicating that the effect 
size was large throughout (Table 10.2).
The outcome of repeated measure analyses: practical consequences
Measures (provision of bibs, shawls, terry cloth wristbands, plasticized toys or books) 
taken to minimize the practical consequences of drooling were analyzed. A MANOVA 
with a repeated measurement design did not show significant changes in the number 
of the different measures. This also applies to the frequencies of urging the child to 
swallow (Hotelling’s trace = .23; p = 0.289), changing shirts or sweaters (Hotelling’s 
trace = .34; p=0.094), changing pants (Hotelling’s trace= .12; p=0.620), and the 
number of washes per week (Hotelling’s trace= .06; p=0.881).  A significant decrease, 
however, was demonstrated in the frequencies of wiping the child’s mouth and chin 
during the day (Fig. 10.2).
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Figure 10.2: Mean frequency of specific actions
 
Frequency of specific actions at baseline (BL), Scopolamine treatment (Sc), and 4, 8, 16 and 24 weeks 
after BoNT injection (B4, B8, B16 and B24). Frequencies of: wiping the child’s mouth and chin(■), mean 
frequency of changing bibs or shawls(♦)
Both, the multivariate tests (Hotelling’s trace= .53; p=0.033) and the tests of within-
subject effects (F=6.7; df=5,155; p<0.001) were significant and Cohen’s d ranged 
from 2.350 to 3.463 comparing the mean baseline scores to the mean scores during 
Scopolamine or 4, 8, 16 and 24 weeks after BoNT injection. Frequencies of changes of 
bibs or shawls also decreased significantly (Fig. 2). Again, multivariate tests (Hotelling’s 
trace= .79; p=0.002) and tests of within-subject effects (F=7.6; df=5,175; p<0.001) were 
significant and Cohen’s d ranged from 2.459 to 3.683.
Parents reported no significant changes in the damage to cloths, toys, books or 
furniture as a result to therapy. However, a continuous decrease existed, from baseline 
up to 24 weeks after BoNT injection, in the damage to communication aids, electric 
devices, or computers (Chi-square=13,11; df=5; p=0.022).
Discussion
The daily care for drooling children is demanding and has practical consequences. In 
this study, a detailed questionnaire was developed to document the impact of drooling 
on Quality of Life of the children and their parents. A significant decrease of drooling 
in specific daily situations was demonstrated after salivary flow rate reduction by 
anticholinergic medication (scopolamine or BoNT injection). This was accompanied by 
a decrease in the frequency of wiping the child’s mouth and chin and the frequency of 
changes of bibs or shawls, making daily care less demanding. Additionally, a decrease 
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of damage to communication aids, electric devices or computers was demonstrated. 
No significant change occurred for the items: ‘sick’, ‘the frequency of changing clothes’, 
or ‘the number of washes per week’. Because sickness is not a daily recurring condition 
and parents were only asked to score over the two weeks prior to assessment, there 
seemed to be a lack of data for proper testing.
Frequencies of changing clothes probably did not change because there might have 
been other reasons than drooling to change clothes, for which we did not score. This 
could also explain why there was no change found in number of washes. Bibs or shawls 
are effective to prevent clothes from getting dirty even in the presence of small amount 
of saliva. This might be the reason why they were not entirely omitted, even in cases 
drooling practically disappeared. 
This study proved that a reduction in salivary flow has significant and relevant effects 
on aspects of QoL. We recommend that all interventions to treat drooling (surgery, 
medication, behavior therapy, etc.) be evaluated not only on salivary flow rate, but also 
on items as are described in the questionnaire.
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Appendix
Questionnaire Section 1
1. Mark in the first column all relevant conditions in which your child is drooling 
and if so, indicate for each condition the degree of drooling in the last two 
weeks prior to this investigation.
Condition Degree of drooling
supported sit No (1) Mild (3) Moderate (5) Severe (7)  Very severe (9)
unsupported sit No (1) Mild (3) Moderate (5) Severe (7)  Very severe (9)
prone position No (1) Mild (3) Moderate (5) Severe (7)  Very severe (9)
supine position No (1) Mild (3) Moderate (5) Severe (7)  Very severe (9)
walking No (1) Mild (3) Moderate (5) Severe (7)  Very severe (9)
intensive movement (sports) No (1) Mild (3) Moderate (5) Severe (7)  Very severe (9)
is sick No (1) Mild (3) Moderate (5) Severe (7)  Very severe (9)
is tired No (1) Mild (3) Moderate (5) Severe (7)  Very severe (9)
eating No (1) Mild (3) Moderate (5) Severe (7)  Very severe (9)
smell of food No (1) Mild (3) Moderate (5) Severe (7)  Very severe (9)
certain tastes or foodstuffs No (1) Mild (3) Moderate (5) Severe (7)  Very severe (9)
drinking No (1) Mild (3) Moderate (5) Severe (7)  Very severe (9)
talking No (1) Mild (3) Moderate (5) Severe (7)  Very severe (9)
sleeping No (1) Mild (3) Moderate (5) Severe (7)  Very severe (9)
concentrated activity No (1) Mild (3) Moderate (5) Severe (7)  Very severe (9)
relaxed, watching TV No (1) Mild (3) Moderate (5) Severe (7)  Very severe (9)
strenuous activity No (1) Mild (3) Moderate (5) Severe (7)  Very severe (9)
is enthusiastic No (1) Mild (3) Moderate (5) Severe (7)  Very severe (9)
swallowing medication No (1) Mild (3) Moderate (5) Severe (7)  Very severe (9)
after swallowing medication No (1) Mild (3) Moderate (5) Severe (7)  Very severe (9)
after brushing teeth No (1) Mild (3) Moderate (5) Severe (7)  Very severe (9)
cries No (1) Mild (3) Moderate (5) Severe (7)  Very severe (9)
allergic reactions in  No (1) Mild (3) Moderate (5) Severe (7)  Very severe (9)
bronchopulmonary tract 
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Questionnaire Section 2
Daily care for drooling children takes extra attention and activities. Please answer the next 
questions as exactly as you can for the last two weeks prior to this investigation.
2. What measures do you take because of drooling?
 a. Child is wearing bib
 b. Child is wearing shawl
 c. Child is wearing terry cloth wristbands
 d. Child gets washable toys
 e. Books are plasticized
 f. Other measures,.......
3. How often his/her mouth or chin is wiped dry? ... times per hour or ... times per day
4. How often he/she is told to swallow? ... times per hour or ... times per day
5. How often his/her bib or shawl is replaced? ... times per day
6. How often his/her clothes are changed? ... times per day
7. How many loads of wash do you have? ... loads of wash per week
8. Has there been damage to: 
 a. clothes yes / no
 b. toys yes / no
 c. books yes / no
 d. furniture yes / no
 e. communication aids yes / no / not relevant
 f. electronic communication devices yes / no / not relevant
 g. computer yes / no / not relevant
 h. audio equipment yes / no / not relevant
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This study offered new scientific information to the treatment options of drooling 
in children with various forms of cerebral palsy. The effect of intra-glandular BoNT 
injections was compared to an established treatment, for which the anticholinergic drug 
scopolamine was chosen. It was demonstrated that Botulinum toxin type-A (BoNT), 
injected into the salivary glands, reduces the salivary flow from these glands substantially 
in the majority of patients (Fig 7.2, Table 7.2). Compared to baseline, the control 
measurements of the primary outcome variables (the salivary flow rate and the drooling 
quotient) showed differences that were significant for at least 6 months following BoNT 
injections. We were able to measure 41% of the patients up to 40 week after the BoNT 
injections. The mean salivary flow from the injected submandibular glands was still in 
the same range as the mean of the whole population at 24 weeks. The same was true for 
the 21% of the patients that were measured 48 weeks after the injections.  Although the 
number of patients after 24 weeks of follow up was to low to execute proper statistical 
analysis, the trend of the depicted curve is promising (Fig 11.1). 
Figure 11.1: Response rate for salivary flow reduction (% of population)
 
BoNT_X: Measurements at subsequent moments (wks) following BoNT injections.
The BoNT effect is mediated by the autonomous nervous system. BoNT was already 
known to have an explicit effect on the parasympathetic part of the nervous system. In 
the treatment of hyperhidrosis, BoNT diminishes the secretion of sweat glands at least 
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for 9 months and many patients benefit for more than a year. This long lasting effect 
is strikingly different from the effect seen in the peripheral nerves of the motor system, 
which is about three to four months.
In this study the reduction in salivary flow was related to a significant decrease in 
drooling throughout the duration of the study (Fig. 8.1 and Table 8.2). The response to 
therapy was high for this new indication. In conclusion: intra-glandular BoNT injections 
are an effective way to treat drooling in multiple handicapped children with cerebral 
palsy. 
11.1 The duration of the effect
In this study 60 to 70% of the patients demonstrated “success to therapy” with 
sufficient reduction of the salivary flow, up to 8 weeks following BoNT injections. This 
success rate gradually declined to 50% between the 8th and 16th week of assessment 
and approximately remained at that level for the rest of the official duration of the study 
(Fig 11.2).
Figure 11.2: Mean Submandibular Salivary Flow in Time
Clof =carrying the last observation forward, N = number of patients, Baseline: Measurement at baseline, 
Scopol: Measurement during scopolamine application, Washout: Measurement after Washout, BoNT_X: 
Measurements at subsequent moments (in weeks) following BoNT injections.
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The data only allowed analysis up to 24-week after the BoNT injections, because 
an increasing number of parents lacked sufficient motivation to come for further 
assessment after that point. However, data were collected from 30 patients until 32 
weeks, whereas 16 patients continued until 40 weeks after the BoNT injections. Eight 
patients came for follow-up visits until 48 weeks after the injections. A time curve of 
the SubFl was constructed starting at baseline with the mean value of the 30 patients 
that continued to BoNT-32 (Fig. 11.1). The resultant curve shows the same course, as 
was the case for the whole population (Fig. 7.2), which supports the consistency in 
our findings. In addition, the mean of the data of the remaining 16 patients at BoNT-
40 and of the 8 patients at BoNT-48 were added (Fig. 11.1). The mean of the data of 
the thirty patients at BoNT-32 showed marginal significance compared to baseline. 
Although the number of patients, at BoNT-40 and 48, was too low to execute proper 
statistical analysis, the trend of the curve is promising. It indicates that the length of 
the effect of BoNT injections might be in the same range as is found for the treatment 
of hyperhidrosis. In theory this would mean that the majority of the patients could 
benefit from treatment more than a year. Further research is needed to confirm this 
and disclose the ultimate duration of the BoNT effect on the salivary glands.
11.2. The injection sites
We choose to inject the submandibular glands. These are the main paired glands 
producing about 70% of high viscosity, resting saliva1. In addition, resting saliva is 
composed of secretions from the parotid glands (~ 25%) and the sublingual glands 
(~ 5%). The large parotid glands are capable of producing great amounts of watery 
saliva that is secreted promptly as a reaction to tactile or gustatory stimulation of the 
oral mucosa for example during eating or drinking. In general, authors agree that the 
amount of saliva production is normal in CP. This study confirms the assumption 
that the submandibular glands contribute for a substantial amount to the total saliva 
production when a person neither eats nor drinks. Nearly half of the patients had a 
submandibular flow that was 60 to 75% of the total salivary production. It is estimated 
that only 25% of the resting saliva production would remain if the submandibular and 
sublingual glands would be inhibited bilaterally2.
The treatment of drooling only by BoNT injections into the submandibular glands as 
a first step in treatment seems to be a reasonable approach, which was proven to 
induce substantial reduction of the salivary flow in resting conditions. However, others 
describe injection techniques for the submandibular glands as well as the parotids.
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There is an increasing clinical acceptance to inject the parotid glands. This approach is 
frequently justified by the fact that the parotids are the largest salivary glands and easy to 
access. From an anatomical point of view this seems to be a valid argument. However, 
the size of the parotid gland is primary related to the specific capacity to produce large 
amounts of serous saliva at functional moments, e.g. during the processing of food or 
drinks. In principal, great precaution should be paid to the saliva production coming 
from the parotid glands. Reduction of it might have a negative influence on feeding and 
deglutition, which will be of disadvantage for some patients. Therefore, injections in the 
parotid glands should be avoided as a first choice of therapy in drooling children with CP.
If, in the approach to treat drooling is chosen for BoNT injections, a two-step approach 
is justified. The submandibular glands are the first to be injected bilateral, followed by 
optional injections in the left or right parotid gland(s) if the clinical effect appears to be 
insufficient. The development of clinical guidelines on this issue is subject for further 
research.
11.3. Compensatory reactions from other glands
Surgical procedures are widely used in the treatment of drooling, which was summarized 
in chapter 1. The ‘rerouting of Wharton’s duct’ or ‘excision of the submandibular 
glands’ are examples. In principle, these interventions are aimed to establish a definite 
reduction of the salivary flow. However, earlier investigations (unpublished) have 
settled the clinical idea that the parotid glands compensate for the diminished salivary 
flow. It is believed that this process starts after several months.
In this study, only the submandibular glands were injected with Botulinum toxin. 
Because of knowledge of the above-mentioned phenomenon, salivary flow rates from 
all major salivary glands, including the parotid glands, were obtained to be able to 
determine any compensatory reaction.
The curves of the submandibular flow (SubFl) as well as the total salivary flow (TSFl) 
were constructed (Fig. 7.2). The curves show the same pattern from washout up to 24 
weeks after BoNT injections. A compensatory reaction from the parotids would be clear 
from an increasing slope in the TSFl-curve at some moment after BoNT injections. 
Nevertheless, great resemblance in pattern exists in the curves of SubFl and TSFl. 
An increase in the parotid flow because of a compensatory reaction following BoNT 
injections was not demonstrated during the entire duration of the study. Extended 
observations are needed to be conclusive on this point, which will also be subject for 
further research.
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11.4. Response or non-response to therapy
Success to therapy was defined in three different ways, each closely related to the 
outcome of separate parts of the study.
The first research question was:
Does BoNT influence the function of the salivary glands?
Beyond any doubt, salivary flow is one of the main factors contributing to the amount 
of drooling. A reduction in the salivary flow, a physiological parameter, would be 
indicative of the anticholinergic action of the tested intervention within the glandular 
parenchyma. Compared to baseline the SubFl showed a mean reduction of 24.7 % 
during scopolamine application and a mean reduction of 42.4 % 2 weeks after BoNT 
injections. This reflects the explicit anticholinergic effect of BoNT. The SubFl remained 
significantly different from baseline throughout the study
In first instance, the definition of ‘success to therapy’ was limited to the question 
whether or not saliva secretion by the salivary glands changed after the interventions.
First definition of response: a subject is assigned as a responder if minimally a 30% reduction 
is achieved in salivary flow compared to baseline. This reduction has to be present in at least 
1 out of 3 of the BoNT measurements at 2, 4 or 8 weeks after BoNT injections*.
Frequency analyses were executed. Success to scopolamine was achieved in 94.9 % 
of the children. Success rates for BoNT were 69.2% two weeks after BoNT injections 
and 48.7% after twenty-four weeks. If the number of responders to scopolamine is 
compared to the BoNT-2 result, the outcome is in favor of scopolamine. However, we 
looked at the data in further detail. From this, it became clear that the majority of non-
responders at BoNT-2 were very close to our demand of a ‘30% reduction of baseline 
salivary flow’. Nevertheless, from a pure methodological point of view these results 
can be attributed to measurement error (chapter 4). 
In theory the difference in response rate can be explained in several ways: 1) the reaction 
to BoNT may be dose related. We did not investigate this because dose finding was 
not an aim of this study, 2) BoNT (or part of it) was not injected in the gland. However, 
ultrasound guidance assured adequate delivery and 3) immunity existed for BoNT. We 
did not rule out this possibility, although, the risk of neutralizing anti-BoNT type-A 
antibodies was low because none of these patients had previously been treated by 
Botulinum toxin.
*The 30% demand is explained by the estimated measurement error in the repeated baseline series of salivary flow 
rate measurements (chapter 4).
194 Chapter 11
The second research question was:
Does drooling diminish substantially when the salivary flow rate changes?
The cause of drooling is determined multifactor. Aspects like tongue trusting, the 
anatomy of the oral region, lip closure, reflexes, and muscular tone play a role in the 
severity of drooling. In addition, factors like age, general health, and mental abilities 
play an important role.
The clinical outcome in this study was evaluated by the drooling quotient, an 
observational method investigating drooling during a limited period of time (chapter 
8: assessment). Based on the Drooling Quotient ‘success to therapy’ was defined.
Second definition of response:  a subject is assigned as a responder if minimally a 50% 
reduction in Drooling Quotient is achieved, compared to baseline. This reduction has to 
be present in at least 1 out of 3 of the BoNT measurements 2, 4, or 8 weeks after BoNT 
injections.
It was decided that a 50% reduction in the DQ reflected a clinical relevant change. 
The submandibular glands produce about 60 to 70% of baseline salivary flow. In 
the event the DQ is reduced by 50% after BoNT injections, the change of flow from 
the submandibular glands, being the only gland exposed to this intervention, must 
have added substantially to this reduction. It must be noticed that scopolamine was 
applied transdermally by the patches. This means that scopolamine was available via 
the vascular system and reached the parotid glands also. During scopolamine 53% of 
the patients were recognized as responders. Response rates to BoNT were 64.1% two 
weeks after BoNT injections and 48.7% after twenty-four weeks.
To investigate the coherence between the two definitions of success to therapy a third 
definition was used.
Third definition of response: a subject is assigned as a responder if minimally a 30% reduction 
in salivary flow in combination with a 50% reduction in DQ is achieved, compared to 
baseline. This reduction had to be present in at least 1 out of 3 of the BoNT measurements 
2, 4, or 8 weeks after BoNT injections. 
The overall percentage of responders was 74.4% (29 out of 39 patients). The response 
rates are summarized in Table 11.1. The conclusion is that the majority of the patients 
reacted well according to the third definition.
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Table 11.1: The response rates according to three definitions for response
  BoNT-2  BoNT-4  BoNT-8  Overall
Definition Resp Non-resp Resp Non-resp Resp Non-Resp Resp Non-resp 
 %(N) %(N) %(N) %(N) %(N) %(N) %(N) %(N)
Def. 1 69.2 (27) 30.8 (12) 64.1 (25) 35.9 (14) 61.5 (24) 38.5 (15) 94.9 (37) 5.1 (2)
Def. 2 64.1 (25) 35.9 (14) 43.6 (17) 56.4 (22) 53.8 (21) 46.2 (18) 79.5 (31) 20.5 (8)
Def. 3 48.7 (19) 51.3 (20) 38.5 (15) 61.5 (24) 43.6 (17) 56.4 (22) 74.4 (29) 25.6 (10)
As stated above, several factors might influence the frequency and severity of drooling. 
A non-response to therapy could be the result of insufficient reduction of salivary flow 
but could also be caused by other (confounding) factors that deteriorate drooling. 
On the other hand the situation can arise that patients with only a slight change in 
their salivary flow, demonstrate an unexpected improvement in drooling, which can 
be caused by modifying factors. These factors might be recognizable characteristics 
of the patient such as age, gender, developmental age, the anatomy of the oral region, 
movement disorder (reflexes and grimaces), epilepsy, or the combination of epilepsy 
and medication, and other factors like thumb-sucking. Another group of contributing 
factors could be more detailed symptoms for which a careful examination was made 
of anatomy (malocclusion), oral motor performance (insufficient lip closure, tongue 
trusting, uncoordinated tongue movements, tongue fasciculation), oral muscular 
tension (hypertonia/hypotonia), oral reflexes (hyper-reflexes/persisting pathological 
reflexes), oral sensitivity (hypersensitivity/hyposensitivity), speech (dysartria), and 
swallowing (dysphagia).
Prior to analysis the factors were graded according to their expected influence on the 
outcome of the interventions (Table 11.2). For example the item ‘movement disorder’ 
(sub-divided into pyramidal/spastic CP, extra pyramidal/athetoid CP, or a mixed CP) 
was expected to have explicit influence on the outcome. Repeated clinical examination 
by the speech therapist indicated that subjects with athetoid movement disorders and 
their facial grimaces had more stimulation of the parotids (not treated in this study) and 
consequently more severe drooling even after BoNT injections in the submandibular 
glands. Another example would be ‘malocclusion’. It was expected that treatment for 
drooling would be less effective in the presence of malocclusion.
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Table 11.2: Theoretical influence of patients’ characteristics on drooling
Grading of expected level of influence on response to therapy
Factor Low Mediate High 
Age  X  
Gender X   
Dev. Age   X 
Mov. Disorder  X  
Epilepsy X   
Epilepsy + Medication  X  
Lip closure   X 
Tongue trusting   X 
Tongue fasciculation X   
Malocclusion   X 
Oral hypertonia  X  
Oral Hypotonia   X 
Oral Hyper-reflexes   X 
Pers. Pathol. Reflexes   X 
Disturbed oral sensibility   X 
Dysartria  X  
Dysphagia   X 
In the 2nd and 3rd  definition of ‘response’ these factors are incorporated. The central 
question was whether or not these biological and physiological factors influenced the 
relation between intervention and outcome in terms of response or non-response of 
which the theoretical concept is depicted in Figure 11.3.
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Figure 11.3: Conceptual interactions of intervention and confounders with outcome
From a methodological point of view it could be stated that factors influencing the 
outcome of responders versus non-responders could either act as a ‘modifier’ or as a 
‘confounder’. Modifiers enhance the result while confounders inhibit it. In this sense 
the outcome of the interventions is a function of the intervention itself as well as the 
influencing factors. The challenge was to split the joint variance of the intervention and 
the individual factors.
In first instance, it was calculated what sample sizes would have been actually needed, 
demanding an Alpha 0.05 and a Power 0.8, to be able to make statements about this 
issue. To execute an uncorrected chi-square test, 47 case and 47 controls would have 
been needed. To do a corrected chi-square test or a Fisher’s exact test, 56 cases and 56 
controls were needed.
The population of this study did not meet these requirements. For this reason, a result 
of analysis of modifying or confounding factors would provide a ‘low grade evidence’. 
All variables listed in table 11.2 were analyzed in relation to the outcome: response 
versus non-response. None of the factors demonstrated significant influence on 
the outcome. In this study 39 patients received BoNT injections, of whom 29 were 
responders and 10 non-responders, according to the 3rd definition.
Given the sample size of 39 case and 39 controls, it could not be concluded whether 
or not any of the identified factors was of influence on the outcome of response to 
therapy.
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11.5. Changes of the parenchyma 
Chemo-denervation, as introduced by BoNT injections, theoretically leads to 
degeneration of the glandular parenchyma. Based on this, it is expected that repeated 
BoNT injections might give increasingly hypotrophy resulting in a longer effect of the 
injections. In the course of the present study all patients underwent BoNT treatment 
under ultra-sound guidance. According to standardized methods cross-sectional 
digital pictures of the submandibular glands were made in different directions. The 
majority of the patients were seen for evaluation at the department of radiology, 
however at variable time intervals. Thus, no definite conclusions could be drawn from 
these data. Nevertheless, the impression exists that the volume of the injected glands 
had decreased and the ultra-sound density was changed several months after BoNT 
injections. This is subject for further research.
11.6. Side effects
Side effects due to scopolamine became apparent within the first three days of 
administration and were reported in 82.2% of cases. Several patients complained 
of more than one symptom. Most often reported adverse effects were xerostomia 
(66.7%), restlessness (35.6%), somnolence (35.6%), blurred vision because of pupillary 
dilatation, and confusion (20%). Four out of the six dropouts from the study had to 
end their participation because of adverse effects to scopolamine. In all four cases, 
restlessness, apparent in their movement performance, and confusion were the main 
reasons to terminate scopolamine use.
Following BoNT injections, incidental side effects were reported. Two patients (5.1%) 
had a transient flu-like syndrome. Another 3 patients complained of mild difficulty with 
swallowing.
Many side effects are seen during the use of anticholinergic drugs, which makes this 
group of drugs unsuitable for long-term use in the treatment of drooling.
With respect to the magnitude and the duration of effect, Botulinum toxin has a 
favorable outcome.
11.7. Treatment strategy
The goals of any treatment of drooling will always be the reduction of visible anterior 
drooling or a decrease of posterior drooling. The first step in investigation should 
include a thorough evaluation and instruction by the speech therapist focused on 
oral stimulation, and eating and drinking programs. Prior to intervention, repeated 
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evaluation of the cause of drooling should be undertaken with special attention to the 
pharyngeal and esophageal phase of swallowing. In cases of impaired swallowing the 
danger of posterior drooling and aspiration should be considered.
The literature is not unequivocal with respect to the outcome of the different therapeutic 
approaches. Neither conservative treatments nor surgical procedures seem to be 
universally successful. In general, surgery is recommended only if conservative 
measures fail to reduce drooling.
The application of anticholinergic drugs to treat drooling should only be advised 
incidentally. It is defensible to prescribe scopolamine or another anticholinergic drug 
with less central side effects (e.g. glycopyrrolate), for moments that an individual 
wishes to be without drooling. This should not last longer than one or two days. 
In the dispute Botulinum toxin injections are new. No guidelines exist to position BoNT 
injections among conservative measure or surgical interventions. There is no medical 
restriction to use BoNT in very young children. However, up to the age of four years 
conservative measures (excluding medication) could be the first choice to treat drooling 
in complex handicapped children. Drooling beyond the age of 4 is regarded as definitely 
pathologic. If conservative treatments fail and drooling does not subside after the first 
dentition has been completed, invasive therapy can be considerate. Between the age 
of 4 and 7 years BoNT might be in favor of surgical procedures. BoNT injections into 
the major salivary glands can be safely executed provided that ultrasound guidance is 
used during the procedure. The effect is temporary, although it might be more than a 
year. This offers a good opportunity to observe the clinical relevance or adverse effects 
of a reduction in salivary flow in any particular child. Besides, the possibility exists that 
drooling will diminish substantially after dental aging. It is imaginable that a drooling 
child is repeatedly treated with Botulinum toxin during several years. After this period, 
dentition is completed which possibly diminishes drooling.
Surgery to the salivary glands should at least be preserved for the age of 7 and older. 
By that time the anatomical relations in the oral region are evident and the problem 
of the drooling is clear. Rerouting of Wharton’s duct should always be avoided in the 
presence of posterior drooling.
A challenge is to find out what child characteristics are decisive for the extent of 
drooling and the response to specific interventions (speech therapy, BoNT injections, 
rerouting of a duct) in a larger population.
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11.8. Methodology and Statistics
11.8.1 The design
Regarding the population, it was expected to meet inter-individual and intra-individual 
variability on relevant parameters (salivary flow rate and Drooling Quotient) during the 
study. To control variability among and within subjects in a randomized clinical trial a 
large number of patients had to be included, which would not be available within the 
time limit of this study.
In a crossover design the demanded number of patients would be considerably 
lower, although the risk of a “carry-over” effect would exist. Regarding the known 
pharmacological properties of scopolamine we could exclude a carry-over effect from 
scopolamine to BoNT with certainty, provided an adequate washout period of 72 hours 
was taken into account. In the event, BoNT treatment would come prior to scopolamine 
a carry-over effect could not be excluded because the duration of the BoNT effect was 
unknown at start of the study and subject of investigation. This demanded a strict 
sequence of treatment: scopolamine before BoNT.
We performed a controlled, open-label, clinical trial with an intention to treat (ITT).
11.8.2 Patient selection, Control of bias and blinding (masking)
All patients were included as consecutive subjects recruited mainly by (in)direct 
advertisement. There has been no specific selection before the first outpatient visit.
A good level of control of bias was achieved by using the same group of patients (within 
subject design) for the experimental treatment (BoNT) and the control treatment 
(scopoderm). This reduced the problem of between-subjects variation between the 
experimental and control group. The within-subject variation was counted with by 
estimating (computer program) the number of patients large enough to reach and 
adequate power.
Two independent employees, handling essential data (the results of salivary flow, 
drooling quotient, and questionnaires) were both blinded to the status and timetable of 
the participating patients. This essential condition was supported by the introduction 
of a scheduled variation in the number of baseline measurements that had to be 
obtained from each child. Besides, the data were related to a registration number and 
not to a specific name.
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11.8.3. Dropouts
Because this study was executed with an “intention-to-treat” a thorough description of 
dropouts was demanded.
A patient that did not meet the inclusion criteria or demands of the qualification period 
was not regarded as a dropout. Failure of a patient to continue the study, for whatever 
reasons, after start of scopolamine treatment was considerate a ‘dropout’. However, 
the protocol anticipated for the possibility that some of the subjects might not fulfill 
the scopolamine period, because of side effects. The occurrence of side effects was 
regarded as an outcome of the study because this could be decisive whether one 
treatment would more beneficial above the other. If, the application of scopolamine 
was discontinued within 48 hours from start the patient was regarded as a dropout. If, 
however, the use of scopolamine lasted more than 48 hours the subject could remain 
in the study provided a control measurement of salivary flow and the drooling quotient 
was obtained within 24 hours (the washout of scopolamine takes 72 hours). Patients 
with scopolamine application longer than 48 hours but a delayed control
Visit, of over 24 hours, were excluded from the study.
After BoNT injections, patients had to fulfill control measurements at 2, 4, 8, 16, and 
24. In case a subject could not attend any of the control visits at 2, 4, or 8 weeks 
exclusion followed. Furthermore, it was the demanded that at least 3 out of the 5 control-
visits were attended. Other reasons for exclusion were: 1) introduction or change 
of medication that could possibly influence salivary secretion, and 2) complicating 
disease. If, at any time of the course, parents refused further cooperation the child was 
considered to be a dropout and the data were handled accordingly. In these situations, 
specific efforts were made to approach the patient and the parents according to ‘good 
clinical practice’.
11.8.4. Handling of data
The database comprised repeated scores of salivary flow rate, the drooling quotient, 
the teacher drooling scale, visual analog scales, and the results of Quality of life 
questionnaires.  Additional data were collected only at the first history taking and 
examination, like: anatomy of the oral and nasal region, motor activities of tongue and 
oral cavity, tactile sensitivity, muscular tone, and reflexes.
For some analyses, missing data of submandibular salivary flow, right or left parotid 
flow rate, and drooling quotient were interpolated according to a ‘carrying the last 
observation forward’-system (CLOF) or a ‘worst case scenario’ (WCS).
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For the ‘carrying the last observation forward’-data the following rules were applied for 
each individual patient:
- If a score in the Scopo-derm” period was missing the data was completed with the 
mean of the BoNT scores at 2, 4, and 8 weeks.
- If washout scores were missing it was completed with the baseline value.
- If a BoNT-2 score was lacking the Scopo-derm” value was filled in.
- In case any of the BONT 4, 8, 16, and 24 scores were missing this was completed 
with the former score.
- In case, particular scores were missing of more than 10 subjects the data were 
removed from the statistical analysis.
For the ‘worst case scenario’-data the following rules were applied:
- In case a score was missing for Scopo-derm” this was completed with the lowest 
score at 2, 4, and 8 weeks of the BONT-series of the same patient.
- Washout missing data were completed with the baseline score.
- If any of the BoNT scores were missing the baseline value was applied in the 
analysis.
11.8.5. Analysis of the data
The inclusion criteria and exclusion criteria for this study were clearly defined (Table 
1.3). Dropouts and those lost to follow-up were extensively described. Thus, all patients 
that were excluded from the study were explained dropouts. Four could not fulfill the 
scopolamine period, 1 patient received additional medication, and one patient became 
sick, which was not related to the interventions of the study. These six patients had in 
common that they dropped out of the study before the BoNT injections were given. 
Therefore, these patients only ended the control treatment and did not participate 
in the experimental treatment of which, consequently, no data were available. Given 
the fact that there was an intention to treat, the data of the dropout patients were 
eliminated from the database.
Several ways of analysis could have been executed in the database. A per protocol 
analysis should have been executed in the original data. In a first overview of the 
database (frequency analysis and scatter diagrams) it was found that list-wise missing 
data were randomly distributed over the measurement moments and patients. In the 
event of random missing data this could mean loss of power because subjects with 
many missing data are excluded from distinguished parts of the analysis. Based on 
this, it was decided not to perform a per protocol analysis but to replace missing data 
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by adjusted data and to perform a “best-case” (clof) and “worst-case” (wcs) scenario 
analysis.
The wcs analysis, in fact, equals an “intention to treat” analysis (ITT). 
The “in treatment” analysis was done with data that were adjusted according to the 
system of “carrying the last observation forward” in which basically each missing data 
point is replaced by the score prior to it. 
After all, there remains a risk that the treatment effect is overestimated. Therefore 
any calculated result in the clof analysis was compared to the outcome of the wcs 
analysis. Resemblance in both outcomes was interpreted as strongly supportive for 
the treatment effect.
It seems reasonable to argue that the true effect in this population is somewhere 
between the outcomes of these approaches.
11.9. Future research
Although, this study has provided evidence for the positive effect of BoNT injections on 
severe drooling in patients with cerebral palsy, many questions remain unanswered.
Does hypo-trophy of the salivary glands occur after repeated BoNT injections? 
What child characteristics are decisive for the severity of drooling and how is their 
mutual relation?
What child characteristics are decisive for a good response to the different treatment 
modalities?
How to decide for either BoNT injections in the submandibular glands, or in both the 
submandibular and parotid glands?
Investigations should be made on the incidence and the magnitude of the problem of 
posterior drooling.
The development of clinical guidelines to position intra-glandular BoNT injections 
among conservative measures and surgical interventions is most essential.
Drooling has to be considerate as one of the essential problems in the care for children 
with cerebral palsy. Their treatment is of major importance for the psychosocial well 
being of the involved child and his or her parents or caretakers. Expert teams that 
evaluate and treat this problem should consist of a speech therapist, physiatrist, child 
neurologist, and ENT surgeon. In addition, the possibility to consult a cranio-maxillo-
facial surgeon, an orthodontologist, and a dentrist with experience in the care for 
handicapped patients is needed.
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Summary
Chapter 1
Severe drooling in children with cerebral palsy forms the central theme of this thesis. 
This condition occurs approximately in one of three children with CP. Persisting 
drooling, being pathologic after the age of four, is difficult to treat and it results in 
a socially disabling condition for the child and its primary caretakers. It is generally 
caused by a poorly developed mechanism of coordination of oro-facial, palato-lingual 
and head and neck musculature.
Therapy comprises behavioral techniques, speech therapy, training of oral motor skills, 
anticholinergic drugs, and surgical procedures of which none is universally successful. 
Botulinum neuro-toxin type-A (BoNT) is a new option in the treatment of drooling. 
In the present study, a controlled clinical trial has been conducted that evaluates the 
treatment of drooling by comparing the efficacy of BoNT (experimental treatment) to 
an anticholinergic agent (control treatment with scopolamine). This study is based 
on the fact that Botulinum Toxin causes pre-synaptic inhibition of cholinergic nerves 
endings. The difference in effect on drooling between scopolamine and BoNT® is 
tested.
Chapter 2
Anticholinergic drug treatment for drooling is widely described in the literature. This 
chapter describes the results of a systematic literature review searching for evidence 
of efficacy of anticholinergic drugs in the treatment of drooling. Only few studies of 
the identified studies were designed good enough to allow conclusions. Given the 
number of studies that could be selected and their design, the evidence of efficacy of 
anticholinergic drugs in the treatment of drooling is low. A meta-analysis could not be 
performed from the selected reports and no individual anticholinergic drug could be 
assigned as ‘the’ standard therapy.
Reviewing the literature, it is concluded that all drug treatment options have their 
limitations. In general, side effects during long-term use constitute a serious problem 
in the treatment with anticholinergics, often necessitating to stop therapy. 
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Chapter 3
A study among 62 healthy non-drooling school children (age 6 - 11 yr) was conducted in 
order to obtain reference data of salivary flow. Sialometry was done by using the swab 
method of which the reproducibility appeared to be good. The test-retest reliability was 
significant. As one of the results of this study it was concluded that the magnitude of 
salivary flow rates was not influenced by age or gender. The outcome was in accordance 
with earlier reports. Lead by the experiences of this study it was decided to use “the 
swab method” in subsequent investigations.
Chapter 4
This chapter describes the outcome of repeated baseline measurements of salivary flow 
rates in multiple handicapped children. The objective was to test the potential clinical 
applicability of the swab method in handicapped children. Two speech therapists were 
trained to use the swab method. They performed a series of baseline measurements 
of salivary flow. The ‘Bland and Altman’ method, especially designed for analysis of 
repeated measurements, was applied. The within-subjects standard deviation (SW) 
was calculated because it would express the magnitude of measurement error and 
biologiacal variation. The estimated SW (0.11 ml/min) appeared to be about 25% 
of the mean salivary flow rate. Consequently, the change in the salivary flow after an 
intervention to treat drooling should exceed this 25% before the effect can be attributed 
to the treatment.
Chapter 5
An ‘in-vitro’ as well as an ‘in-vivo’ pilot study was executed to evaluate the technique of 
the BoNT injections in the salivary glands.
The in-vitro study revealed that the lobular subdivision of the glands is essential. To 
gain adequate spread of BoNT through the glandular parenchyma a total volume of at 
least 1.0 ml should be fractionated over two or three injection sites.
Ultrasound visualization, used during the injections in the in-vivo study, is thought to 
be essential because it guides the injection needle, making it possible to inject BoNT 
at the proper place. It is the only possibility for real-time control to assure an optimal 
clinical result. Adequate ultrasound guidance prevents BoNT from being injected into 
structures that surround the glands, e.g. the musculature. The possible consequences 
of a false route are discussed in the chapter.
Additionally, the use of general anesthesia in youngsters, aging 4 to 16 years, is 
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recommended to avoid improper injections because of restlessness and movements, 
due to fear or the primary movement disorder of the patient.
Chapter 6
A pilot study (N = 3) was undertaken to explore the feasibility of the proposed protocol 
of the salivary flow measurements and the BoNT injections, which were described in 
chapter 5. The measurement procedures and the injection technique were well tolerated 
by all three participating children. Compared to baseline, salivary flow was maximally 
reduced by 51 to 63%. The clinical outcome and the parents’ comments encouraged 
continuing with a larger study.
Chapters 7 en 8
The core of the study is dicussed in these chapters.
In 2000 and 2001, 53 severely drooling children with a CP were seen in the outpatient 
clinic. The inclusion criteria are presented in  Table 1.3. Forty-five children were included 
in the trial, during which the effect of BoNT (the experimental intervention) on salivary 
flow and drooling was compared to scopolamine (the control intervention). Figure 1.8 
(also Figure 7.1) clarifies the dropouts and the number of patients in each phase of the 
study. The results of 39 children could be analyzed.
The salivary flow rate and severity as well as frequency of drooling were measured. After 
inclusion, children were measured subsequently during baseline, a 10-days period of 
Scopoderm-TTS® treatment, a washout period, and after BoNT injections.
The central question was whether scopolamine and BoNT had distinguishable effects 
on the salivary flow rate from the injected glands. To evaluate this the saliva production 
was measured at baseline and after interventions.
Analyses of variance were used to evaluate the differences between the subsequent 
measurements. For all results an adequate level of significance was demanded (p ≤ 
0.05).
In chapter 7 it is concluded that both, scopolamine and Botulinum toxin, had a good 
anticholinergic effect within the parenchyma of the submandibular gland. Among the 
participating children, both treatments resulted is a significant reduction of the salivary 
flow rates when compared to baseline. Responders to BoNT achieved a reduction in 
submandibular salivary flow by far exceeding that of scopolamine. This reflected the 
explicitly strong anticholinergic effect of BoNT. Compared to baseline, the submandibular 
salivary flow showed a mean reduction of 24.7% during scopolamine application 
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and a mean reduction of 42.4% two weeks after BoNT administration. The greatest 
reductions in salivary flow were achieved 2, 4, and 8 weeks following BoNT. Throughout 
the study, the salivary flow remained significantly lower compared to baseline. Flow 
measurements 2, 4 and 8 weeks after injections, demonstrated significantly greater 
reductions in the mean salivary flow rate compared to scopolamine.
A 30% reduction of baseline salivary flow rate was demanded for a child to be assigned 
as a responder*. According to this definition, the success rate to scopolamine was 
~95% of the population and ~70% to BoNT. Explanations for this differences are 
dicussed in the chapter.
Because of the prerequisites that are formulated in the inclusion criteria (diagnosis and 
the degree of drooling) the results of this study cannot be straightforwardly generalized 
to any other population. In theory, however, it is expected that the physiological effect 
of intra-glandular BoNT injections will be present in any population, provided no 
glandular diseases or abnormalities are present.
Chapter 8 presents the second part of the clinical trial . The objective was to evaluate 
the effect on clinical apparent drooling of the application of scopolamine compared 
to BoNT injections. Drooling was measured by means of the ‘Drooling Quotient”, 
an observational semi-quantitative method. In addition, the parental opinion was 
evaluated by means of the Teacher Drooling Scale and by the use of Visual Analog 
Scales. Analysis of the data prior to and after intervention demonstrated significant 
differences in drooling. BoNT injections reduced drooling for at least 6 months for a 
large part of the population.
The response rate to therapy was estimated according to our definition of success. 
A reduction of 50% of baseline drooling was demanded to assign a patient as a 
responder to therapy. The outcome demonstrated good results for BoNT (~64%) and 
scopolamine (53%).
In the discussion of the chapters 7 and 8 the advantages and disadvantages of the 
two drooling treatment modalities (scopolamine and BoNT) are discussed. Many 
side effects are seen during the use of anticholinergic drugs, making this group of 
drugs unsuitable for long-term use in the treatment of drooling. With respect to the 
magnitude and the duration of effect as well as the few side effects, Botulinum toxin 
has a favorable outcome.
*The 30% demand is explained by the estimated measurement error in the repeated baseline series of salivary flow 
rate measurements (chapter 4).
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Chapter 9
This chapter presents a case study in which the problem of posterior drooling is 
described. Posterior drooling in the presence of impaired swallowing bears the risk 
of saliva aspiration. BoNT injections injected in the salivary glands were effective to 
decrease the amount of swallowed saliva resulting in a remarkable improvement of 
the clinical condition. After repeated treatments, the patient experienced no aspiration 
pneumonia anymore.
Chapter 10
A questionnaire was developed, containing items of quality of life. The selected items, 
concerning daily situations and daily care, were regarded a representative aspects of 
quality of life in relation to the clinical problem of drooling. Parents were asked to 
fill in lists at pre-scheduled time-intervals throughout the study. The outcome of this 
study demonstrates significant improvement on the majority of the items as a result to 
therapy. Daily care becanme less demanding and a lower rate of damages to computers 
and communication devices was recorded.
This study proved that reduction in salivary flow and a diminished drooling has 
significant and relevant effects on aspects of QoL of both the participating children 
with CP and their parents. It is recommended that all interventions to treat drooling 
(surgery, medication, behavior therapy, etc.) be evaluated not only on primary variables 
such as the salivary flow, but also on consequences for QoL.
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Samenvatting
Hoofdstuk 1: algemene inleiding
Het centrale thema van dit proefschrift is het kwijlen bij kinderen met een cerebrale 
parese (CP). Kwijlen wordt in de literatuur ook wel omschreven als ‘onwillekeurig 
speekselverlies uit de mond’, hetgeen normaal is bij opgroeiende kinderen tot de 
leeftijd van ongeveer 18 maanden. Aanhoudend kwijlen na de het vierde jaar wordt als 
pathologisch beschouwd.
De incidentie van kwijlen bij kinderen met een CP wordt in de literatuur verschillend 
opgegeven. Ook de wijze waarop de speekselproductie en het kwijlen worden beoordeeld 
loopt sterk uiteen. De speekselvloed uit de verschillende speekselklieren en de ernst 
van het kwijlen zijn moeilijk in maat en getal uit te drukken. De speekselproductie 
kan van minuut tot minuut variëren en wordt beïnvloed door factoren zoals honger, 
dorst, vermoeidheid, angst en opwinding. Samengevat kan gesteld worden dat circa 
30 % van de kinderen met een CP in lichte tot ernstige mate kwijlt. Het kwijlen vormt 
een sociaal probleem voor kind en gezin veroorzaakt door de onesthetisch aanblik 
en onaangename geur. De verstaanbaarheid van de spraak wordt negatief beïnvloed. 
Kwijlen werkt stigmatiserend. Kwijlende kinderen met een normaal mentaal vermogen 
worden vaak op een lager niveau aangesproken. Zestien procent van de ouders van 
kinderen met een CP geeft aan dat het kwijlen, afgezien van de emotionele en sociale 
belasting, een dagelijks terugkerend probleem is met intensieve verzorging, zoals het 
bij voortduring afvegen van het mondgebied, aansporen tot slikken en verschonen van 
slabben en kleding.
Naar schatting heeft eveneens 1/3 van de kinderen met een CP een gestoorde 
mondmotoriek met onvoldoende of inefficiënte tongbeweging, onvolledige lipsluiting, 
een lage slikfrequentie, een verlaagde gevoeligheid in het mondgebied en verlaagde of 
pathologische reflexen. Kwijlen bij kinderen met een CP ontstaat in principe door een 
slechte verwerking van het speekselaanbod in de mond en is over het algemeen niet 
het gevolg van een verhoogde speekselproductie. Door een slechte coördinatie van de 
spieren die betrokken zijn bij het slikken verzamelt zich  speeksel in de wangzakken, 
onder de tong of in de hypopharynx met als gevolg speekselvloed aan de lippen 
(anterior drooling) of ongecontroleerde overloop in de achterste keelholte (posterior 
drooling). 
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De behandeling van kwijlen heeft altijd als doel het zichtbare speekselverlies of de 
mate van posterior drooling te verminderen. De interventies kunnen feitelijk in drie 
categorieën worden onderverdeeld (zie ook: tabel 1.1):
- Conservatieve behandeling
- Invasieve/niet-chirurgische behandeling
- Chirurgische behandeling
De conservatieve benadering is er op gericht om het speeksel in de mondholte beter 
te verwerken. Dit verschilt van de chirurgische benadering waarbij het doel is de 
speekselvloed te verminderen door verwijdering van een van de klieren, of het speeksel 
op een andere plaats in de mond aan te bieden zodat het beter weggeslikt kan worden. 
De invasieve/niet-chirurgische behandeling is er op gericht de speekselproductie 
te verminderen. Bij deze benadering wordt de innervatie van de speekselklieren 
beïnvloed. De behandeling van kwijlen middels injecties met Botuline Toxine in de 
speekselklieren is hier een voorbeeld van en vormt de experimentele behandelmethode 
die is onderzocht in dit promotieonderzoek.
De hypothese van dit onderzoek is gebaseerd op het gegeven dat Botuline Toxine 
(BoNT) de prikkeloverdracht van cholinerge zenuwuiteinden naar het doelorgaan remt. 
De postganglionaire parasympathische zenuwen, die de speekselklieren innerveren, 
zijn voorbeelden van dergelijke zenuwen. Van BoNT zijn meerdere subtypen bekend, 
waarvan het Botuline toxine type-A het meest wordt toegepast. De werking van BoNT 
berust op het feit dat het molecule, bestaande uit 2 ketens van eiwitten, in staat is om 
aan het pre-synaptische uiteinde van de postganglionaire parasympathische zenuw te 
binden en via een proces van endocytose in het cytoplasma binnen te dringen (figuur 
1.6a t/m e). Daarna wordt het BoNT gesplitst in een lange en een korte keten. De korte 
keten is het actieve deel dat zich kan binden aan SNAP-25 (synaptosomal associated 
protein), een enzym dat in het celmembraan nodig is voor het vrijmaken van de 
neurotransmitter ‘acethylcholine’. Na binding van de korte BoNT-keten aan het SNAP-
25 wordt de fysiologische reactie geblokkeerd en zijn de speekselklieren gedenerveerd. 
Theoretisch zou hierdoor de speekselproductie verlaagd kunnen worden. In dit 
promotieonderzoek is onderzocht of BoNT (experimentele behandeling), geïnjecteerd 
in de speekselklier, voldoende remmende werking op het speekselklierparenchym 
vertoont om een tot een klinisch merkbare afname van de speekselvloed te komen. 
Het effect van BoNT wordt vergleken met dat van het anticholinergicum ‘scopolamine’ 
(controlebehandeling).
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Onderzoeksvragen:
1. Heeft BoNT invloed op de speekselproductie van de glandulae submandibularis?
2. Vermindert het kwijlen indien de speekselproductie afneemt?
3. Verbetert de kwaliteit van leven door de interventies?
Vanaf Januari 2000 werden 53 patiënten poliklinisch beoordeeld om de inclusiecriteria 
te toetsen (tabel 1.3). Uiteindelijk werden 45 patiënten, met een gemiddelde leeftijd van 
9,5 jaar geïncludeerd.
Het onderzoek is goedgekeurd door de medisch ethische beoordelingscommissie van 
de regio Arnhem/Nijmegen (CWOM: Commissie Wetenschappelijk Onderzoek met 
Mensen).
Hoofdstuk 2: een literatuuranalyse: het effect van anticholinergica bij de behandeling van 
kwijlen
Dit hoofdstuk omvat een systematisch overzicht van de wereldliteratuur (‘systematic 
review’) waarin gezocht wordt naar bewijs voor de effectiviteit van anticholinergische 
medicatie bij de behandeling van kwijlen bij kinderen met CP. Een dergelijke ‘review’ is 
bedoeld om de uitkomsten van onderzoek dat reeds is verricht en gepubliceerd kritisch 
te analyseren en de resultaten te vergelijken.
Relevante publicaties werden met een computermatige zoekactie geïdentificeerd 
voor de periode van vóór juni 2002. Gebruik werd gemaakt van de zoekmachines in 
de Medline database (vanaf 1966), Pubmed (vanaf 1966), de Cochrane database en 
Current Contents (vanaf 1996). De gebruikte sleutelwoorden staan weer gegeven in 
tabel 2.1.
Er werden uitsluitend klinische studies geselecteerd die als doel hadden om bij 
patiënten het kwijlen te behandelen. De publicaties dienden in het Engels, Duits, 
Frans of Nederlands te zijn verschenen. Brieven, samenvattingen en verslagen van 
presentaties werden niet in de analyse opgenomen. Tabel 2.2. geeft de selectiecriteria 
voor de aangetroffen publicaties weer. De publicaties werden geblindeerd en door drie 
reviewers onafhankelijk beoordeeld en in een consensusbijeenkomst besproken aan 
de hand van een gestructureerde controlelijst (tabel 2.3). De eerste computerzoekactie 
leverde 64 publicaties op waarvan 36 werden afgewezen op basis van de samenvatting. 
Van 28 geanalyseerde publicaties werden 7 artikelen geselecteerd voor verdere analyse. 
Het betrof 3 ‘randomized clinical trials’ (RCT), 3 cohort studies en 1 studie met een 
experimenteel design.
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RCT’s leveren vanwege het onderzoeksdesign de beste bewijskracht. Slechts 1 van de 
3 RCT’s kon de toets van de opgestelde criteria doorstaan. In de ‘evidence synthesis’ 
leverde deze studie, in relatie tot de onderzoeksvraag, ‘hoge bewijskracht’. Een andere 
studie leverde ‘middelmatig’ bewijs en de laatste RCT ‘laag’ bewijs.
Cohort studies hebben minder bewijskracht maar kunnen secundair bewijs leveren 
indien een methodologisch goed verslag wordt gegeven. Eén van de gevonden 
cohortstudies was matig informatief over de effectiviteit van anticholinergica. De 
andere cohortstudies leverden onvoldoende of geen informatie op. De experimentele 
studie was goed opgezet en leverde expliciet ondersteunend bewijs.
Er bleken dus weinig publicaties te zijn die de effectiviteit van anticholinergica tegen 
kwijlen bewezen. Het uitvoeren van een evidence synthese was niet mogelijk omdat 
in de studies de bepaling van de speekselvloed en de ernst van het kwijlen te veel 
verschilden.
Geconcludeerd werd dat:
-  een uitspraak over de bewezen effectiviteit van anticholinergica bij de behandeling 
van het kwijlen, bij kinderen met een CP, niet was te geven. In de klinische praktijk 
lijken anticholinergica het kwijlen bij kinderen met een CP wel te verminderen.
-  voorts kon geen uitspraak worden gedaan over de langetermijneffecten van 
anticholinergica.
-  tenslotte, anticholinergica geven altijd bijwerkingen zonder dat duidelijk werd in 
welk percentage van de gevallen bijwerkingen noodzaakten tot beëindiging van de 
therapie.
Hoofdstuk 3: speekselproductie bij gezonde kinderen
Bij 62 gezonde schoolgaande jongens en meisjes in de leeftijd van 6-11 jaar werd de 
ongestimuleerde speekselproductie gemeten teneinde een referentiegroep te creëren 
voor de kwijlende kinderen die behandeld zouden gaan worden.
Onderzocht werd of bij gezonde kinderen de leeftijd of het geslacht, invloed hadden 
op de speekselproductie. Er werd geen verschil gevonden in de productieniveaus van 
speeksel tussen jongens en meisjes. Ook bleek de speekselproductie niet beïnvloed 
te worden door de leeftijdsgrenzen waarbinnen gemeten is. Het niveau van de 
speekselproductie zoals gemeten aan de parotisklieren (0.15 ml/min) bleek groter 
dan wat in de literatuur wordt vermeld met andere meetmethoden. Het is mogelijk 
dat de wattenmethode enige tactiele stimulatie geeft op het moment dat de watten 
in aanraking komen met het wangslijmvlies. Het relatieve aandeel van de parotis 
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productie in de totale speekselproductie nam daardoor wat toe. De speekselvloed 
vanuit de glandulae submandibularis en sublingualis (0.32 ml/min) kwam overeen 
met de gegevens zoals die in de wereldliteratuur vermeld worden.
De reproduceerbaarheid van de metingen met de wattenmethode bleek goed te zijn 
ongeacht de speekselklier die werd onderzocht. Hoewel er per kind enige variatie 
bestond tussen het niveau van de 1ste  en de 2de speekselmeting, werden geen 
significante verschillen gevonden  voor de groep. Dit komt overeen met de resultaten 
van andere studies en ondersteunt het idee dat er voor gezonde kinderen geen sprake 
is van een leercurve in het accepteren van de watten in de mond.
Hoofdstuk 4: evaluatie van de meetmethode
In dit hoofdstuk is aandacht besteed aan een nadere analyse van de ‘swab method’ 
ofwel de wattenmethode. Met deze kwantitatieve meetmethode is tijdens dit onderzoek 
de speekselproductie onderzocht. De toepasbaarheid en de reproduceerbaarheid van 
de wattenmethode zijn getoetst omdat in de literatuur geen gegevens te vinden waren 
voor kinderen met een cerebrale parese of een vergelijkbare handicap. De statistische 
methode met de berekening van de ‘within-subject standard deviation’ (SW), zoals 
beschreven door Bland en Altman, werd toegepast om de meetfout (measurement 
error) en de biologische variatie van de speekselproductie (biological variation) te 
kunnen kwantificeren.
Voor analyse werden de gegevens gebruikt van 45 ernstig kwijlende kinderen. Er bleek 
een goede constantheid te bestaan tussen de waarden van speekselmetingen van 
opeenvolgende metingen. Bovendien waren duplo-metingen niet verschillend, hetgeen 
aangeeft dat de biologische variatie bij de gekozen opzet verwaarloosbaar was.
De SW werd berekend en bleek geschikt om de ‘measurement error’ en de ‘biological 
variation’ te kwantificeren. Op deze manier kon worden aangegeven in welke mate de 
speekselproductie moest veranderen om het effect van een uitgevoerde behandeling 
niet toe te schrijven aan meetfouten of de biologische variatie in de speekselproductie 
van de onderzochte personen.
Hoofdstuk 5: de techniek van het injecteren 
Op basis van de farmacologische eigenschappen van BoNT wordt aangenomen dat het 
vrijkomen van acethylcholine kan worden geblokkeerd indien het toxine in het weefsel 
wordt geïnjecteerd en vervolgens de presynaptische uiteinden van de postganglionaire 
parasympathische zenuwen kan bereiken. Bij deze toepassing moet rekening worden 
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gehouden met ongewenste neveneffecten als het BoNT niet exact op de juiste plaats 
wordt gespoten en bijvoorbeeld in de omgevende structuren terechtkomt. Dit geldt 
met name voor de spieren die direct in de buurt van de speekselklieren liggen en 
betrokken zijn bij het slikken.
In dit hoofdstuk wordt verslag gedaan van een in-vivo studie en van een in-vitro 
studie.
Voor de in-vitro studie werd een speekselklier (glandula submandibularis) geïnjecteerd, 
die enkele minuten daarvoor bij een patiënt werd verwijderd tijdens een radicale 
nekdissectie. Het doel was om de verspreiding van BoNT in het parenchym te bepalen 
en vast te stellen hoeveel volume-eenheden van een Botox® (Allergan BV, Nieuwegein, 
Nederland) oplossing noodzakelijk waren voor 
een adequate verdeling over de speekselklier. Tijdens de proef werd de klier 
gefractioneerd geïnjecteerd met Omnipaque. De samenstelling hiervan is vergelijkbaar 
met die van een BoNT oplossing. Er werd een serie röntgenopnamen gemaakt om 
de verspreiding te kunnen visualiseren (figuur 5.2.) Geconcludeerd werd dat de 
glandula submandibularis wordt onderverdeeld door septa hetgeen in relatie tot de 
therapie met BoNT relevant bleek te zijn. Om een goede verdeling in het klierweefsel 
te krijgen moeten tenminste 2 depots van de oplossing worden gespoten, waarbij een 
totaalvolume van 1 tot 1,5 ml wordt gebruikt om een adequate verspreiding in het 
weefselparenchym van de speekselklier te verkrijgen.
In de in-vivo studie wordt beschreven hoe de intra-glandulaire injecties met BoNT bij 
patiënten de patiënten werd uitgevoerd. Echografische controle van de injecties bleek 
nodig. De speekselkier kan hiermee goed in beeld worden gebracht. Een aantal primaire 
afwijkingen kan worden gediagnosticeerd. De injectienaald wordt gevisualiseerd tijdens 
het spuiten en foutieve deposities kunnen worden voorkomen.
Algehele narcose was nodig voor het adequaat uitvoeren van de procedure bij 
gehandicapte kinderen in de leeftijd van 3 tot 16 jaar. Onrust door angst of bewegingen 
door de primaire motorisch stoornis kan met algehele anesthesie worden voorkomen. 
Dit geeft de beste garantie dat Botox op de juiste plaats wordt geïnjecteerd.
De mogelijke bijwerkingen van foutieve injecties in het gebied naast de glandulae 
parotis en submandibularis zijn nader uitgewerkt.
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Hoofdstuk 6: Botuline toxine injecties in de glandulae submandibularis: een pilotstudy
Het doel van dit studieonderdeel was het protocol van speekselmetingen en BoNT 
behandeling te testen. De resultaten van de eerste cases (N = 3) die behandeld zijn 
met BoNT worden in dit hoofdstuk besproken.
Gedurende 4 maanden werden drie kinderen met CP en ernstig kwijlen na de 
behandeling gevolgd. De resultaten waren gunstig. De speekselproductie vertoonde, 
ten opzichte van baseline, een reductie van maximaal 51 tot 63%. In alle 3 de gevallen 
was het effect meetbaar tijdens de eerste speekselvloedmeting 2 weken na de injecties. 
Het tijdstip van het maximale effect verschilde per kind en varieerde van 4 tot 16 weken. 
De vermindering van de speekselproductie leidde in 1 geval tot stoppen van het kwijlen 
gedurende de hele studie, in 1 geval nam het kwijlen aanzienlijk af en bij het laatste 
kind was er een lichte vermindering van het kwijlen overdag maar een forse afname 
gedurende de nacht. Door alle ouders werden de veranderingen als zeer positief 
ervaren. Bij 1 kind werd een tijdelijke indikking van het speeksel gezien, hetgeen niet 
tot complicaties leidde.
Op basis van deze bevindingen werd de aanbeveling gedaan om een studie te verrichten 
bij een grotere groep kinderen.
Hoofdstuk 7 en 8: Botuline toxine injecties bij de behandeling van kwijlen
In de hoofdstukken 7 en 8 worden de resultaten van de Botuline Toxine behandelingen 
in een grotere groep van 45 kinderen beschreven. Deze kinderen namen deel aan een 
‘controlled clinical trial’. De toepassing van een standaard behandeling (scopolamine) 
werd vergleken met de experimentele behandeling (Botuline Toxine injecties). Figuur 
1.7 laat het verloop tijdens het onderzoek zien. Tijdens het onderzoek vielen 6 kinderen 
af. De gegevens van 39 kinderen werden geanalyseerd.
Tijdens de baselineperiode werd de speekselvloed en de mate van het kwijlen bij alle 
patiënten diverse keren gemeten. Daarop volgde de eerste behandelfase met 10 dagen 
Scopoderm-TTS®  (Novartis Consumer Health BV, Breda, Nederland). Scopoderm 
is een anticholinergicum dat middels een pleister via de huid wordt toegediend en 
daarna via de bloedbaan verschillende organen bereikt. Na stoppen van de Scopoderm 
en een uitwasperiode van 4 weken werd éénmalige BoNT geïnjecteerd in de glandulae 
submandibularis, waarvan de dosering was gerelateerd aan het lichaamsgewicht en 
varieerde van 30 tot 50 U Botox®, verdeeld over de beide speekselklieren. Uitsluitend de 
glandulae submandibularis werden geïnjecteerd omdat deze klieren in een rustsituatie 
circa 60 – 70% van de speekselproductie verzorgen.
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De speekselproductie van de glandula parotis en van de glandula submandibularis 
beiderzijds werd met regelmatige intervallen gemeten d.m.v. de wattenmethode (ml/
min). Niet van alle meetmomenten waren de waarden bruikbaar, bijvoorbeeld omdat 
een kind verkouden was op het moment van meten. Tijdens de analyses werd speciaal 
aandacht besteed aan de statistische methodes om de betekenis van de missende 
waarden in de conclusie te verantwoorden.
Hoofdstuk 7 beschrijft de effectiviteit van BoNT op de speekselproductie bij kwijlende 
kinderen met een CP. Het verschil tussen de speekselproductie tijdens Scopoderm en 
na de Botox® injecties werd onderzocht.
Het bleek dat de speekselproductie tijdens de uitwasperiode, na de eerste behandeling 
met scopolamine, weer terugkeerde naar het niveau van de baselinemetingen (p = 
0.733; 95% confidence interval of the difference –0.0582 to 0.0821). Dit betekent dat 
de duur van de uitwasperiode na scopolamine voldoende was.
Scopolamine gaf een speekselreductie van 24.7% en BoNT 42%. Ten opzichte van 
baseline bleek de verschilscore voor scopolamine (p = 0.001) en voor BoNT (p ≤ 
0.002) significant. Voor BoNT werd de maximale reductie behaald bij respectievelijk 2, 
4 en 8 weken ná de injecties. Ook bleek BoNT bij de metingen na 2,4 en 8 weken een 
significant betere speekselreductie te geven dan scopolamine (p ≤ 0.014).
Als maat voor het succes van de behandelingen werd aangenomen dat de 
speekselproductie in vergelijk met baseline meer dan 30% moest afnemen. Onder 
deze aanname bleek scopolamine bij ~95% van de kinderen effectief te zijn. Het 
succespercentage 2 weken na de Botox injectie bedroeg ~70% en nam geleidelijk af 
tot ~49% na 24 weken.
De volgende centrale onderzoeksvraag was of het ‘kwijlen’ zou afnemen als de 
speekselproductie verminderde. Dit wordt in hoofdstuk 8 beschreven.
De mate van kwijlen werd geëvalueerd met de Drooling Quotiënt (DQ), de Teacher 
Drooling Scale (TDS) en aan de hand van Visueel Analoge schalen (VAS). De DQ is 
een observatie methode waarbij de vorming van nieuw speeksel aan de rand van de 
lippen of op de kin iedere 15 seconden wordt gescoord gedurende 10 minuten. Uit 
de positieve scores van de totaal 40 observaties werd een percentagegetal berekend, 
hetgeen de uitkomstmaat voor het onderzoek vormde. De TDS is een 5 puntsschaal 
die op basis van informatie, verkregen van ouders, de ernst van het kwijlen uitdrukt. 
De VAS werden gebruikt om op een aantal stellingen of vragen een waardeoordeel te 
verkrijgen van de ouders over het kwijlen in de thuissituatie.
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Uit de analyses bleek dat de uitwasperiode na scopolamine voldeed. Er bleek geen 
verschil in DQ tussen de meting op baseline en die ná ‘uitwassen’ van scopolamine 
(p = 0.32). Deze bevinding minimaliseert het risico dat er een overdrachtseffect kon 
bestaan van scopolamine naar BoNT.
Het bleek dat een verminderde speekselproductie (hoofdstuk 7) grote overeenkomst 
vertoonde met de vermindering van het kwijlen (hoofdstuk 8). Alle metingen van de 
DQ na scopolamine en BoNT vertonen een significante verandering in vergelijk met de 
baselinemetingen (p < 0.001). De grootste afname van het kwijlgedrag werd 2 weken 
na de BoNT injecties bereikt. Echter na 24 weken, het eindpunt van de studie analyses, 
werd bij een deel van de populatie nog steeds een aanmerkelijk effect gevonden.
Als maat voor succes ten aanzien van het kwijlgedrag werd gedefinieerd dat er in 
vergelijk met baseline een reductie van 50% in de DQ moest optreden bij de metingen 
na behandeling met respectievelijk scopolamine en BoNT. Tijdens scopolamine kon 
53% van de kinderen worden aangemerkt als responder. Twee weken na BoNT was dit 
percentage 64.1%. Bij 24 weken liep dit geleidelijk terug tot 48.7%. De resultaten van 
de TDS en de VAS kwamen overeen met de uitkomsten van de DQ.
Hoofdstuk 9: posterior drooling
‘Anterior drooling’ is het onwillekeurig speekselverlies uit de mond. Onder ‘posterior 
drooling’ wordt  de lekkage van speeksel over de tongbasis in de hypopharynx verstaan. 
Posterior drooling kan tot ernstige complicaties leiden. Tengevolge van pharyngeale 
slikstoornissen kan chronische aspiratie het gevolg zijn. Dit veroorzaakt bij een 
onbekend aantal kinderen met een cerebrale parese een recidiverende pneumonie.
Tevens bestaat een bedreiging door een gastro-oesophageale reflux met o.a. indirecte 
aspiratie van voedsel in de bovenste luchtwegen. Het is aannemelijk dat een relatie 
bestaat tussen een gastro-oesophageale reflux en een toename van de speekselvloed.
Een patiënt wordt beschreven bij wie herhaalde injecties met BoNT zijn gegeven in 
verband met  posterior drooling. Een rolstoelgebonden jongen van 9.4 jaar oud met 
een spastisch athetotisch beeld, werd op de polikliniek gezien i.v.m. ernstig kwijlen. 
Hij bleek de laatste 2 jaar gemiddeld 7 recidiverende pneumonieën door te maken. 
Vanwege de gepresenteerde problematiek werd deze patiënt geïndiceerd voor een 
dubbelzijdige injectie met Botuline toxine in  de glandulae submandibularis.
De injecties resulteerden in een aanzienlijke afname van de speekselproductie en een 
afname in het zichtbare kwijlen, gemeten met de DQ en de TDS.
De grote winst bleek te liggen in het uitblijven van longontstekingen en dat de conditie 
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van de patiënt aanmerkelijk verbeterde. Op geleide van de klinische symptomen van het 
posterior drooling werd hij vervolgens met intervallen van 7 maanden en 12 maanden 
herhaald geïnjecteerd.
Hoofdstuk 10: kwaliteit van leven in relatie met kwijlen
De invloed van kwijlen bij spastische kinderen op de kwaliteit van leven werd geëvalueerd 
middels een uitgebreide vragenlijst die speciaal voor dit doel was ontwikkeld. De 
ouders van de deelnemende kinderen werd verzocht vóór en ná een behandeling 
met anticholinergische medicatie een vragenlijst in te vullen. Van 42 kinderen werden 
de gegevens ontvangen en verwerkt. In de ontwikkelingsfase van de vragenlijst zijn 
specifieke dagelijkse situaties geïdentificeerd die aanleiding geven tot toename van het 
kwijlen. Ten gevolge van de behandeling nam het kwijlgedrag in deze situaties af. De 
zorgbehoefte nam tevens af en de tijdsbesteding door ouders verbeterde.  Het bleek 
minder nodig de kin en mond af te vegen en slabber of het sjaaltjes te verschonen. Er 
ontstond minder schade aan communicatieapparatuur en computers.
Het op deze wijze inventariseren van aspecten van de kwaliteit van leven leverde 
zinvolle informatie op ten aanzien van de behandelingseffecten.
In feite zouden alle therapieën, chirurgisch of niet chirurgisch, op deze wijze moeten 
worden geëvalueerd om zicht te krijgen en op de effecten van het kwijlen op de kwaliteit 
van leven van zowel kind als omgeving.
Hoofdstuk 11: algemene discussie
In hoofdstuk 11 wordt een algemene discussie gevoerd en worden aanbevelingen 
gegeven voor verder onderzoek.
De doelstelling van deze studie was om het effect van Botuline Toxine op de 
speekselproductie te vergelijken met een ander anticholinergisch medicament 
(scopolamine) dat al vaker als behandeling werd toegepast. Aangetoond werd dat 
BoNT, gespoten in de speekselklier, de speekselproductie substantieel vermindert. 
Het percentage kinderen met een positieve respons bedroeg op de korte termijn 70% 
en voor de  langere termijn 50% (circa 6 maanden). Voor de patiënten die ook nog 
na deze tijd konden worden gemeten bleef de gunstige trend aanwezig tot 48 weken 
na de BoNT behandeling. Gebaseerd op anderen onderzoeken lijkt het aannemelijk 
dat de werking van BoNT in het autonome zenuwstelsel langer aanhoudt dan in het 
willekeurige zenuwstelsel.
Als niet gegeten en gedronken wordt bestaat de speekselproductie in een rustsituatie 
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voor circa 70% uit submandibulair speeksel, 25% uit de glandulae parotis en 5% 
uit de glandulae sublingualis. In dit onderzoek werd gekozen om uitsluitend de 
submandibulaire klieren te injecteren met BoNT. De resultaten bevestigden dat de 
‘rust’ speekselproductie voor een groot deel door de submandibularis klieren wordt 
verzorgd. Als een speekselreducerende ingreep gewenst is i.v.m. kwijlen bij kinderen 
met een CP dan is een eerste benadering met injecties in de submandibulaire klieren 
een logische stap.
In de literatuur wordt in toenemende mate een pleidooi gehouden voor het injecteren 
van de parotiden omdat dit anatomisch gezien de grootste speekselklieren zijn en 
omdat ze tijdens eten en drinken in korte tijd, zeer veel sereus, waterig speeksel, 
kunnen produceren. Het is echter niet aan te raden om primair deze klieren te 
behandelen omdat dat gemiddeld ~ 1/3 van de kinderen met een CP al een gestoorde 
mondmotoriek heeft en derhalve moeite ondervindt met de verwerking van voedsel. 
Bij onvoldoende resultaat na injectie van de submandibularis kan men overwegen om 
de parotiden gedeeltelijk aanvullend te behandelen. De ontwikkeling van richtlijnen 
hiervoor is een uitdaging voor verder onderzoek.
In het verleden zijn chirurgische ingrepen veel toegepast. Deze zijn voor geselecteerde 
gevallen nog steeds aangewezen. In principe worden dergelijke ingrepen gedaan om 
definitief tot een vermindering van speekselproductie te komen, of het speeksel op 
een anatomisch andere plaats aan te bieden zodat het beter verwerkt kan worden. 
Ongepubliceerde observaties (afdeling mond- en kaakchirurgie, Catahrina ziekenhuis 
te Eindhoven) suggereren dat bij verwijdering van een speekselklier er compensatie 
van speekselproductie kan optreden vanuit de resterende speekselklieren die na enkele 
maanden meer zouden gaan produceren. In ons onderzoek is compensatie vanuit de 
parotis klieren is niet waargenomen (Figuur 7.2).
Op drie manieren werd een positieve reactie op de aangeboden behandelingen 
gedefinieerd. 
De eerste definitie had als eis dat ten opzichte van baseline de speekselproductie met 
30% moest verminderen. Er bleek een verschil te bestaan  tussen het succespercentage 
op Scopolamine en BoNT, ten gunste van scopolamine. Bij nadere analyse van de data 
bleek dat een vrij groot aantal van de niet-reagerende patiënten op BoNT zeer dicht 
tegen de 30-procents grens aanzat.
De tweede definitie voor succes verlangde dat ten opzichte van baseline de DQ, als 
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maat voor het kwijlen met tenminste 50% zou verminderen. Bij deze analyse vielen de 
cijfers gunstiger uit voor BoNT.
De derde definitie bestond uit een samenvoeging van de eerste en de tweede definitie. 
Om als responder aangemerkt te worden moest ten opzichte van baseline 30% reductie 
in speekselproductie en 50% reductie in kwijlen behaald worden. Dit moest tenminste 
gescoord kunnen worden op een van de meetmomenten op BoNT-2, BoNT-4 of BoNT-
8. Deze definitie aanhoudende was het algehele succes percentage 74.4% voor BoNT.
Gegeven het aantal patiënten dat aan dit onderzoek deelnam was subgroepanalyse niet 
mogelijk. Statistisch kon niet worden vastgesteld of anatomische factoren, mondmotorische 
vaardigheden, de mentale ontwikkeling, de mate van spasticiteit of omgevingsfactoren 
van invloed waren op het al of niet positief reageren op behandeling.
Bij langdurige denervatie van het klierparenchym (door BoNT) wordt op theoretische 
gronden hypotrofie van het weefsel verwacht. De klinische indruk is dat het volume van de 
geïnjecteerde speekselklieren afnam. Dit vormt een onderwerp voor nader onderzoek.
Tijdens de toediening van Scopolamine werden in ~82% van de gevallen bijwerkingen 
gezien. Het meest werd melding gemaakt van een droge mond, onrust, verwardheid 
en gestoorde visus. Er werden weinig en overwegend milde bijwerkingen na de 
BoNT injecties gezien. Twee patiënten vertoonden een griepachtig gevoel en 2 
andere patiënten meldden lichte slikklachten tot enkele uren na de behandeling. Dit 
werd toegeschreven aan een lokale zwelling van de speekselklier. Op basis van de 
geobserveerde bijwerkingen kan gesteld worden dat de behandeling met BoNT weinig 
risico kent.
Een uitdaging voor de nabije toekomst is om de BoNT injecties bij de behandeling 
van ernstig chronisch kwijlen een juiste plaats te geven tussen de conservatieve en 
chirurgische therapieën. Verder moet onderzocht worden welke factoren de aard en de 
ernst van het speekselverlies bepalen om vervolgens te komen tot een therapeutische 
beslisboom.
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Veel mensen hebben bijgedragen aan dit proefschrift. In de loop van de tijd ben ik 
onder de indruk geraakt van de belangeloze inspanning die mensen opbrachten om 
het project telkens een stukje vooruit te helpen. Ieder op zijn eigen terrein. Onnodig 
te zeggen dat dit bewerkelijke onderzoek zonder deze inzet, niet zou zijn gelukt. Ik 
wil allen hiervoor hartelijk danken. Op het gevaar af mensen ongenoemd te laten wil 
ik me er toch aan wagen een aantal van hen met name te noemen. Om geen pijnlijke 
keuzes te hoeven maken, zal ik dit chronologisch doen. Anders gezegd; in “volgorde 
van opkomst” bij dit drooling project.
Lieve Lina, in de loop van de jaren zijn al heel wat ideeën over promotieonderwerpen 
de revue gepasseerd. De dreiging van een promotietraject heeft al geruime tijd boven 
onze relatie gehangen. In de gesprekken daarover ben je altijd stimulerend geweest en 
belichtte op reële wijze ook de gezinsbelangen. Het is goed gegaan en ik ben je intens 
dankbaar voor je steun en interesse. Menigmaal hebben we gesproken over de ins en 
outs van het project en ik heb ronduit kunnen profiteren van de adviezen van iemand die 
“een beetje van buitenaf” meekeek en meedacht, met een goede dosis mensenkennis 
en gevoel voor verhoudingen. In mindere tijden was je er met je persoonlijke steun. 
Gewoon bedanken zou te weinig zijn. Bovendien schijn ik de postpromotionele “dip” 
nog te krijgen. Het zal wel druk blijven. Nu het voorbij is weet je dat ik heel wat plannen 
heb om de tijd te gaan vullen. Daar hoort lekker samen er op uit trekken zeker bij. Altijd 
jouw wens, en trouwens ook de mijne, al klinkt dat misschien ongeloofwaardig omdat 
gezelligheid het jarenlang heeft moeten afleggen tegen dit project.
Lieve Femke, geweldig, zoals je mee bent gegroeid met dit project. Je toonde je steeds 
nieuwsgieriger en je vragen over het onderzoek werden steeds verfijnder. Ik ben er trots 
op dat ik als vader dit met jou heb mogen delen. Net als het onderzoek, ben jij in die 
jaren volwassen geworden en ik hoop dat onze wederzijdse intellectuele belangstelling 
zich zal blijven verdiepen.
Roeland: Jij bent in deze jaren uitgegroeid van beginnende puber die na een voordracht 
vroeg: ‘Wat had je voor cijfer’, tot iemand die door zijn reacties op het onderzoek te 
kennen geeft te beseffen wat het kan betekenen als je opgroeit met een handicap. 
Beiden hebben we zitten ploeteren; jij aan je examen en ik aan mijn proefschrift: 
Brothers in arms!     
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Drs. R.A.J. Rijken, beste Dick. Bij jou heb ik de opleiding tot revalidatiearts kunnen 
volgen. Als geen ander heb jij mij bijgebracht dat het belangrijk is dokter voor de patiënt 
te zijn maar daarnaast wetenschappelijk onderzoek te doen. En als het aan jou lag, om 
je eigen worden te gebruiken, “een stuk onderzoek waar de patiënt iets aan had”. 
Je was dan ook erg teleurgesteld toen ik het project over de preventieve nachtelijke 
beademing bij de N.M.A patiëntjes niet meer haalbaar achtte. Wel nu, een beetje later 
in mijn carrière, ik hoop dat het met dit proefschrift is goed gemaakt. Ik dank je voor 
de motiverende toewijding tijdens de opleiding.
Mijn eerste promotor professor J.J.Rotteveel, beste Jan. Ik herinner mij goed dat we in de 
loop van 1999 serieus plannen maakte voor mijn promotie. Hoewel niet de hoogleraar 
van mijn afdeling (die hadden we toen niet) wilde je dat ik promoveerde met als hoger 
doel mijzelf en de revalidatiegeneeskunde vooruit te helpen. De behandeling van 
spasticiteit had ons beider belangstelling en het is specifiek jouw verdienste om het 
kleine maar klinisch en sociaal belangrijke onderwerp van “drooling” eruit te lichten 
en bij mij te introduceren. Het was wennen aan het idee dat ik over een mogelijke 
behandeling van kwijlen zou publiceren. Zelfs over dat wennen hebben we boeiende, 
soms hilarische gesprekken gevoerd. Binnen korte tijd hadden we een kundige groep 
om ons heen en startte het project. Goede herinneringen bewaar ik aan de befaamde 
avondvergaderingen die ik wellicht nog ga missen ook. Onder het genot van een glas 
wijn zijn op die avonden vele ideeën naar voren gekomen. Consequent en consistent 
heb je leiding gegeven aan het project en de goede weg bewaakt. Jan, zonder jou was 
het niet gelukt. De promotie is teneinde, de samenwerking en de vriendschap gelukkig 
niet. Samen hebben we onderwerpen genoeg voor onderzoek en met name ook de 
zorg rondom het kind met bewegingsstoornissen.
Mijn tweede promotor professor F.J.M. Gabreëls, beste Fons. We kennen elkaar al 
sinds 1986. Ik was toen assistent niet in opleiding en jij de vaste consulent van de 
St.Maartenskliniek. Later werd ik, inmiddels revalidatiearts, consulent binnen het 
‘interdisciplinair kinderneurologisch centrum’. Op jouw afdeling heb ik me altijd, 
mede dankzij jouw belangstelling, zeer welkom gevoeld. Het was dan ook logisch dat 
jij toetrad als vast lid van de droolinggroep. Ik heb genoten van je beschouwingen op 
onze avondvergaderingen. Bij het raamwerk voor het proefschrift zelf heb ik dankbaar 
gebruik gemaakt van jouw visie.
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Mevr. K. van Hulst, lieve Karen. Wat hadden we zonder jou gemoeten; er zou zeer 
beslist geen project zijn geweest. Altijd aanwezig, opgewekt, origineel, meedenkend, 
kritisch, betrokken, begaan met de kinderen en hun ouders, nuchter, consequent, 
waarschuwend, organiserend, attent, humoristisch om maar een paar van je aangename 
eigenschappen te noemen. Jouw inzet is feitelijk niet met een bedankwoordje af te 
doen. Het was ronduit een voorrecht om met jou die 4 jaar te kunnen werken. Het is 
bijna niet voor te stellen hoeveel maal jij het onderzoek bij de kinderen hebt herhaald. 
Jij was het die de contacten onderhield met de verpleegafdelingen en het laboratorium. 
De ouders hebben veel aan je gehad door je vertrouwenwekkende manier van optreden 
en de vele nuttige adviezen die je tussendoor wist te geven. Ik stel voor dat we gewoon 
doorgaan met samenwerken.
Ook dank aan Mevrouw C. Godschalk, beste Carla. Als tweede logopediste was je tijdelijk 
betrokken bij het drooling project. Je bleek goed te zijn in het maken van schema’s 
waardoor alles nog overzichtelijk werd. Dank voor je inzet voor de kinderen.
Drs. J. van der Burg, beste Jan. Voor dat het project startte vroeg ik of je zin had om 
mee te doen. Daar hoefde je niet over na te denken en gaf direct een positief antwoord. 
Ik dank je voor al die keren dat je met mij de discussie wilde aangaan. Je intellectuele 
humor heeft me menig maal op de been gehouden en gestimuleerd. Je betrokkenheid 
is groot geweest en het mes snijdt in dit geval wellicht aan twee kanten. In feite heb 
jij een parallel onderzoek opgezet waar gelukkig voor jou veel mogelijkheden inzitten. 
Met veel belangstelling zal ik de ontwikkelingen volgen.
Mevr. R. van der Heijden, beste Ricky. We kennen elkaar al zeer lang en je bepaalde 
in de begin jaren ’90 in feite het gezicht van de revalidatie in het “Radboud”. Je 
aankondiging om te stoppen met werken zat me niet lekker en op slinkse wijze heb 
ik je tot over je oren in het drooling project kunnen trekken. Daar heb je nog mooi 
ruim 3 jaar aan vastgezeten. De organisatie lag bij jou en met het ‘IKEA’-meetlint heb 
je heel wat afspraken uitgezet op de jaarkalender. Dank voor de oplettende houding 
en de goede organisatie. Jouw inzet ging ver. Zelfs ’s avonds werd je door de ouders 
gebeld op de 06-nummer (dat ik hier niet zal herhalen). Thuis hadden ze mogelijk wel 
genoeg van de drooling-telefoon. Samen met Karen heb je  er op fantastische wijze 
voor gezorgd dat het allemaal mogelijk werd. We zijn dikke vrienden geworden en ik 
zal je nooit vergeten.
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Mijn volgende woord van dank gaat uit naar de ouders die zoveel vertrouwen hebben 
gesteld in ons drooling project en er ontzettend veel voor over hadden om uit alle 
windstreken voor behandeling en controles te komen. De kinderen die telkens weer 
bloot werden gesteld aan nare onderzoeken met van die watten in hun mond. Wat 
fantastisch dat jullie dat allemaal gedaan hebben. We weten nu dat het merendeel van 
jullie goed op de behandeling kan reageren. Voor enkelen was het resultaat minder, 
maar daar werken we nog aan!!!!
Mij eerste co-promotor dr. J. van Limbeek, beste Jacques. Je hebt als geen ander 
invulling gegeven aan de statistische analyses voor het project. Je gaf ruiterlijk toe 
dat je daarin af en toe wel wat eigenwijs was. En niet onterecht, zo bleek, want zonder 
één aanpassing en met wat toelichting hebben we samen 4 reviewers (statistici) bij 
Neurology weten te overtuigen. Ik heb veel van je geleerd over de benadering van een 
probleem, de methodologie, de statistiek en het schrijven van een goed artikel.  Je 
fabelachtige overzicht aangaande de statistiek en methodologie gold in mindere mate 
voor het nakijken van een compleet manuscript; het was telkens weer genieten als je 
vertwijfeld over de stapels papier op je bureau keek en ik je hoorde zeggen: “waar heb 
ik het nou toch gelaten”. We hebben veel plezier gehad en ik snap nog steeds niet waar 
je, ook in de avonduren, de tijd vandaan haalde om mij bij te staan.
Mijn tweede co-promotor dr. F.J.A. van den Hoogen, beste Frank. Het heeft wel iets om 
je overbuurman te vragen als co-promotor. Een van je eerste grappen was ‘of de jonge 
promovendus wellicht in de vrije uren ook tijd had om de tuin te komen doen’. Hoewel 
het op sommige momenten moeilijk bleek om privé en project te scheiden is het zóver 
nooit gekomen. Bedankt voor je betrokken inzet en de uitmuntende correcties die 
je hebt gegeven op de conceptartikelen. Je hebt ervaring opgedaan in Engeland en 
daarom mocht jij als enige zeggen: ”Peter, ik weet wat je bedoelt, maar het staat er 
niet”. We bespraken het reeds, en ik zie er naar uit, om samen met Jan Rotteveel verder 
te gaan in dit onderwerp, ook op chirurgisch gebied. Jouw kennis en inzicht is daarbij 
zeer gewenst.
Dr. F. Joosten, beste Frank. In de eerste uren van het project was je erbij, tot zeer 
veel genoegen van alle projectleden. Prachtige plaatjes toverde je tevoorschijn op de 
monitor. Het ECHO-geleid prikken van Botuline Toxine in de speekselklieren bleek een 
voorwaarde. Met jou legde ik de basis voor de “technical note” die inmiddels in de 
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literatuur al vaak is aangehaald. Het was buitengewoon prettig om met je samen te 
werken. Bij je vertrek heb je gelukkig gezorgd voor een fijne opvolger zodat het project 
vlekkeloos door kon. Ik dank je voor dit alles.
Drs. L. van Die, beste Lia. Al weer heel wat keren stonden we gezamenlijk op de 
operatiekamers bij de KNO. We vormen een goed team en ik ga ervan uit dat we dit 
in de nabije toekomst kunnen voortzetten, gezien de belangstelling die er landelijk is 
voor onze kleine ingreep. Je hebt al eens genoemd dat je mij wilt opleiden in de ECHO-
grafie zodat ik het zelf kan gaan doen. Het lijkt me een goed idee als we dat nog even 
uitstellen.
Drs. D. van der Schaaf, beste Dick. Het verzamelen van data is één ding, het verwerken 
komt daarna. Wat fantastisch dat jij computeren als je hobby hebt. We hebben genoten 
van je software en de vele bruikbare oplossingen en ik zal maar zeggen:”je bent nog 
niet van de droolinggroep af”.
Mevr. P.G. Anderson, MA, beste Patsy. “NO MERCY” bleek zo’n beetje het motto te 
zijn waarmee je de concepten van mijn artikelen hebt bekeken en met je beruchte rode 
pen bewerkt. Van je opbouwende kritiek, ook op methodologisch gebied, heb ik veel 
geleerd.
Mevr C. Steinmann, lieve Corry. Als ik het over mijn secretaresse heb dan ben jij dat. In 
directe zin heb je niet zoveel gedaan voor het project omdat het hoofdzakelijk op het 
Radboud plaatsvond. Je werk op de achtergrond was echter fantastisch en onmisbaar. 
Onze samenwerking is een soort vanzelfsprekend geworden na al die jaren. Ik hoop 
het nog lang te kunnen voortzetten.
Frans v.d. Brandt en medewerkers van het laboratoruim. Onnoemelijk veel buisjes met 
speeksel hebben jullie verwerkt: klasse werk. De analyse ervan gebeurt in Amsterdam 
en zal onderdeel zijn van het vervolgproject.
Dr. D. Burger, apotheker, beste David. Saskia vd Velde en Anita Huisman van de 
apotheek. Veel energie hebben jullie gestoken in het protocol om de route van de 
Botuline Toxine goed te laten verlopen. Jullie waarschuwingen “de Botox is bijna op” 
kwamen altijd goed op tijd. Heel veel dank.
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Afdeling BOB, beste Gidi, Gerard en Mea en verpleegkundigen. Met de klinische 
opnames en de dagbehandelingen voor de kinderen van het project hebben jullie 
mij een enorme dienst bewezen. Een goed geoliede afdeling met een hoog service 
niveau.
Medewerkers van de poli kindergeneeskunde. Jullie hebben onderdak verleend voor 
het doen van de metingen door Karen. Ook toen ik kamers nodig had om de kinderen 
voor dagbehandeling op te vangen waren jullie bereid. Dat was een goede zaak.
Voor de collegae anesthesisten op de KNO was het fenomeen kwijlen nieuw. Hartelijk 
dank dat jullie met zoveel flexibiliteit de ‘drooling kinderen’ hebben opgevangen.
Dag-unit KNO, beste Annelies, Angelique, Tineke. Wat was het telkens gezellig om even 
te komen buurten en lekker lang doen over het maken van de afspraken. Goeie koffie 
hebben jullie daar, nooit een Bosscher Bol gezien. Maar behalve de lol ook serieus 
gewerkt. Het was geweldig om te zien wat voor een fijne band jullie met de kinderen en 
hun ouders wisten op te bouwen. Het maakte het voor hen makkelijker om nog eens 
op herhaling te komen. De soepele organisatie en de attente houding heb ik bijzonder 
gewaardeerd.
Dr. C. Ingels, beste Coen. Zonder het waarschijnlijk zelf te weten heb je samen met 
Frank van den Hoogen veel betekend voor het drooling project, door mij in het begin 
ruimhartig tijd op jullie dag-unit en OK te gunnen. 
Verpleegkundig operatie Team KNO/kaakchirurgie, beste Ireen, Annemiek en anderen. 
Het was eng toen ik de eerste keer met het gevaarlijk Toxine op de OK kwam, maar de 
noodzakelijke voorzorgsmaatregelen waren snel in het programma opgenomen. Uit 
de reacties merkte ik tot mijn vreugde dat het drooling project na enige tijd echt ging 
leven op de OK. Bedankt voor de ondersteuning in de zoektocht naar mogelijkheden 
om de kinderen telkens weer in het programma te krijgen. 
Ook dank aan Mieke Peters voor het telefonisch overleg en de accurate planning.
Collegae en secretaresses van het Radboud. Beste Henk & Henk, Annet en Mirjam. 
Jullie stimulerende woorden waren af en toe hard nodig, het deed me goed. Bedankt 
voor de waarnemingen. Ik kan het niet vergoeden, helaas. Henk van de Meent, ik 
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verwacht dat je interesse in kinderen met bewegingsstoornissen in de toekomst  zal 
leiden tot mooie gezamenlijke projecten. 
Veel dank Karin, Desiree en Francien voor het aannemen van onnoemelijk veel 
telefoontjes en het opmaken van moeilijke tabellen voor lezingen en manuscripten.
Drs. L. Rotteveel, beste Lisselotte. Geheel zelfstandig heb je een onderdeel van het 
project afgerond met de statistische verwerking van de data als hoogtepunt. Je was een 
kei en het artikel werd geplaatst. Reuze bedankt.
Collegae kinderrevalidatieartsen, beste Margriet en Nique. De maten op de 
St.Maartenskliniek. Jullie bedankt voor de support en voor de vele waarnemingen die 
nodig waren om mij dit onderzoek te kunnen laten uitvoeren.
De leden van de manuscriptcommissie professor G. Padberg, professor K. Graamans 
en professor K. Postema wil ik hartelijk danken voor het kritisch en gedetailleerd lezen 
van het manuscript. Het was fijn om uw positieve reacties terug te krijgen.
Ook buiten de het Universiteitsziekenhuis St.Radboud en St.Maartenskliniek hebben 
zich mensen ingezet en zijn steunend geweest met hun belangstelling. Te beginnen 
bij mijn familie, Piety voor je omslagontwerp, Rob, Johan, Emilia bedankt voor jullie 
steun. Speciale dank aan mijn moeder, dat je mij met belangstelling hebt gevolgd. 
Samen weten we het: Pa zou tevreden zijn geweest.
Bijzonder veel dank aan Tom van den Brink en Ben van der Klift: van mijn vrienden 
ken ik jullie het langst. Je hebt mij de eer gegund als paranimph te willen optreden. Ik 
bewaar goede herinneringen aan de voorbesprekingen tijdens het zeilen. Gerard de 
Jong, je hebt deze lange jaren niet nagelaten je bij een goed glas wijn van haver tot gort 
over dit onderzoek te laten informeren.
Dank voor de prettige samenwerking met professor van Nieuw Amerongen en Enno 
Veerman, Acta te Amsterdam.
Katleen Broeckhoven, Jannie van den Broek en Rob van den Sigtenhorst, Allergan, 
bedankt voor jullie onvoorwaardelijke steun. 
Dierbare vrienden, iedereen die onbedoeld niet genoemd is: Hartelijk dank.
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Curriculum vitae
Peter Jongerius werd op 17 November 1955 geboren in Oosterbeek en is daar opgegroeid. 
Binnen de mogelijkheden van de mammoetwet heeft hij alle schooltypen gevolgd 
op het Redichem college te Oosterbeek en later op het christelijk lyceum te Arnhem 
waar hij in 1976 het VWO diploma behaalde. In hetzelfde jaar begon hij met de studie 
geneeskunde aan de Rijks Universeit te Utrecht. In 1983 werd het artsexamen gehaald. 
Aansluitend was hij gedurende 2 jaar ‘AGNIO’ algemene heelkunde in het Overvecht 
ziekenhuis te Utrecht (1984/1985) en het Havenziekenhuis te Rotterdam (1985/1986). 
Na eerst een periode als AGNIO werkzaam geweest te zijn in het revalidatiecentrum 
van de Sint Maartenskliniek te Nijmegen, kon hij vanaf 1 maart 1987 aldaar de opleiding 
tot revalidatiearts volgen (opleider: R.A.J. Rijken) met deelopleidingen in Canisius 
Wilhelmina ziekenhuis en het Universitair Medisch Centrum Sint Radboud te Nijmegen. 
Tijdens deze periode ontstond de speciale belangstelling voor de kinderrevalidatie. 
Op 15 maart 1991 werd de opleiding afgerond en bestond de unieke kans om zijn 
eerdere medeopleider in de kinderrevalidatie, drs. R.S. Blankesteijn, op te volgen. 
Vanuit het revalidatiecentrum werd hij als kinderrevalidatiearts o.a. gedetacheerd naar 
de revalidatieafdeling van het “Radboud”. Als hoofd van die afdeling (1993/2001) 
heeft hij met zeer veel genoegen, samen met de collegae, gewerkt aan de uitbouw 
van deze afdeling om de voorwaarden voor de medisch specialistenopleiding en de 
komst van een hoogleraar vorm te geven. Thans is hij grotendeels werkzaam in de St. 
Maartenskliniek met een deelaanstelling in het UMC Sint Radboud, met als speciaal 
aandachtsgebied de behandeling en begeleiding van kinderen met een cerebrale 
parese, in het kader waarvan dit proefschrift is geschreven.
In Utrecht leerde hij Lina Tacoma kennen, waarmee het liefde op het eerste gezicht 
was. In 1984 trouwden zij en hebben inmiddels een gelukkig gezin samen met Femke 
en Roeland.

